Determining S6K1 localisation and interactions with mTORC1 in live cells using fluorescence lifetime imaging microscopy by Ahmed, Abdullah R.
Determining S6K1 localisation 
and interactions with mTORC1 in 
live cells using fluorescence 
lifetime imaging microscopy 
A thesis submitted to and awarded by 
 Oxford Brookes University  
in partial fulfilment of the requirements of the award of 
 DOCTOR OF PHILOSOPHY  
Department of Biological and Medical Sciences 
September 2018 
Abdullah R Ahmed 
Collaborating establishments: STFC, Evotec, PP-UK 
 
 
 
 
 
 
 
 
 
 
 
 
In dedication to my mother Sajdah Masarrat, a single parent, without whom I would not 
have achieved my academic accomplishments. I express my sincere gratitude for her 
constant support and prayers. Her endless love and positive attitude has inspired me to 
reach my full potential. Without her I would not have completed my greatest achievement 
yet, my PhD.  
  
 
  
5 
 
Author’s declaration 
I hereby declare that this submission is my own work under the supervision of 
Professors Anthony Parker, Chris Stubbs and Chris Hawes and that, to the best of 
my knowledge and belief, it contains no material previously published or written by 
another person or material which has to a substantial extent been accepted for the 
award of any other degree or diploma at any university or other institute.  
 
 
Name: Abdullah Ahmed 
Signature: 
 
Date: 27/09/18 
 
  
  
7 
 
Acknowledgements 
There are a number of people that without their help this thesis would not have been 
possible. Many thanks and gratitude to my supervisors Tony Parker (STFC), Chris 
Stubbs (STFC) and Chris Hawes (Oxford Brookes) for their guidance as well as 
support from Professor Stanley Botchway (STFC), Dr Rahul Yadav (Evotec), Dr 
Richard Hitchman (Evotec) and Professor Ray Owens (PP-UK). I am thankful to the 
BBSRC for an iCASE PhD studentship (BB/L016052/1) and thank STFC for funding 
access to the Central Laser Facility, Protein Production UK for access to their 
laboratory and expertise and Evotec for training, facility access and financial 
support.  
My sincere gratitude to Dr Maud Dumoux for helping with the expression and 
purification of the SensOR protein. I would also like to thank Dr Alessia Candeo for 
the work done using Light sheet microscopy and Marta Szynkiewicz for her 
laboratory support. My heartfelt thank you to Dr John Barker (SVP, Evotec) for 
supporting this project, Dr Stephanie Duclos (Evotec) for supporting the construct 
designs, Dr Ewa Pilka (Evotec) for the large-scale purification from insect cells as 
well as the rest of the Evotec protein production team: Adrian Gray, Douglas 
Hewstone, Uzzol Miah and Berenice Rotty. 
A special thank you to all my family and colleagues at the Research Complex at 
Harwell (RCaH), specifically Dr Sarah Needham, Dr Indran Mathavan, Sofia 
D’Abrantes and Dr Kay Sowoidnich for their continuous support and motivation. I 
would also like to extend my appreciation to Dr Konstantinos Beis and Dr Ken Raj 
and their groups for their discussions, help and support.  
I also acknowledge Cancer Research Technology Ximbio (UK) which will provide a 
portal for trading the plasmids developed in this research project.  
 
  
9 
 
Table of Contents 
Author’s declaration ................................................................................................. 5 
Acknowledgements .................................................................................................. 7 
Abstract ..................................................................................................................17 
List of presentations and publications .....................................................................18 
List of Figures .........................................................................................................19 
List of Tables ..........................................................................................................22 
Abbreviations ..........................................................................................................23 
1.0 Introduction .......................................................................................................29 
1.1 An overview of the mTOR signalling pathway ................................................29 
1.2 Lysosomal membrane a hub for mTORC1 nutrient sensing ..........................32 
1.3 Role and function of Ribosomal Protein S6 kinase 1(S6K1) ..........................33 
1.4 Sub-cellular localisation of S6K1 and phosphorylated S6K1 ..........................36 
1.5 S6K1 co-immunoprecipitation with raptor, mTOR and Rheb ..........................38 
1.6 Architecture of mTORC1 and structure of S6K1 ............................................39 
1.7 Rapamycin and new generation mTOR inhibitors ..........................................42 
1.8 Mass protein expression using the Baculovirus system .................................47 
1.9 Principles of fluorescence ..............................................................................48 
1.10 Green Fluorescent Protein (GFP) technology ..............................................50 
1.11 Concepts of confocal and multiphoton microscopy ......................................53 
1.12 Introduction to Förster resonance energy transfer (FRET) and Fluorescence-
lifetime imaging microscopy (FLIM) .....................................................................59 
1.13 Molecular Structure and Conformation Studies Using FRET .......................65 
1.14 Review on imaging mTORC1 in live cells ....................................................67 
1.15 Aim and development ..................................................................................70 
2.0 Materials and methods ......................................................................................73 
2.1 Materials .......................................................................................................73 
2.1.1 Chemicals ...............................................................................................73 
2.1.2 Primers ...................................................................................................73 
2.1.3 DNA plasmids and vectors ......................................................................74 
2.1.4 Cell lines .................................................................................................75 
2.1.5 Cell culture reagents ...............................................................................75 
2.1.6 Antibiotics ...............................................................................................75 
2.1.7 Antibodies ...............................................................................................75 
2.2 Methods ........................................................................................................76 
10 
 
2.2.1 Amplification of cDNA by polymerase chain reaction (PCR) ................... 76 
2.2.2 Agarose gel electrophoresis of PCR products ........................................ 77 
2.2.3 DNA PCR product extraction from agarose and clean up ....................... 78 
2.2.4 Cutting of pOPIN vectors using restriction digestion ............................... 79 
2.2.5 In-Fusion reaction with pOPIN vectors.................................................... 80 
2.2.6 Transformation using cloning-grade Escherichia coli (E. coli) ................. 81 
2.2.7 Colony selection and starting culture ...................................................... 82 
2.2.8 Transformed bacterial glycerol stock preparation ................................... 83 
2.2.9 Miniprep of plasmid DNA ........................................................................ 83 
2.2.10 DNA plasmid construct verification by PCR screening .......................... 84 
2.2.11 Construct verification using Sanger sequencing ................................... 85 
2.2.12 Maxiprep of plasmid DNA ..................................................................... 85 
2.2.13 Generation of single amino acid mutations in plasmids ........................ 86 
2.2.14 Cloning of EGFP-S6K1 ......................................................................... 87 
2.2.15 Cloning of S6K1-mCherry and S6K1-mTurquoise2 ............................... 88 
2.2.16 Cloning of raptor-YFP ........................................................................... 90 
2.2.17 Cloning of mutant (ΔN) mTOR-mCherry ............................................... 90 
2.2.18 Cloning of mCherry-S6K1-EGFP (SensOR) ......................................... 91 
2.2.19 Cloning of mCherry-S6K1-EGFP-2STREP ........................................... 92 
2.2.20 Generation of EGFP-F29A S6K1 mutant .............................................. 94 
2.2.21 Generation of EGFP- S6K1 T389A mutant ........................................... 94 
2.2.22 Cloning of raptor-His (EV5831) ............................................................. 94 
2.2.23 Cloning of S6K1-FLAG and raptor-His (EV5832_EV5831) ................... 95 
2.2.24 Cloning of FLAG-S6K1 and raptor-His (EV5830_EV5831) ................... 95 
2.2.25 Cloning of TOS-ΔS6K1-FLAG and raptor-His (EV5834_EV5831) ......... 96 
2.2.26 Cloning of mTOR-myc and mLST8 (EV5827_EV5828) ........................ 97 
2.2.27 Cloning of N-truncated mTOR-myc and mLST8 (EV5833_EV5828) ..... 98 
2.2.28 Cloning of mTOR-myc, S6K1-FLAG and mLST8 (EV5827_ 
EV5832_EV5828)............................................................................................ 98 
2.2.29 Cloning of mTOR-myc, S6K1-FLAG, raptor-His and mLST8 (EV5827_ 
EV5832_EV5831_EV5828) ............................................................................. 99 
2.2.30 Mammalian cell culture ....................................................................... 100 
2.2.31 Long-term mammalian cell storage ..................................................... 101 
2.2.32 Trypan blue exclusion test of cell viability ........................................... 101 
2.2.33 Insect cell culture ................................................................................ 102 
11 
 
2.2.34 Long-term storage of insect and baculovirus infected insect cells (BIICs)
 ...................................................................................................................... 102 
2.2.35 Thawing mammalian and insect cell /BIICs ......................................... 103 
2.2.36 Growing mammalian spheroids ........................................................... 103 
2.2.37 Mammalian cell transfection using plasmid DNA ................................. 104 
2.2.38 Insect cell baculovirus-plasmid preparation infection ........................... 104 
2.2.39 SensOR purification from insect cells .................................................. 107 
2.2.40 mTORC1 purification from insect cells ................................................ 107 
2.2.41 Cell fixation ......................................................................................... 108 
2.2.42 Immunofluorescence labelling of fixed cells ........................................ 109 
2.2.43 Western blot analysis for phospho-S6K1 and mTORC1 proteins ........ 109 
2.2.44 Pull-down assays of S6K1-mTORC1 interactions ............................... 112 
2.2.45 Cell starvation, amino acid activation and inhibition studies ................ 112 
2.2.46 Confocal imaging of live and fixed cells ............................................... 113 
2.2.47 Quantifying percentage of cytoplasmic or nuclear fluorescence in cells
 ...................................................................................................................... 113 
2.2.48 UV-Vis and fluorimeter studies ............................................................ 114 
2.2.49 Determining quantum yields of AZD2014 in solution ........................... 114 
2.2.50 Two-photon FRET-FLIM setup for interaction and spectroscopy studies
 ...................................................................................................................... 115 
2.2.51 One-photon FRET-FLIM setup for interaction and spectroscopy studies
 ...................................................................................................................... 119 
2.2.52 Lightsheet setup for monitoring AZD2014 uptake in spheroids............ 119 
2.2.53 Quantifying uptake of AZD2014 in cellular models .............................. 120 
2.2.54 Lambda scan for multiphoton excitation of AZD2014 .......................... 120 
3.0 S6K1 interaction and phosphorylation with mTORC1 in living cells ................. 123 
3.1 Brief introduction ......................................................................................... 123 
3.2 Results ........................................................................................................ 124 
3.2.1 PCR screening of EGFP-S6K1, S6K1-mCherry and S6K1-mTurq2 
constructs ...................................................................................................... 124 
3.2.2 Expression and imaging of tagged S6K1 in live mammalian cells ......... 125 
3.2.3 Western blot validation of tagged S6K1 constructs ............................... 127 
3.2.4 Live cell translocation of fluorescently tagged S6K1 from the nucleus to 
the cytoplasm ................................................................................................ 128 
3.2.5 S6K1 translocation with serum/AA starvation or inhibitor treatment ...... 131 
3.2.6 S6K1 translocation with S6K1 TOS and phospho-domain mutations .... 133 
3.2.7 mDsRed acceptor unsuitability for multiphoton FRET-FLIM .................. 134 
12 
 
3.2.8 S6K1 interaction with raptor in live cells using FRET-FLIM ................... 138 
3.2.9 S6K1 interaction with mTOR in live cells using FRET-FLIM .................. 140 
3.2.10 Lack of S6K1 interaction with Rheb in live cells using FRET-FLIM ..... 141 
3.2.11 S6K1 pull-down with raptor, mTOR and Rheb .................................... 143 
3.2.12 S6K1 interaction with FKBP12 in live cells using FRET-FLIM ............. 143 
3.2.13 PCR screen of ΔmTOR-mCherry and sequencing of raptor-YFP ........ 145 
3.2.14 Imaging S6K1 translocation with mutated (ΔN) mTOR ....................... 147 
3.2.15 Imaging S6K1 translocation with PRAS40 and 4EBP1 ....................... 150 
3.2.16 4EBP1 interaction with raptor using FRET-FLIM................................. 152 
3.2.17 Phospho-S6K1 inhibition with rapamycin and Rheb ............................ 153 
3.2.18 Imaging S6K1 translocation with both Rheb and rapamycin ............... 154 
3.2.19 Immunofluorescence labelling of p-S6K1 in fixed cells ....................... 155 
3.2.20 S6K1 and p-S6K1 artefacts from immunofluorescence labelling ......... 158 
3.2.21 p-S6K1 immunofluorescence labelling of translocated S6K1 .............. 159 
3.2.22 Quantification of overexpressed p-S6K1 with Rheb in fixed cells ........ 160 
3.2.23 Variation in endogenous p-S6K1 with antibody labelling ..................... 161 
3.2.24 Localisation of endogenous p-S6K1 with Rheb in fixed cells .............. 161 
3.2.25 Quantification of endogenous p-S6K1 with Rheb in fixed cells............ 162 
3.2.26 PCR screen of mCherry-S6K1-EGFP ................................................. 162 
3.2.27 S6K1 live cell FRET bio-sensor western blot validation ...................... 163 
3.2.28 Phospho-S6K1 localisation in living cells using SensOR .................... 164 
3.2.29 Imaging p-S6K1 with activation and inhibition in living cells ................ 168 
3.2.30 In vitro and in vivo temperature studies of purified SensOR ................ 170 
3.2.31 In vitro activation of SensOR with ATP ............................................... 171 
3.3 Discussion .................................................................................................. 172 
3.4 Conclusions ................................................................................................ 189 
4.0 Directly imaging AZD2014 and INK128 pan-mTOR inhibitors in living cells .... 191 
4.1 Brief introduction ......................................................................................... 191 
4.2 Results ........................................................................................................ 192 
4.2.1 UV-Vis spectroscopy analysis of rapamycin, AZD2014 and INK128 ..... 192 
4.2.2 Fluorescence spectroscopy analysis of AZD2014 in solution ................ 194 
4.2.3 Determining the quantum yields of AZD2014 in solution ....................... 195 
4.2.4 Multiphoton excitation spectrum of AZD2014 ........................................ 198 
4.2.5 AZD2014 FRET characterisation with EGFP ........................................ 199 
4.2.6 AZD2014 TCSPC measurements in solution ........................................ 200 
4.2.7 Fluorimetry analysis of INK128 ............................................................. 201 
13 
 
4.2.8 Fluorescence lifetime and φF of INK128 in solution ............................... 203 
4.2.9 Uptake of AZD2014 in living cells .......................................................... 204 
4.2.10 Imaging AZD2014 in other living mammalian cell lines ....................... 206 
4.2.11 Quantifying AZD2014 accumulation in living cells ............................... 207 
4.2.12 Uptake of INK128 in living cells ........................................................... 210 
4.2.13 Uptake and imaging of AZD2014 in living HEK293 spheroids ............. 212 
4.2.14 AZD2014 photo-activated disassembly and cell death of spheroids .... 214 
4.2.15 Unsuitability of GFP tagged S6K1 acceptor for one-photon FRET-FLIM
 ...................................................................................................................... 216 
4.2.16 AZD2014 interaction with EGFP-mTORC1 using multiphoton FRET-
FLIM .............................................................................................................. 218 
4.2.17 Co-localisation of AZD2014 with Rheb in living cells ........................... 222 
4.2.18 mTOR inhibition using AZD2014 with SensOR ................................... 223 
4.3 Discussion ................................................................................................... 226 
4.4 Conclusions ................................................................................................. 233 
5.0 mTORC1 large-scale expression and purification ........................................... 235 
5.1 Brief introduction ......................................................................................... 235 
5.2 Results ........................................................................................................ 236 
5.2.1 PCR screen validation of mCherry-S6K1-EGFP-STREP (SensOR) ...... 236 
5.2.2 Expression and pilot purification of mCherry-S6K1-EGFP-STREP 
(SensOR) ...................................................................................................... 237 
5.2.3 Purification of mCherry-S6K1-EGFP-STREP (SensOR) ....................... 241 
5.2.4 Generation of mTORC1 virus for structural studies ............................... 243 
5.2.5 Small scale scouting expression of mTORC1 proteins in insect cells .... 244 
5.2.6 Small scale purification of S6K1-raptor constructs ................................ 254 
5.2.7 Large scale pilot expression and purification of S6K1-raptor ................. 256 
5.3 Discussion ................................................................................................... 261 
5.4 Conclusions ................................................................................................. 267 
6.0 Overall summary and future work ................................................................... 269 
6.1 Overall summary ......................................................................................... 269 
6.2 Future work ................................................................................................. 276 
References ........................................................................................................... 283 
Appendices ........................................................................................................... 309 
Appendix A ........................................................................................................ 309 
A.1 NucleoSpin® Gel and PCR Clean-up Kit contents ................................... 309 
A.2 Quick-Fusion cloning kit contents ............................................................ 309 
14 
 
A.3 Protocol for LB Agar ................................................................................ 309 
A.4 Protocol for LB ........................................................................................ 309 
A.5 Protocol for LB glycerol ........................................................................... 309 
A.6 QIAprep Spin Miniprep kit contents ......................................................... 310 
A.7 pOPIN primers ........................................................................................ 310 
A.8 QIAGEN Plasmid Plus Maxi kit contents ................................................. 310 
A.9 QuikChange Multi Site-Directed Mutagenesis Kit .................................... 311 
A.10 pOPIN vectors ....................................................................................... 311 
A.10.1 pOPINN-EGFP ...................................................................................... 311 
A.10.2 pOPINE-3C-mCherry ............................................................................. 312 
A.10.3 pOPINE-3C-mTurq2 .............................................................................. 312 
A.10.4 pOPINE-3C-EGFP ................................................................................. 313 
A.10.5 pOPINE-3C-YFP ................................................................................... 313 
A.10.6 pOPINEneo-3C-2STREP ....................................................................... 314 
A.10.7 pBAC4x-1 .............................................................................................. 315 
    A.11 mLST8 sequence ................................................................................. 316 
    A.12 TBST (1X) ............................................................................................ 316 
Appendix B ....................................................................................................... 317 
B.1. Western blot analysis of endogenous and overexpressed pS6K1 .......... 317 
B.2. Co-localisation of S6K1 with Rheb in live cell ......................................... 318 
B.3 Full length blots for mTORC1 pull-down .................................................. 319 
B.4 Lifetime comparison of EGFP in live vs fixed HEK293 cells .................... 320 
B.5 High Rheb expression does not lead to correlated phospho-S6K1 levels 321 
B.6 Differences in endogenous phospho-S6K1 localisation with various 
antibodies ...................................................................................................... 322 
B.7 Immunofluorescence secondary antibody controls .................................. 323 
B.8 Endogenous phospho-S6K1 may be mostly nuclear and induced by Rheb 
overexpression .............................................................................................. 324 
B.9 Quantifying endogenous phospho-S6K1 with overexpressed Rheb ........ 325 
B.10 EGFP-mTOR FRET-FLIM interaction with mCherry-raptor .................... 326 
Appendix C ....................................................................................................... 327 
C.1 UV-VIS spectrum of DMSO only ............................................................. 327 
C.2 Molar extinction coefficients (ε) of AZD2014, INK128 and rapamycin ..... 328 
C.3 Excitation spectra of AZD2014 in various solvents .................................. 329 
C.4 AZD2014 two-photon excitation and single photon calibration ................ 330 
C.5 AZD2014 two-photon excitation and single photon calibration ................ 331 
15 
 
C.6 Multiphoton (600 nm) FLIM of HEK293 only at 0.5 mW ........................... 332 
C.7 Multiphoton (600 nm) FLIM of EGFP-S6K1 only at 0.5 mW ..................... 333 
Appendix D ....................................................................................................... 334 
D.1 Pilot expression and purification of SensOR ............................................ 334 
D.2 QC expression and purification of raptor and S6K1 constructs ................ 335 
D.3 Chromatagram obtained for S6K1-FLAG + raptor-His after purification using 
the ÄKTA protein purification system. ............................................................ 336 
D.4 Coomassie of large scale iMAC of raptor and S6K1 ................................ 337 
D.5 Coomassie Phynexus run raptor and S6K1 elutions ................................ 338 
D.6 Sequence Annotated by Structure (SAS) of S6K1 ................................... 339 
 
 
  
  
17 
 
 
Abstract 
The S6K1 kinase functions downstream within the mTORC1 pathway to regulate 
cell proliferation, aging and adiposity. Using GFP technology and advanced imaging, 
localisation of S6K1 has been established (47% nucleus and 53% cytoplasm). S6K1 
strongly (Δτ=200 ps) interacts with the complex scaffold protein, raptor, and when 
the presence of the latter protein is increased, S6K1 translocates to the cytoplasm. 
S6K1 weakly interacts with mTOR (Δτ=100 ps) and not with Rheb which is required 
for the inhibitor function of rapamycin (71% vs 8.9% decrease in phospho-S6K1 
without Rheb). The development of a novel biosensor (SensOR) shows 
phosphorylation of S6K1 occurring mainly in the cytoplasm of living cells (from 
τm=2.5 to 2.3 ns).  
In Chapter 4, AZD2014 and INK128, both pan-mTOR inhibitors, show fluorescent 
properties that can be used to investigate their cellular action. The fluorescence 
quantum yields for AZD2014 and INK128 are 0.47 and 0.33, respectively. Cellular 
uptake of the drugs is rapid with a half-life of 60 seconds and 42 seconds, 
respectively. Both drugs localise to mTORC1 related sub-cellular sites. Using cell 
spheroids to mimic a tumour environment, it was observed the outer spheroid layers 
take up AZD2014 5x faster than the inner layers. AZD2014 functions by interacting 
strongly with S6K1 (EFRET=18%) and Rheb (EFRET=16%) and less with mTOR and 
raptor (EFRET=11%).  
Chapter 5 investigates mass production techniques for generating sufficient 
quantities of S6K1 and mTORC1 proteins for future structural work. Although the 
baculovirus-insect cell expression system produced ~1mg of S6K1-raptor protein, 
impurities and degradation were present. Large quantities of the SensOR 
(3.7mg/ml) have been generated and purified. Solution phase studies show an 
open-closed SensOR conformation (from 2.7ns – 2 ns) upon the addition of ATP.    
Overall the research shows how FRET-FLIM technology can be usefully employed 
to elucidate where active drug targets must localise with regard to targeting mTOR 
phosphorylation. 
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1.0 Introduction 
 
1.1 An overview of the mTOR signalling pathway 
The mechanistic or mammalian Target Of Rapamycin (mTOR) protein was identified 
as a consequence of the discovery of rapamycin inhibitor effects in the 1960s. 
Rapamycin is named after the island (Rapa Nui) where it was discovered from soil 
samples and exhibited anti-fungal, anti-proliferative and immunosuppressive 
properties (Dumont and Su, 1995). Since the first extractions of rapamycin from soil 
containing Streptomyces hygroscopicus, there have been decades of widespread 
research into understanding and determining its mechanism of action. In the 1990s, 
both Michael Hall’s group and George Livi’s group independently screened the yeast 
genome and identified two target genes: Target of Rapamycin 1 (TOR1) and Target 
of Rapamycin 2 (TOR2); stemming from the cytotoxic effects of rapamycin binding 
to the TOR specific intracellular protein, FKBP12 (Heitman, Movva and Hall, 1991; 
Koltin et al., 1991). Soon after, Sabatini (Sabatini et al., 1994), Schreiber (Brown et 
al., 1994), Abraham (Sabers et al., 1995) and Berlin (Chiu, Katz and Berlin, 1994) 
separately discovered the single mammalian homologue form of TOR although each 
group giving it different names; FK506-binding protein 12-Rapamycin-Associated 
Protein 1 (FRAP1), Rapamycin and FKBP12 Target 1 (RAFT1) and mechanistic 
Target Of Rapamycin (mTOR). The latter name was adopted by consensus and 
registered by the Human Genome Organisation (HUGO) gene nomenclature in 
2009.  
The “unearthing” of mTOR resulted in a drive to understand the involvement of this 
large (289 kDa) protein within the biological context of the cell. Before long, it was 
found that mTOR, a serine-threonine kinase, existed as part of two multi-protein 
complexes: mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2) 
(Laplante et al., 2009). Following these discoveries, progress was rapid as the 
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Rheb, raptor, mLST8, PRAS40 and DEPTOR subunit proteins were found to be 
associated with mTORC1 by co-immunoprecipitation assays (pull-downs) (Betz and 
Hall, 2013; Aylett et al., 2016).  Whilst two mTOR complexes were identified, 
rapamycin was found to be effective in inhibiting mTORC1, preventing the 
phosphorylation of S6K1 and 4EBP1, both downstream proteins (Dennis, Kimball 
and Jefferson, 2013). Studies on the upstream of TOR complexes were first 
performed in Drosophila melanogaster (Stocker et al., 2003) and later in mammalian 
models, and identified Rheb, a small GTPase, regulated by the Tuberous Sclerosis 
Complex (TSC1/TSC2) to promote cellular growth through mTOR activation and 
subsequently S6K1 phosphorylation (Long, Lin, et al., 2005; Long et al., 2007). 
To understand further the mTOR protein pathway, pull-down assays have also 
shown interactions with the rictor, Protor, mLST8, Sin1 and DEPTOR subunit 
proteins, to form mTORC2 which phosphorylates AKT(PKB), SGK1 and PKCα 
involved in insulin signalling and glucose metabolism (Laplante et al., 2009; Stuttfeld 
et al., 2018). Both mTOR complexes are now identified as being at the heart of 
several signalling cascades involving a multitude of upstream and downstream 
proteins that form the mTOR pathway (Figure 1.1) which includes links to other 
signalling pathways, fully justifying mTOR being termed as a ‘master regulator’. 
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Figure 1.1: Schematic of the mTOR signalling pathway. Upstream proteins (in white or grey filled 
circles) and respective upstream pathways are shown. The JAK/STAT and MAPK/ERK proteins feed 
into the mTOR pathway. The mTORC1 pathway is shown in blue filled circles. The mTORC2 pathway 
is shown in yellow filled circles. Phosphorylated substrates are depicted with phosphorylation (p) in red 
filled circles. Activating processes are shown with green arrows whilst inhibitory processes are shown 
with red arrows.   
Although each mTOR complex performs diverse functions within the cell, the 
mTORC1 pathway is of particular interest  functioning in the co-ordination of energy 
(ATP), nutrients (amino acids), oxygen (hypoxia) and growth factor availability to 
regulate key biological processes such as cellular growth, metabolism and protein 
synthesis (Saxton and Sabatini, 2017). Thus, targeting mTOR1 represents a novel 
strategy to fight against cancer, type II diabetes, cardiovascular and neurological 
diseases (Laplante and Sabatini, 2012; Crino, 2016; Xie, Wang and Proud, 2016). 
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Hence, advancing the understanding of mTOR and its interactions with its subunit 
partner proteins is seen as key to the development of more effective therapies.   
1.2 Lysosomal membrane a hub for mTORC1 nutrient sensing 
The importance of mTOR is now recognised and emphasised by the extensive 
studies into both its structure and biochemistry. A recent review has described many 
aspects of the nutrient-sensing role of the mTORC1 pathway (González and Hall, 
2017) and the notion of lysosomal membrane being a hub for mTORC1 activation 
has also been studied (Saxton and Sabatini, 2017). As shown in Figure 1.2, the 
mTORC1 complex is thought to translocate to the lysosomal membrane where it is 
tethered by both Rheb and the Ragulator–RAG GTPases (Yonehara et al., 2017). 
Recently, other complexes associated with nutrient-sensing have been identified 
such as the v-ATPase (Zoncu et al., 2011), KICSTOR (Wolfson et al., 2017) GATOR 
(Parmigiani et al., 2014) and CASTOR complexes (Chantranupong et al., 2016). 
However, the S6K1 involvement within the mTOR pathway has not received much 
attention to date, and forms a major component of the work covered in this thesis. 
The role and importance of S6K1 in the mTOR pathway is therefore reviewed and 
discussed next.  
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Figure 1.2: Lysosomal membrane in mTORC1 nutrient sensing. A scaffolding complex 
on the lysosomal membrane is shown consisting of the v-ATPase pump, the Ragulator, 
SLC38A9 transporter, the Rag GTPases and KICSTOR are shown. The tethering of 
mTORC1 is also shown as well as regulation of the Ragulator-Rag complex by the GATOR 
complex and amino acid sensing proteins such as Sestrin2 and CASTOR1. Figure adapted 
from (Saxton and Sabatini, 2017).  
1.3 Role and function of Ribosomal Protein S6 kinase 1(S6K1) 
The Ribosomal S6 Kinase (RSK) family consists of protein kinases implicated in a 
wide range of cellular processes (Anjum and Blenis, 2008). There are two 
mammalian homologues S6K1 and S6K2 of the p70 RSK subgroup. While S6K2 is 
known to be targeted by mTOR (Park et al., 2002) and has been investigated (Pardo 
and Seckl, 2013), less attention has been paid to understanding S6K1. The S6K1 
kinase phosphorylates various substrates that control protein synthesis, in particular 
Ribosomal Protein S6 (RPS6) which is part of the 40S ribosomal subunit (Roux et 
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al., 2007). S6K1 also functions in cell proliferation, apoptosis, metabolism, cell 
structure (Tavares et al., 2015) and has been shown to regulate aging (longevity) 
and adiposity (Selman et al., 2009; Arif et al., 2017), memory (Caccamo et al., 
2015), immunity (Kim et al., 2014), muscle hypertrophy (Marabita et al., 2016) and 
more recently, in cell migration and tumour growth (Zhang et al., 2018). A summary 
of some of the most important functions of S6K1 is depicted in Figure 1.3. Cell 
proliferation, size and health are major characteristics of cancer, obesity and aging 
and in this context the role S6K1 plays in cell proliferation and its diverse 
functionality in the mTOR pathway makes it a desirable target for treatments of a 
wide range of disease states (Dann, Selvaraj and Thomas, 2007).  
 
Figure 1.3: Functions of S6K1 in the mTOR pathway. The various roles of S6K1 are shown above 
with black lines projecting from the S6K1 protein. The figure above is updated from (Magnuson, Ekim 
and Diane C. Fingar, 2012).  
S6K1 is transcribed by the RPS6KB1 gene which, due to alternative start codons, 
produces multiple isoforms; p85 S6K1 (85 kDa), p70 S6K1 (70 kDa) and in human 
breast cancer cell lines p60 S6K1 (Kim et al., 2009). Humans can also produce a 
rare third form of S6K1 known as p31 S6K1 which is generated from the alternative 
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splicing of the RPS6KB1 transcript by the SF2/ASF protein (Fenton and Gout, 2011; 
Magnuson, Ekim and Fingar, 2012; Rosner, Schipany and Hengstschläger, 2012; 
Ben-Hur et al., 2013; Tavares et al., 2015; Amaral et al., 2016). There is no 
evidence suggesting that mTOR phosphorylates p31 S6K1 (Rosner and 
Hengstschläger, 2011) and this is likely due to the latter lacking the C-terminus 
containing the phosphorylation site.  
Both p85 S6K1 and p70 S6K1 are known as p70 S6 Kinase 1 or simply S6K1 
(Figure 1.4) and share similarities in domain structures but the mTOR 
phosphorylation sites are different, occurring at threonine residue 412 and 389 
respectively (Rosner and Hengstschläger, 2011). Important questions arise such as 
where in the cell does the phosphorylation occur and how does the phosphorylation 
relate to the localisation of mTORC1? 
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Figure 1.4: S6K1 isoform generation. S6K1 is produced from the RPS6KB1 gene which due to 
alternative splicing and alternative translation start sites, generates three isoforms. The p31 isoform 
contains a Nuclear Localisation Sequence (NLS) and a partial kinase domain. Both p85 S6K1 (also 
known as Alpha 1) and p70 S6K1 (Alpha II) have a kinase domain (containing an activation loop), a C-
Terminal tail (containing a turn motif and hydrophobic motif) and an autoinhibitory domain. All S6K1 
isoforms have been reported to contain a TOR Signalling motif (TOS) with the amino acid sequence 
FDIDL. Amino acids that are phosphorylated by mTOR are indicated by their positions within the length 
of proteins. Figure adapted from (Rosner and Hengstschläger, 2011).  
1.4 Sub-cellular localisation of S6K1 and phosphorylated S6K1  
Determining the sub-cellular localisation of S6K1 is important to help understand not 
only its function but also the workings of the mTOR complex within the cell. Many 
observations regarding the localisation of S6K1 have been made in mammalian 
cells; fractionation studies have indicated the presence of S6K1 both in the 
cytoplasm and the nucleus (Rosner and Hengstschläger, 2011; Rosner, Schipany 
and Hengstschläger, 2012). However, only cytoplasmic localisation was observed in 
fixed cells (X. K. Lun et al., 2017). S6K1 has also been reported to localise in the 
mitochondria and stress granules (Djouder et al., 2007; Sfakianos et al., 2018). 
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localisation of S6K1 was seen (Reinhard et al., 1994). The only published live cell 
image of S6K1 used fluorescently labelled GFP-S6K1 expressed in plant cells 
where both nucleus and cytoplasmic localisation were observed (Mahfouz, 2006). 
Thus, to date, the overall picture from all the various investigations from using 
different techniques and cell lines looking at S6K1 cellular distribution have reached 
different conclusions, and such controversy is understandably a key issue in relation 
to the mTOR pathway, but this is not the only issue. 
The cellular localisation of the phosphorylated form of S6K1, mediated by mTOR, is 
also debated widely in the field. Identifying regions of the cell where S6K1 
phosphorylation occurs has been, for the most part, approached using indirect and 
disruptive cell fractionation methods that appear to indicate that phosphorylated p70 
S6K1 isoform translocates from the cytoplasm into the nucleus (Rosner and 
Hengstschläger, 2011). However, fractionation studies are prone to artefacts due to 
pooling of proteins from various organelles. With this in mind, others have resorted 
to the use of fixed cell immunofluorescence to detect phosphorylated S6K1 (p-
S6K1). One approach has been to use amino acid regulation where phosphorylation 
was deregulated and phosphorylation subsequently activated, the procedure 
demonstrated an increase in p-S6K1 within the nucleus (Rhoads et al., 2008; Kim et 
al., 2013) following phosphorylation. Although, the immunofluorescence labelling 
supports the fractionation work, cell fixation is not without its limitations. It has also 
been reported to induce artefacts due to loss of untethered soluble proteins and 
poor labelling (Schnell et al., 2012). A live cell FRET (Fluorescence Resonance 
Energy Transfer) sensor (Komatsu et al., 2011), and more recently, an improved 
version (Komatsu et al., 2018), has been developed to track S6K1 activity in real-
time by measuring the phosphorylation of one of its substrates, rictor associated 
with mTORC2 (Treins et al., 2010) in the cytoplasm. These sensors contain a hybrid 
form of partial rictor and S6K1 domains and can only indirectly report on mTORC1 
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activity in the cytoplasm and does not localise into the nucleus. A much-needed 
improvement to directly monitor mTOR-mediated phosphorylation of S6K1 would not 
only overcome the well-known problems with cell fixation but also provide a more 
physiologically accurate insight into live cell mTOR signalling.  
1.5 S6K1 co-immunoprecipitation with raptor, mTOR and Rheb 
Knowing the intra-cellular location of a protein helps us to elucidate how and with 
what other proteins it may interact within the same site. To date, S6K1 and raptor 
interactions have been studied in both mammalian and plant cells (Hara et al., 2002; 
Nojima et al., 2003; Ali and Sabatini, 2005; Mahfouz, 2006; Dennis, Kimball and 
Jefferson, 2013) using conventional pull-down assays but the interactions of these 
two proteins in living cells are unknown. The current thought in literature proposes 
that the raptor protein acts as a ‘scaffold’ owing to its ability to bind mTORC1 
substrates S6K1 and 4EBP1 (Hara et al., 2002; Beugnet, Wang and Proud, 2003; 
Choi, McMahon and Lawrence, 2003; Schalm et al., 2003; Wang, Rhodes and 
Lawrence, 2006; Lee et al., 2008), other regulatory proteins, such as the inhibitory 
PRAS40 (Oshiro et al., 2007), TAK1 (Shin et al., 2013) and activators such as the 
Rag GTPases mentioned in section 1.2 (Sancak et al., 2008).  
It is thought that all known S6K1 isoforms have a TOR Signalling (TOS) motif, on 
their N-terminus (Figure 1.4) (Schalm and Blenis, 2002; Kim et al., 2009). The TOS 
motif of p85 S6K1 and p70 S6K1 mediates interaction with the N-terminus region of 
raptor; however, reports on the precise nature of the interaction vary. Overall pull-
down assays with mutations in the S6K1 TOS sequence fail to bring down raptor 
(Nojima et al., 2003; Ali and Sabatini, 2005). In contrast, cross-linking mass 
spectrometry indicates that the TOS motif does not interact with raptor (Coffman et 
al., 2014). Other mTOR substrates such as 4EBP1 and PRAS40 also have their 
own unique TOS motifs, allowing them to bind to raptor (Beugnet, Wang and Proud, 
2003; Schalm et al., 2003; Wang, Rhodes and Lawrence, 2006; Sancak et al., 2007; 
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Lee et al., 2008). It has been proven that S6K1, 4EBP1 and PRAS40 mutually 
compete for the same binding site on raptor (Schalm and Blenis, 2002; Oshiro et al., 
2007; Wang et al., 2007; Dennis, Kimball and Jefferson, 2013).  
The literature reports interactions between truncated (mutated) S6K1 with mTOR 
(Ben-Hur et al., 2013) but full length S6K1 has shown no interaction (Ben-Hur et al., 
2013; Brown et al., 2017) by pull-down with mTOR. However, pull-down of mTORC1 
have found the S6K1 component bound to it, although the exact interacting 
components were not defined (Brown et al., 1995; Ali and Sabatini, 2005). 
There is no evidence that Rheb interacts with S6K1, raising the question of how 
mTOR phosphorylates S6K1 directly, as S6K1 phosphorylation  is considerably 
enhanced by Rheb and increased by raptor (Garami et al., 2003; Inoki et al., 2003; 
Yonezawa et al., 2004; Ali and Sabatini, 2005; Long, Ortiz-Vega, et al., 2005; Wang, 
Rhodes and Lawrence, 2006; Ge, Yoon and Chen, 2011; Yadav et al., 2013; Jain et 
al., 2014; Martin et al., 2014). However, contrary to the above, others report that 
raptor, as well as PRAS40, have an inhibitory effect on phosphorylation (Hara et al., 
2002; Kim et al., 2002; Manifava et al., 2016). The effect of raptor on S6K1 
phosphorylation in the mTOR field remains unclear and the understanding of the 
interaction between raptor and S6K1 would be aided by structural studies.  
1.6 Architecture of mTORC1 and structure of S6K1 
The structure of a protein or a protein complex is imperative for the understanding of 
its activity and its mechanism within the cell and goes towards defining strategies to 
design and develop drug targets. Although, X-ray crystallography is considered to 
be the ‘gold standard’ for determining structures with atomistic levels of resolution, 
the technology is difficult to apply to protein complexes. The recent advances in 
cryo-EM technology, driven by better detectors and processing, has paved the way 
to studying large macromolecular protein complexes (Murata and Wolf, 2018). Cryo-
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EM has been extensively applied to study mTORC1, firstly identifying the dimeric 
state of mTOR and secondly identifying the assembly of its interacting subunit 
proteins. The mTOR protein was originally thought to be monomeric (Yang et al., 
2013) and later found to be dimeric (as shown in Figure 1.5A), with a single subunit 
of raptor, mLST8, Rheb, PRAS40, FKBP12-rapamycin on each  molecule of mTOR 
(Yip et al., 2010; Aylett et al., 2016; Yang et al., 2016, 2017). It is now established 
that raptor is necessary for mediating mTOR (N-terminus to C-terminus) 
dimerisation.  
Although no structural information on S6K1 complexed with raptor or mTOR is 
available, the latest publication of the structure of mTORC1 at 3.0 angstrom 
resolution shows the TOS motif of S6K1 bound to Arabidopsis thaliana (At) raptor 
(Figure 1.5B). The study also revealed  a short region of S6K1 sequence binding to 
FRB domain of mTOR, indicating some form of secondary recruitment mechanism 
(Yang et al., 2017). It was further shown that the binding of Rheb to the mTOR 
complex induces a global mTOR conformational change which enhances the 
catalytic activity of the active site (Yang et al., 2017). Whilst the work provides key 
insights into the activation of mTORC1, the use of plant raptor protein rather than 
mammalian or human raptor raises some uncertainty in relation to the accuracy and 
relevance of these insights in regard to human mTORC1.   
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Figure 1.5: Current structures of mTORC1 and S6K1. Three-dimensional structures obtained by 
cryoEM and X-ray crystallography of A) Dimeric mTORC1 where colour key shows interacting subunit 
proteins: raptor, mTOR, mLST8 and Rheb. B) raptor (blue) bound to the TOS motif of S6K1 (red). C) 
Partial length S6K1 (346 amino acids) with zinc and an S6K1 inhibitor, PF-4708671 bound in the ATP 
binding site. All images were generated using PyMOL (version 2.1) using PDB codes: 6BCU, 5WBK 
and 4L46. 
No full length structure of S6K1 has been solved to date. Identifying the 
conformations for phosphorylated and dephosphorylated S6K1, could be key to 
better understanding the action of mTOR. One of the first partial structures of S6K1 
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phosphorylated and unphosphorylated S6K1 kinase domains with staurosporine 
bound were structurally similar with the most notable exception that the activation 
loop in the phosphorylated form became ordered (Sunami et al., 2010). Other 
published crystal structures of the S6K1 kinase domain with and without inhibitors 
soon followed (Wang et al., 2013; Niwa et al., 2014). These kinase structures were 
similar to that of the previous S6K1 kinase domain structure, with the subtle 
difference in the presence of a zinc ion in the activation loop (Figure 1.5C). Most 
importantly, it was observed that the threonine 389 residue was phosphorylated 
during the refinement process (Wang et al., 2013) independently of other kinase 
proteins that have been reported to prime S6K1 for mTOR mediated 
phosphorylation (Keshwani et al., 2011). This finding indicates the potential to 
monitor mTOR activity directly. Although, as of yet, there is no concrete structural 
evidence for differences between phosphorylated and dephosphorylated forms of 
S6K1, the former may be linked to a conformational change as evident by functional 
studies that examined N- and C-terminus truncations (Schalm, Tee and Blenis, 
2005; Magnuson, Ekim and Diane C. Fingar, 2012). As the cell uses kinase proteins 
to activate processes, the ability to de-activate dysfunctional ones through drugs is 
vital for therapy.  
1.7 Rapamycin and new generation mTOR inhibitors  
The last two decades has seen immense research efforts in drug design and 
development focusing on inhibiting the mTOR kinase protein to prevent cancer 
growth (Sparks and Guertin, 2010; Weinberg, 2016). It is reported that mTOR is 
hyperactivated in almost 70% of all human cancers (Xie, Wang and Proud, 2016). 
Thus, the ability to manipulate the mTOR kinase through pharmaceutical 
intervention plays a fundamental part in the battle against cancer. Some of the types 
of mTOR inhibitors currently available are shown in Figure 1.6A and Figure 1.7. 
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The first generation inhibitors of mTOR (rapalogs) were based on the rapamycin 
molecule (Figure 1.7A), now known to target only mTORC1. There appears to be a 
growth of evidence for the lack of efficacy of rapalogs (dosage and duration related) 
as well as emerging rapalog resistance in a number of tumours (Faes, Demartines 
and Dormond, 2017). This ‘enigma’ regarding the efficacy of rapamycin 
(Mukhopadhyay et al., 2016) may be explained by its binding mechanism. The 
rapamycin-FKBP12 complex, as mentioned above, binds to the FRB domain of 
mTOR (Banaszynski, Liu and Wandless, 2005). It was originally thought that 
rapamycin causes the disassembly of mTORC1 (Oshiro et al., 2004; Yip et al., 
2010; Jain et al., 2014) or may cause the degradation of raptor via caspase activity 
(Martin et al., 2016). However, in light of recent structural studies this seems not to 
be the case because the binding of rapamycin-FKBP12 onto mTOR allosterically 
restricts the entry of mTOR substrates accessing the active site for mTOR mediated 
phosphorylation (Aylett et al., 2016; Yang et al., 2016). Rapamycin is reported to 
inhibit S6K1 phosphorylation completely and 4EBP1 phosphorylation incompletely 
on mTORC1 while its effects on mTORC2 are uncertain and effects may be cell line 
dependant (Choo et al., 2008; Choo and Blenis, 2009). As S6K1 (70 kDa) and 
4EBP1 (15 kDa) differ in size, and if raptor is indeed involved in their recruitment, it 
is likely that this allosteric restriction coupled with substrate competition for raptor 
binding would lead to reduced phosphorylation (as illustrated in Figure 1.6B).  
Second generation mTOR kinase inhibitors (also known as mTORKis or TORKinibs) 
bind to the mTOR kinase domain (Figure 1.6C), and are mechanistically ATP-
competitive inhibitors that provide broader selectivity by inhibiting both mTORC1 
and mTORC2 function (Xie, Wang and Proud, 2016). These types of inhibitors have 
already been shown to be more effective than rapamycin and rapalogs (Zheng and 
Jiang, 2015). One potential candidate that is currently undergoing clinical trials is the 
AZD2014 molecule (Figure 1.7B) (Liao et al., 2015). AZD2014 (3-[2,4-Bis((3S)-3-
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methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide) was 
optimised from the successful AZD8055 compound. AZD2014 is more soluble and 
less toxic (safer) for clinical use compared to its predecessor, AZD8055. The 
AZD2014 molecule has an IC50 value of 2.8 nM, making it one of the most effective 
inhibitors discovered and although it may bind to some phosphatidylinositol 3-
kinase-related kinases (PIKKs) proteins, it has been shown to be unselective 
towards a panel of 200 other tested kinases (Pike et al., 2013). AZD2014 is showing 
great promise as an anti-cancer reagent, particularly with combination therapies 
(Harada et al., 2015). Preclinical (Flannery et al., 2018), pharmacological 
characterisation (Basu et al., 2015) and xenograft models (Guichard et al., 2015) in 
mice have been performed. The exact mechanism of action of AZD2014 in a live 
human cancer cells is yet unclear and warrants further investigation as studies have 
demonstrated that AZD2014 may bind directly to the kinase domain of mTOR (Pike 
et al., 2013) while other studies have shown mTOR complex dissociation with 
AZD2014 treatment (Zheng et al., 2015).  
INK128 is another second generation pan-mTOR inhibitor (Figure 1.7C) also 
undergoing clinical trials (Tabernero et al., 2012) and has proven to be highly potent 
with an IC50 value of 1 nM (Hsieh et al., 2012). Phase 1 clinical trials have evaluated 
the drug to be safe with minimal side effects (Burris et al., 2017). This inhibitor has 
been used in preclinical models of breast cancer cell lines where greater inhibition to 
both mTOR complexes were found in comparison to rapamycin and equal effects to 
rapamycin in the mouse model. The work on INK128 demonstrates the drug to have 
great potential and we can look forward to results from future trials working against 
aggressive disease states such as leukaemia (Gökmen-Polar et al., 2012; Guo and 
Kwiatkowski, 2013; Ingels et al., 2013; Janes et al., 2013). The clinical potential 
revealed by INK128 demands a complete understanding of its mechanism of action. 
It has been reported that INK128 induces apoptosis, mTOR complex disassembly 
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and inhibits cell migration (Li et al., 2015; Calton and Vollrath, 2016; Zeng et al., 
2016). 
At the leading edge of mTOR drug discovery is the recent development of third 
generation inhibitors, designated the name RapaLink owing to its design of 
combining the rapamycin molecule with a second generation inhibitor with a long 
linker sequence. Such new inhibitors appear to be even more potent with the novel 
ability to also affect tumours that have developed resistance against second 
generation mTOR inhibitors (Rodrik-Outmezguine et al., 2016; Fan et al., 2017). 
From a pharmaceutical perspective, although the chemical optimisation of mTOR 
drugs is important, it only provides a small snapshot of a drug’s capabilities. The 
ability of a drug to localise to its target, on a subcellular level will dictate the 
effectiveness of the drug which ultimately must meet and bind to its target; an issue 
which is undervalued in the field and one with major practical challenges to observe 
in living cells.  
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Figure 1.6: Mechanism of action of mTOR inhibitors. A) Various mechanisms of actions of mTOR 
inhibitors such as rapamycin, AZD2014 and Rapalink. B) Structure of mTORC1 with bound FKBP12-
rapamycin showing restriction of entry of recruited substrates to the active site with raptor. Yellow 
triangle area shows narrow v-shaped entry to the active site of mTOR.  C) Structure of mTOR-mLST8 
with an ATP-competitive inhibitor (PP242) bound to the kinase domain. Images generated in NGL 
Viewer (Rose and Hildebrand, 2015) using the PDB codes: 5FLC and 4JT5.  
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Figure 1.7: Chemical Structures of mTOR inhibitors. The chemical structures are shown for A) 
rapamycin B) AZD2014 and C) INK128. All chemical structures were generated in MarvinSketch 
(version 15.10.19.0) 
 
1.8 Mass protein expression using the Baculovirus system 
The role of structural studies in providing insight into protein function as well as the 
means to target it through chemical inhibition has been highlighted in the previous 
sub-chapters. However, the greatest challenge in modern day structural biology is 
the generation of large amounts of pure and stable protein, particularly where multi-
protein complexes are involved. One of the most advanced methods to express 
protein in mass quantities is the baculovirus expression system (Nettleship et al., 
2010; Chambers et al., 2018). The baculovirus is a virus capable of infecting insect 
cells. The virus contains circular double-stranded DNA (80 -180 kbp) that is 
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packaged in a rod shaped capsid. One of the most popular choices of baculovirus 
for protein expression is the Autographa californica multiple nuclear polyhedrosis 
virus (AcMNPV) (Rohrmann, 2013). These viruses can be modified by replacing the 
polyhedrin gene with a gene(s) of interest. These viruses can then be used to infect 
insect cells on a large scale with the expression and production of mass quantities 
of recombinant protein (Hitchman et al., 2011). In addition, these virus particles are 
released directly into the media of the insect cells allowing for further infection and 
details of this technique are given in Chapter 2, Material and Methods. 
1.9 Principles of fluorescence  
As micromolecular and nanomolecular entities are too small to be seen by the 
naked eye, making the invisible visible, like proteins, is essential in biology. The 
phenomenon of fluorescence was thoroughly investigated in the 1840s (Herschel, 
1845) and later in 1852 by George Stokes (Stokes, 1852), building on observations 
from previous centuries, of ‘glow’ from certain types of materials and chemicals 
(Beecher, 2015). Stokes named this observation ‘fluorescence’ because the 
emission of this type of light had a longer wavelength to that of the absorption light. 
Light is considered to be a wave of energy that is composed of small packets of 
stored energy known as photons (E)  (Planck, 1900) as shown in Equation 1.1: 
 
where E is minimum energy of a photon, h is Planck’s constant and ν  is the frequency of light (speed 
of light (c)/ wavelength (λ)) 
When a fluorescent molecule absorbs a photon of light, it becomes instantly excited 
from the electronic ground state (So) to an electronic excited state (typically S1), the 
molecule seeks to return to the ground state and this can be by emitting a 
fluorescent photon. Normally this photon is at a lower energy than the original 
E= ℎ𝑣𝑣 = ℎ 𝑐𝑐
𝜆𝜆
 (1.1) 
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photon absorbed, termed red shift or Stokes shift. Fluorescence is a radiative 
process (kr). However, excited state energy can also be dissipated as heat or lost to 
quenching processes (where the electronic energy is transferred to a neighbouring 
molecule) or vibrational states emission i.e. IR spectra, these are non-radiative 
processes (knr). Although not important here, the excited state of the molecule may 
also evolve to a triple state (t1), a step where the spin of the excited state electron is 
flipped and where phosphorescence, a much longer timescale process, can occur 
(Lakowicz, 2006). These processes are summarised in the Jablonski diagram in 
Figure 1.8.  
 
Figure 1.8: Jablonski diagram. Horizontal lines show energy levels with thinner ones showing 
transitions between sub-energy levels. Ground state energy level is shown as S0 and a higher excited 
state energy level as S1. A transitional state (T1) is also shown. Straight arrows show radiative 
processes and zig-zagged arrows show non-radiative processes. Electron spins (anti-parallel or 
parallel) are also shown next to each electronic state with time-scales for each process.  
Fluorescence is a probability and time-dependent phenomenon and its intensity 
change usually follows an exponential profile in function of time. Measuring this 
change, the fluorescence decay, we can obtain the fluorescence lifetime of the 
excited state molecule. The fluorescence lifetime is a statistical distribution of the 
S0 
S1 
Absorption T1 
Internal conversion 
Intersystem crossing 
N
on
-r
ad
ia
tiv
e 
re
la
xa
tio
n 
Fl
uo
re
sc
en
ce
 (τ
) 
10
-15
 sec 
10
-12
 sec 
10
-9
 - 
10
-7
se
c 
10
-8
 sec 
50 
 
time the population of molecules spend in the excited state, following the absorption 
of a photon (Lakowicz, 2006). This fluorescence emission process usually occurs in 
the nanosecond timescale and can be defined by Equation 1.2:  
 
where lifetime (τ) is inversely proportional to the sum of radiative (kr) and non-radiative (knr) processes.  
Thus, measuring the exponential decay of the fluorescence intensity (It) over time (t) 
following a short excitation pulse, yields parameters to extract the lifetime (τ) 
(Ishikawa-Ankerhold, Ankerhold and Drummen, 2012) as shown in Equation 1.3:  
 
where fluorescence intensity (It) is proportional to the excited state population and I0 is fluorescence 
intensity at time 0, t is time and τ is the fluorescence lifetime. 
A fluorescent molecule may however interact with other molecules, undergo a 
conformational change or exhibit changes in its spectral properties depending on its 
environment which can affect the excited state lifetime (Bindels et al., 2014; Marcu, 
French and Elson, 2014). Therefore, lifetime can be used as a readout to investigate 
protein-protein interactions and also protein activity (Schoberer and Botchway, 
2014).  
1.10 Green Fluorescent Protein (GFP) technology  
The  most commonly used fluorescent “tag” (also known as a fluorophore) in protein 
biology is the Green Fluorescent Protein (GFP), a 27 kDa protein composed of 238 
amino acids that was isolated from the jellyfish Aequorea Victoria in the 1960s 
(Shimomura, Johnson and Saiga, 1962; Prendergast and Manni, 1978). This natural 
protein was found to emit green light (from its intrinsic chromophore) upon blue light 
τ = 1
𝑘𝑘𝑟𝑟+𝑘𝑘𝑛𝑛𝑟𝑟
 
τ = − 𝑡𝑡
ln�𝐼𝐼𝑡𝑡 𝐼𝐼0� �
 
(1.2) 
(1.3) 
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excitation and its gene was extracted for expressing fluorescent tagged protein 
constructs directly in living cells (Chalfie et al., 1994).  
Over the last few decades, the development of multi-spectral fluorescent proteins 
(FPs), based on mutated GFP and coral variants, have provided a toolbox for 
researchers that have allowed them to use the cell as a ‘test tube’ to observe 
multiple protein localisations, behaviours, interactions and activities (Shaner, 
Steinbach and Tsien, 2005; Dean and Palmer, 2014; Nienhaus and Nienhaus, 2014; 
Costantini et al., 2015). Using FPs in the live cell certainly is advantageous over 
conventional test-tube based approaches such as immunoprecipitation and 
subcellular localisation fractionation which involve grinding the cell and its 
components together. Often, these approaches are harsh, damaging and may result 
in false protein interactions and localisations caused by organelle-pooling and 
mixing (Salomon, Janssen and Neefjes, 2010; Suzuki et al., 2010).  
Most commonly used FPs are those that are GFP-based such as Enhanced Green 
Fluorescent Protein (EGFP) (Zhang, Gurtu and Kain, 1996), the Yellow Fluorescent 
Protein (YFP) (Rekas et al., 2002), and a Cyan Fluorescent Protein (CFP) variant, 
mTurqouise2 (Goedhart et al., 2012) as well as Red Fluorescent Proteins (RFP) that 
are Discosoma coral derived such as the monomeric DsRed (mDsRed) (Robinson 
and Marchant, 2005) and the more recent, mCherry (Bevis and Glick, 2002). The 
structures and the spectral properties of these FPs are illustrated in Figure 1.9. 
Current reviews provide details for newer generation monomeric FPs in relation to 
their quantum yields and photostability, properties that are important to live cell 
imaging of tagged proteins (Cranfill et al., 2016; Rodriguez et al., 2017; Specht, 
Braselmann and Palmer, 2017).  
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Figure 1.9: Structural and spectral properties of FPs. A) Structure of EGFP and its chromophore tri-
peptide contained within its beta barrel structure. B) Structures of cyan, yellow and red fluorescent 
proteins (mTurquoise2, YFP, mDsRed/ mCherry). Structures generated in Pymol using the PDB code: 
2Y0G. C) Excitation and emission spectra of green, cyan, yellow and red fluorescent proteins 
generated using https://www.fpbase.org/spectra.  
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1.11 Concepts of confocal and multiphoton microscopy 
As well as the use of FPs, other forms of fluorophores can also be used such as 
quantum dots, nanoparticles, inorganic ions and organic dyes (particularly from the 
Alexa Fluor and Atto family) to label proteins, antibodies, DNA, lipids and organelles 
within the cell (Specht, Braselmann and Palmer, 2017). To observe these labelled 
components, the combination of both microscopy and laser technology created a 
ground-breaking era in which researchers could probe and see the “invisible”. The 
light microscope revolution was initiated by the construction of the first fluorescence 
microscope in the 1900s by Oskar Heimstädt who employed a lamp as a source of 
excitation, see short review (Lichtman and Conchello, 2005). This model was later 
improved by Philipp Ellinger and August Hirt in the late 1920s through the invention 
of the first epi-fluorescence (wide field) microscope (Ellinger and Hirt, 1929). 
Although the instrument was promising, the low excitation power coupled with 
inefficiently bright labelling techniques at the time proved to be an obstacle. This 
design was advanced further in the late 1960s by introducing a dichroic mirror 
(Ploem, 1967), a special filter placed at a 45º degree angle to the direction of 
excitation that allowed the reflection of the excitation light but transmission of the 
Stokes-shifted emitted light from the sample to the eyepiece (Figure 1.10A).  
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Figure 1.10: Comparison between wide field and confocal microscopy. Excitation source light is 
shown in blue. Focal plane is shown by dotted black line. Sample fluorescence (in green), dichroic 
mirror and objective are also shown. (A) Wide field setup. (B) Confocal setup. Pinholes are shown by a 
slit in dark black line, lenses are shown by blue filled eclipse circles and the detector (eyepiece) is 
shown by a schematic of an eye.  
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At the same time, the development of lasers presented a step change in the 
microscopy revolution (Maiman, 1960). Lasers offered high-powered monochromatic 
light that could be focussed by a lens to a diffraction-limited single point. In 1957, 
Marvin Minsky used a carbon arc lamp source, as lasers were not yet invented 
(Minsky, 1988) and combined it with point scanning (Figure 1.11A). Although this 
was done at the time by moving the stage, modern day microscopes can achieve 
this by utilising moving mirrors known as galvo mirrors (Jonkman and Brown, 2015). 
The implementation of a pinhole (aperture) (Figure 1.10B) before the detector and 
before the excitation source not only improves the contrast of the image by blocking 
out any out of focus light from above or below the focal plane of interest, but also 
allows the optical sectioning in the z plane of the sample (Sheppard and Choudhury, 
1977; Wilson and Sheppard, 1984; Kimura and Wilson, 1991; Singh and 
Gopinathan, 1998). These 2D stacks through an object can be collated and 
reassembled to form a 3D image (Figure 1.11B). As both pinholes form conjugate 
planes, it is this modality that gives confocal microscopy its name. Laser (light) 
sources in combination with the discovery of GFP in the 1960s (Shimomura, 
Johnson and Saiga, 1962), developments in highly-sensitive detector systems and 
computer processing, have greatly improved signals from biological samples which 
can now be imaged with high resolution (Korobchevskaya et al., 2017).  
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Figure 1.11: Confocal Laser Scanning Microscopy. A) The raster scanning of a beam of light (black 
straight and dotted arrows) in the x-y direction (2D), point by point is shown where the gridded squares 
represent single pixels. A sample is shown by a glowing object. B) The light source (laser shown by a 
blue filled triangle) is depicted with beams of light (dotted blue lines) raster scanning through many z 
planes of the sample.  
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A further development to the confocal laser scanning microscope was the addition of 
multiphoton microscopy. Although the concept of multiphoton excitation was 
proposed by Maria Göppert-Mayer in 1931, it was not until the development and 
usage of ultrafast short pulsed lasers that allowed scientists to observe and utilise 
this phenomenon in microscopy. Multiphoton excitation relies on the simultaneous 
absorption of multiple photons. In the case of two-photon excitation (2-PE), two 
photons each with half the energy of a single photon, are absorbed at a single point 
in the focal plane (Ustione and Piston, 2011) as shown in Figure 1.12. In relation to 
Planck’s law seen in Equation 1.1, these low energy photons generally correspond 
to an excitation wavelength double that of a single photon wavelength. Naturally 
such a process is highly rare and the probability extremely low, the typical cross 
section (σ) (measurement for the probability of absorption) for a single photon 
absorption “pumping” a molecule into its electronic excited state is 10-18 cm2 whilst 
for two photon it is of the order of 10−50 cm4 s which equates to 1 Göppert-Mayer 
(GM) unit (Ishikawa-Ankerhold, Ankerhold and Drummen, 2012). The cross section 
for GFP is 10 GM. The innovation of ultrafast pulsed (picosecond-femtosecond, 10-
12-10-15 s) mode locked lasers provide high peak power to increase photon flux and 
density which when coupled with a high numerical aperture objective, increases the 
rate of 2-PE absorption as shown in Equation 1.4 (So et al., 2000): 
𝑁𝑁𝑎𝑎 =
𝑝𝑝02
𝜏𝜏𝑝𝑝
𝛿𝛿
𝑓𝑓𝑝𝑝
�𝑁𝑁𝑁𝑁
2
2ℎ𝑐𝑐𝜆𝜆
�
2
 
where Na is the probability of photons absorbed by 2-PE per pulse of excitation. P0 is the average laser 
power, δ is the two photon absorption cross section of the fluorophore, λ is the two-photon excitation 
wavelength, τp is pulsewidth of the laser, f is the repetition rate of the laser, NA is the numerical 
aperture of the objective, h is Planck’s constant and c is the speed of light.  
Most importantly, due to the non-linear characteristics of two-photon excitation (i.e. 
probability proportional to the square of intensity) it allows optical sectioning without 
(1.4) 
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the use of a pinhole as the density of photons are only sufficient to drive the 2-
photon process in the focal plane (Ustione and Piston, 2011). Advantages of using 
near-infrared excitation for multiphoton excitation over traditional single photon 
excitation include much lower total photo-bleaching, reduced sample photo-damage 
and cytotoxicity as well as the ability to penetrate deeper into thick biological tissues 
with reduced scattering and auto-fluorescence excitation, see Figure 1.11 (Straub et 
al., 2000; Masters and So, 2001; Tauer, 2002; Zipfel et al., 2003).  
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Figure 1.12: Comparison between one-photon and two-photon excitation. A) Shows the 
absorption of a single (e.g. 488 nm) photon to the excited state. B) Shows the simultaneous absorption 
of two-photons (e.g. 976 nm, each with half the energy of a single 488 nm photon) to the excited state. 
Schematics of one-photon versus two-photon fluorescence emission are shown.  
1.12 Introduction to Förster resonance energy transfer (FRET) and 
Fluorescence-lifetime imaging microscopy (FLIM) 
The birth of laser scanning microscopy and GFP technology has given rise to the 
growth of many quantitative techniques to study biological processes such as 
protein-protein interactions, protein activity as well as a whole array of other 
molecular interactions within living cells (Jensen, 2012). A powerful technique for 
monitoring molecule-molecule interactions is Förster Resonance Energy Transfer 
(FRET) where two molecules (e.g. proteins) are labelled with fluorophores. An initial 
excited molecule (donor) transfers its electronic energy to an adjacent second 
molecule (acceptor) (Selvin, 2000; Sekar and Periasamy, 2003), as shown in Figure 
1.13. For FRET to occur, the two molecules must be within very close proximity, 
typically within 10 nm of each other. This non-radiative energy transfer results in the 
fluorescence emission of the acceptor although this is not always the case, as some 
“dark” acceptors do not emit fluorescence (Lakowicz, 2006; Murakoshi et al., 2015). 
The loss of fluorescence emission from the donor by the acceptor is termed 
quenching. To meet the requirements of FRET, the two fluorophores must exhibit 
spectral overlap that is the emission spectrum of the donor must overlap significantly 
with the excitation spectrum of the acceptor (a condition termed resonance). As well 
as meeting the conditions of being within 10 nm of each other, their dipole-dipole 
moments must also be aligned (k2 factor) (Marcu, French and Elson, 2014). Thus, 
the FRET efficiency (shown in Equation 1.5) relates to the distance (r) of the 
fluorophores and to dipole-dipole coupling; this equation demonstrates the inverse 
6th power law: 
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𝐸𝐸𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 =
1
1+ � 𝑟𝑟𝑅𝑅0
�
6 
where EFRET is FRET efficiency, r is the distance between donor and acceptor, R0 is the distance at 
which 50% FRET occurs and the inverse 6th power law takes into account the dipole-dipole coupling.   
 
Figure 1.13: Principle of FRET. A) and B) Energy level diagrams showing when the conditions of 
FRET are met for both donor and acceptor molecules. The ground state (S0) and the first excited 
electronic state (S1) are shown by horizontal black lines. The process of FRET is shown by a zig-
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zagged arrow in grey. C) Simplified cartoon schematic showing the energy transfer process between 
the donor (e.g. protein A labelled with EGFP) and the acceptor (e.g. protein B labelled with mCherry). 
FPs are widely used as fluorophores for FRET experiments ranging from green-red 
FRET pairs such as the EGFP-mCherry combination to that of blue-yellow FRET-
pairs as mTurquoise2-YFP which offer larger dynamic quenching due to greater 
spectral overlap (Bajar et al., 2016; Martin et al., 2018). Dyes such as those from the 
Alexa family can also be used as fluorophores (Berney and Danuser, 2003). 
However the advantage of using FPs is that molecules can be tagged, expressed 
and monitored in living cells. Although FRET may appear to be a simple approach, it 
relies on measuring accurately the intensity of the fluorescence and therefore taking 
measurements requires spectrally resolving the wavelengths of fluorescence of the 
donor (unquenched) and the acceptor, as well as other background signals and 
detector thresholds. Furthermore, effects from photo-bleaching whereby a 
fluorophore no longer fluoresces through photochemical modification over the 
illumination time makes interpretation of the FRET results challenging and open to 
misinterpretation (Piston and Kremers, 2007).  
A much more robust way of performing FRET experiments is to use the time domain 
to measure the fluorescence intensity. Simply, this compares the natural 
fluorescence lifetime (τ) of the donor to the change in excited lifetime when 
quenched in the presence of the acceptor.  Thus, FRET results in the shortening of 
the lifetime of the donor and hence observing molecule-molecule interactions is not 
purely dependent on fluorescence intensity (Sauer, Hofkens and Enderlein, 2011). 
The FRET efficiency is given by (Equation 1.6):  
𝐸𝐸𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 = 1 −
𝜏𝜏𝐷𝐷𝐷𝐷
𝜏𝜏𝐷𝐷
 
where FRET efficiency (EFRET) is related to the lifetimes of the donor with the acceptor (τDA) 
and the donor without the acceptor (τD).  
(1.6) 
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Imaging the lifetime of a fluorophore is known as Fluorescence Lifetime Imaging 
Microscopy (FLIM) (Becker, A Bergmann, et al., 2004; Stubbs et al., 2005; Becker, 
2012; Yadav et al., 2013; Suhling et al., 2015; Meyer-Almes, 2017). FLIM was 
pioneered in the late 20th century and gradually improved by others (Gerritsen et al., 
2002), eventually leading to the FLIM of cells, labelled organelles and proteins 
(Periasamy et al., 1996; Peter et al., 2005; Stubbs et al., 2005; Llères, Swift and 
Lamond, 2007; Becker, 2012). Today, FLIM is a versatile tool and can be combined 
with multiphoton microscopy to provide a powerful instrument for live cell imaging. 
FLIM can be performed in two ways: time domain, and frequency domain. Briefly, 
the frequency domain method uses a pulsed (modulated) excitation source and 
using homodyne detection methods, to measure the way the phase in the 
fluorescence emission intensity varies in relation to the modulated excitation. This 
results in a frequency-domain FLIM signal from which fluorescence lifetimes can be 
extracted (Verveer and Hanley, 2009). Time-domain FLIM can be performed in two 
ways, either using time-gating where the fluorescence is measured at various times 
according to the excitation pulse using fast-gated image intensifiers (Scully et al., 
1996) or using Time-Correlated Single Photon Counting (TCSPC) (Becker, Axel 
Bergmann, et al., 2004). The FLIM and time-resolved fluorescence data reported in 
this thesis has used TCSPC which delivers higher temporal resolution with photon 
efficient detection and minimal noise (Marcu, French and Elson, 2014) and details of 
this technique are given in Chapter 2, Material and Methods. Briefly, for TCSPC 
the sample is point-scanned with a high repetition rate pulsed laser. The time of 
single fluorescent photons reaching the detector with respect to the excitation pulse 
is measured using a photon-counting detector at each X,Y point producing a FLIM 
image where each pixel can be analysed to obtain its own fluorescence decay 
profile and thus its lifetime (Becker et al., 2004; Stubbs et al., 2005) as summarised 
in Figure 1.14. 
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Figure 1.14: Overview of time domain FLIM using TCSPC. 1) An ultrafast pulsed laser is used to 
excite a cell expressing GFP (shown in green where each box represents a pixel). 2) Fluorescent 
photons (hv) emitted from the sample are collected at the detector and their relative arrival times with 
respect to the excitation pulses of the laser are measured using the TCSPC module. 3) A histogram of 
photon arrival times is built which is convolved with the IRF (measurement of the sensitivity of the 
instrument). 4) A final decay profile (shown in red) is produced for each pixel.  
Software fits the decay to a model function such as a mono-exponential one which 
can be used for GFP analysis. Parameters such as lifetime (τ) and the chi-square 
(x2) of the fit (a determination for the ‘goodness’ of the fit) can be obtained for each 
pixel (Becker et al., 2004). Ultimately, the software generates a pseudo-coloured 
FLIM image where the colour of each pixel represents a lifetime value (Figure 1.15). 
Thus, the combination of FLIM with FRET allows for the accurate determination of 
the dynamics of molecular species and mapping their sub-cellular interactions within 
living cells at diffraction limited resolution  (Peter et al., 2005; Wallrabe and 
Periasamy, 2005; Llères, Swift and Lamond, 2007; Laptenok et al., 2010; Sun, Day 
and Periasamy, 2011; Schoberer and Botchway, 2014). If the donor lifetime is 
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quenched in the presence of an acceptor, its lifetime will shorten and this will relate 
to a different colour in those pixels (Figure 1.15B). This change in lifetime is 
indicative of a direct and physical interaction, making FRET-FLIM most suited for 
studying cancer signalling pathways such as the mTOR pathway where protein-
protein interactions are a vital constituent for understanding biological functions 
(Yadav et al., 2013).  
 
Figure 1.15: Use of FRET-FLIM to determine protein-protein interactions. A) Protein A tagged with 
a donor is shown with a corresponding FLIM image where each pixel is artificially coloured with its 
respective lifetime value. The average lifetime distribution of all pixels is also shown in a histogram. B) 
Protein A tagged with a chromophore (donor) and Protein B tagged with another chromophore 
(acceptor) are shown when the conditions of FRET are met. A shortening of the donor lifetime is shown 
in the FLIM image where a change in colour of pixels indicates a different (shortened) lifetime value.  
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1.13 Molecular Structure and Conformation Studies Using FRET 
FRET can also be used to measure protein activity by following the way its structure 
changes as it performs its biological role (Hochreiter, Garcia and Schmid, 2015). 
FRET sensors provide the ability to study how protein conformation is related to 
function and quantitatively enables the determination of receptor, ion, metal, 
membrane and post-modification activity within living cells (Lindenburg and Merkx, 
2014). Currently, bio-FRET sensors are routinely used in most laboratories and a 
rapidly growing area of focus is their use to determine phosphorylation (kinase 
activity) (Demeautis et al., 2017; Komatsu et al., 2018). There are various ways to 
construct a FRET sensor to determine phosphorylation but the two most common 
methods are shown in Figure 1.16, where partial sequences of proteins (typically a 
ligand domain containing a short region of the substrate phospho-domain and a 
sensor domain usually containing the kinase domain of the effector are linked 
together) are used with a FP attached to either end of the construct (Komatsu et al., 
2011). Alternatively, the full length protein of interest can be tagged with a FP to 
each end (Zhou et al., 2015; Bertolin et al., 2016). The structural changes of the 
protein upon phosphorylation brings the FRET donor and acceptor pair into or out of 
contact and the change in lifetime this provides can be monitored with FRET-FLIM, 
allowing for the direct and precise determination of when and where the 
phosphorylation is occurring within the live cell.  
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Figure 1.16: Kinase FRET sensor mechanisms. A) A ligand domain (phospho-peptide of substrate) 
in orange linked by a long linker region (black line) to a sensor domain (kinase domain of kinase 
protein of interest) in green with a FP on either side is shown. This construct is shown in both open and 
closed conformations which are related to FRET efficiency. However, this form of sensor may not be 
reversible and therefore may only provide a single snapshot of activity. B) Kinase protein shown in grey 
tagging on either end of its termini with a FP is shown. Changes in conformation of the protein can be 
related to phosphorylation (FRET) activity.  
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1.14 Review on imaging mTORC1 in live cells  
Despite over 23,000 (Pubmed, 2018) published articles on mTOR to date, only a 
small handful of publications have investigated mTOR in living mammalian cells. 
Various subunit proteins of the mTORC1 have been labelled with FPs and their sub-
cellular localisations studied and determined (Table 1.1). Taken together, a common 
localisation feature of all these proteins is the cytoplasm, alluding to the likelihood 
that the mTORC1 may assemble in the cytoplasm. The localisation of S6K1 
however remains unknown.  
Table 1.1: Summary of live localisations of FP labelled mTORC1 subunit proteins  
Protein  Label Localisation Reference 
mTOR EGFP 
YFP and Venus 
HaloTag 
Mostly 
cytoplasmic with 
some nuclear  
(Liu and Zheng, 
2007; Qian et al., 
2010; Mori et al., 
2013; Yadav et 
al., 2013) 
raptor mDsRed 
GFP 
Cerulean 
Cytoplasmic  
Lysosomes 
(Qian et al., 2010; 
Yadav et al., 
2013; Martin et 
al., 2014; 
Manifava et al., 
2016) 
Rheb EGFP 
mDsRed 
mCherry 
CFP 
YFP 
Cytoplasmic with 
strong ER, Golgi 
and perinuclear. 
Some nuclear  
(Takahashi et al., 
2005; Buerger, 
DeVries and 
Stambolic, 2006; 
Li et al., 2007; 
Zhou et al., 2009; 
Hanker et al., 
2010; Ismail et 
al., 2011; Yadav 
et al., 2013) 
4EBP1 CFF  
YPet- Cerulean  
 
Equally 
cytoplasmic and 
nuclear 
(Rong et al., 
2008; Zhou et al., 
2015) 
 
It is important to stress that co-localisation of proteins does not necessarily signify a 
direct physical interaction, thus it is necessary to investigate mTORC1 sub-cellular 
interactions. FRET-FLIM, however does strongly suggest interactions. FRET has 
been employed to study mTORC1 interactions and activity in living cells. One of the 
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first studies to determine mTOR and raptor interactions used steady-state FRET 
(Qian et al., 2010), this was later improved by using FRET-FLIM (Yadav et al., 
2013). The latter study was the first to determine direct interactions between Rheb 
and mTOR in the live cell. In particular, significant presence of both mTOR and 
Rheb were found in the nucleus as well as large punctate structures upon amino 
acid and serum starvation with EGFP-mTOR. Although the identities of these 
punctate structures were not defined, the importance of mTORC1 in the nucleus 
was highlighted because the involvement of nuclear mTOR signalling is generally 
overlooked. In addition, mTOR has also been investigated directly by tagging 
4EBP1 with various FPs using a FRET sensor and has been found to be active in 
the cytoplasm, lysosome, nucleus and at the plasma membrane (Zhou et al., 2015). 
This raises the question whether mTOR activity (i.e. 4EBP1 phosphorylation) is 
more active in some areas of the cell and lower in other sub-cellular structures. 
However, as rapamycin and rapalogues partly inhibit 4EBP1 phosphorylation, these 
findings on mTOR activity suggest a better downstream target of the pathway is 
needed for accurately monitoring mTORC1 in living cells.  
Real-time imaging of endogenously labelled raptor with GFP has led to the 
discovery of the recruitment of mTORC1 onto lysosomes within a few minutes after 
amino acid starvation in living cells (Manifava et al., 2016; Lawrence et al., 2018). 
Upon replenishing the amino acids, these lysosome structures of raptor-GFP 
disappeared and soon returned to a homogenous expression in the cytoplasm. It 
was also identified through western blotting that following replenishment of the 
amino acids, the phospho-S6K1 expression remained elevated after mTORC1 
detachment from the lysosomes. Further live-cell work has shown similar results 
with GFP-tagged Rags and mutant Rags to increase lysosomal recruitment and 
substrate phosphorylation (Lawrence et al., 2018). This could provide insight into the 
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mechanism of Rheb (see section 1.5) which tethers mTORC1 to the lysosomal 
membrane and activates the mTOR kinase protein (Hao et al., 2018).  
Directly observing the localisation of the remaining components of the mTORC1 
pathway, namely S6K1 and PRAS40, as well as their interactions within the complex 
offers a new and unexplored avenue in the less studied live-cell mTOR world. 
Although much attention has been given to the upstream part of the complex, little is 
known regarding the downstream substrate interactions with the mTOR complex.  
Investigating the localisation, interaction and phosphorylation of the S6K1 substrate 
with regards to mTORC1 is therefore explored in this research and provides new 
advancement to the study of mTOR drug interactions using FRET-FLIM. It is hoped 
that these studies will provide a better understanding of the mechanism of mTOR 
activation in a cellular context, ultimately leading to the design and development of 
novel treatments against mTOR-related disease states for future clinical work.  
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1.15 Aim and development   
This research project forms an integral part of the program aimed at studying the 
mechanism of mTORC1 both biochemically and structurally. The research in this 
work is composed of three parts. The first investigates the subcellular localisation of 
S6K1, its recruitment onto mTORC1 as well as its direct interactions with it and the 
localisation of its phosphorylated form within living cells. To date, current work has 
failed to provide conclusive evidence regarding such matters. The second explores 
the use of both single-photon and multi-photon microscopy in exciting naturally 
fluorescent pan-mTOR inhibitors (second generation) to observe both their sub-
cellular localisation and their mechanism of action with respect to other mTORC1 
subunit proteins. The final part of this project deals with the structural biology 
aspect, where attempts to express and purify mTORC1 proteins and a FRET bio-
sensor (SensOR) in large quantities are carried out using a baculovirus expression 
system in insect cells. It is hoped that the latter in vitro work compliments the in vivo 
studies and gives further insight into the workings of the mTORC1 signalling 
pathway for effective strategies to prevent and treat mTOR disease states.  
Firstly, it is proposed that fluorescently tagged S6K1 constructs be generated by 
cloning and splicing the full length cDNA S6K1 sequence into GFP vectors (mTurq2, 
mCherry and EGFP based) using in-fusion cloning. These constructs will be 
expressed in mammalian cells (HEK293, HeLa and U2OS) by means of chemical 
transfection and then imaged using confocal microscopy. The subcellular 
localisation of S6K1 in living cells is still unknown to-date. Using the results obtained 
from identifying the sub-cellular localisation of GFP-tagged S6K1 in living cells, the 
interaction of S6K1 with mTOR and other mTORC1 subunit proteins that localise 
within the same localisation site will be investigated using advanced FRET-FLIM 
imaging and pull-down assays. Although S6K1 is known to interact with raptor, its 
interaction with mTOR is uncertain and its interaction with Rheb is unknown. In 
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addition, the regulation of ectopically-expressed S6K1 with co-expressed mTORC1 
subunit proteins (particularly Rheb and raptor) will be explored by Western blot 
analysis especially since raptor’s role in regulating S6K1 appears to be an ongoing 
debate in the literature. Other fluorescently-labelled binding partners of raptor such 
as 4EBP1 and PRAS40 will also be co-expressed with S6K1 to investigate any 
substrate competition using three colour confocal imaging. Collectively, these 
findings will provide information regarding both the assembly of the S6K1 onto the 
mTORC1 and sub-cellular sites for expected mTOR activity. Ultimately, from this, 
the localisation of phosphorylated S6K1 will be examined using 
immunofluorescence labelling of fixed cells as well as developing a novel live cell 
approach using a S6K1 phosphorylation FRET-biosensor with FRET-FLIM 
technology.  
Secondly, once the localisation of phosphorylated-S6K1, hence mTOR activity, has 
been identified, this information will then be used to investigate the sub-cellular 
target sites of second generation mTOR inhibitors, namely AZD2014 and INK128. 
Although the efficacy of mTOR drugs has been well-studied in the field, their 
localisation within the cellular system has not been explored. The absorption 
spectra, fluorescence emission spectra and fluorescence lifetimes of AZD2014 and 
INK128 in various solvents such as DMSO and PBS will be characterised and used 
as bench marks for predicting cellular environmental stability. These findings will be 
taken forward to in vivo work where cellular uptake and subcellular localisation of 
AZD2014 and INK128 using one-photon and two-photon confocal microscopy will be 
determined with direct excitation wavelength in various mammalian cell lines such 
as HEK293, CHO and MCF7. The exact mechanism of action of AZD2014 will also 
be explored by determining its binding with GFP-tagged mTORC1 subunit proteins 
using FRET-FLIM. AZD2014 has shown selectivity to other kinases during screening 
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and thus although not known, its interaction with the S6K1 kinase appears to be a 
likely candidate.  
Thirdly, it is intended that new S6K1 FRET bio-sensor and mTORC1 subunit 
constructs suitable for insect cell expression will be made. The baculovirus 
expression system will be used for large-scale production and purification of these 
proteins for both in vitro studies and future cryo-EM or X-ray crystallography for 
identifying atomically-resolved interactions. It is expected that the data obtained 
from this programme will further develop mTORC1 signalling interactions and 
assembly, eventually leading to novel treatments where targeting these interactions 
provides better therapy.   
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2.0 Materials and methods 
 
2.1 Materials 
All chemicals and reagents in this work were purchased and used without further 
treatment or purification.  
2.1.1 Chemicals 
General laboratory reagents were purchased from Sigma-Aldrich (UK) and Millipore 
(UK), currently under Merck (UK) or from Fisher Scientific, Invitrogen, Gibco and Life 
Technologies, currently under Thermofisher Scientific (UK). Other chemical 
reagents and kits (all chemicals included) were obtained from Qiagen (UK), 
Machinery-Nagel (U.S.A.) and Agilent (UK) unless otherwise stated. Inhibitors were 
purchased from MedChem Express (Europe). Purified GFP was a kind gift from Dr 
Cameron Naylon. 
2.1.2 Primers 
All DNA primers were purchased from Integrated DNA Technologies (IDT) (UK) at a 
25 nmole (0.27 mg) DNA oligo concentration with standard desalting to remove any 
impurities. All primers were designed with a Tm close to 60ºC, although this varied 
slightly depending on the GC content. Gene-specific primers with 15 bp extension 
homologous to vector ends were designed for In-Fusion™ cloning (Nettleship et al., 
2010) using an automated primer design tool: https://www.oppf.rc-
harwell.ac.uk/Opiner/ or for fusing two inserts together using SnapGene® software 
(from GSL Biotech; available at snapgene.com). Primers for mutant constructs were 
designed using the automated primer design tool: 
https://www.genomics.agilent.com/primerDesignProgram. Primer stocks of 100 µM 
were made by re-suspending lyophilised primers with nuclease-free water (Sigma-
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Aldrich). Stocks were then diluted 1:10 to make working stocks of 10 µM and stored 
at -20ºC.  
2.1.3 DNA plasmids and vectors 
S6K1-GFPSpark HG10099-ACG, Sino Biological (China) 
HA-mCherry-raptor Plasmid #73386, Addgene 
mDsRed-raptor Yadav et al.  2013 
EGFP-Rheb Yadav et al.  2013 
mDsRed-Rheb Yadav et al.  2013 
EGFP-mTOR1 Yadav et al.  2013 
FLAG-mTOR Plasmid #26603, Addgene 
4EBP1-GFPSpark HG10022-ACG, Sino Biological (China) 
HA-YFP-PRAS40 Plasmid #73389, Addgene 
mCherry-FKBP12 Plasmid #67900, Addgene 
YFP-mTOR Plasmid #73384, Addgene 
YFP-Rheb Gift from Dr. Kun-Liang Guan2 
CFP-Rheb Gift from Prof Won Do Heo3 
EGFP-raptor Gift from Prof. Jacek Jaworski4 
pOPINE-3C-EGFP Plasmid #41125, Addgene 
pOPINE-3C-mCherry PP-UK 
pOPINE-3C-mTurquoise2 PP-UK 
pOPINE-3C-YFP PP-UK 
pOPINN-EGFP Plasmid #53541, Addgene 
pOPINEneo-3C-2STREPStop PP-UK 
pBAC4x-1 Merck 
AcMNPV-DsRed Gift from Arnold Poterszman 
1 mTOR sequence contains additional glycine amino acid after methionine (ATG) start codon 
2 Zhou X et al. PNAS. 2009;106(22):8923-8
3 Yeung T et al. Science. 2008;319(5860):210-3 
4 Urbanska M et al. J Biol Chem. 2012;287(36):30240-56
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2.1.4 Cell lines 
Human Embryonic Kidney Cells (HEK293) and HeLa (cervical) cells were purchased 
from ATCC (U.S.A), certified as mycoplasma (contamination) free. Michigan Cancer 
Foundation-7 (MCF-7) breast cancer and epidermoid carcinoma A431 cells were 
available from the Octopus (Research Complex, UK) cell line bank. Human Bone 
Osteosarcoma Epithelial U20S cells and a clonal isolate of Spodoptera frugiperda 
(Sf), the Sf9 insect cell line were obtained from PP-UK (Research Complex, UK). 
HEK293F cells and the Sf21 insect cell line were provided by Evotec (UK) Ltd. 
Competent Escherichia coli (E. coli) cells: XL10-Gold® ultracompetent cells were 
bought from Agilent (UK), One Shot™ OmniMAX™ Chemically competent were 
bought from Invitrogen™ (UK) and Stellar electrocompetent cells from Takara Bio 
(Europe).  
2.1.5 Cell culture reagents 
All cell culture reagents were from Thermofisher Scientific (GibcoTM). 
2.1.6 Antibiotics 
Carbenicillin (CB) 50 mg/ml Sigma-Aldrich (UK) 
Kanamycin (Kan) 35 mg/ml Sigma-Aldrich (UK) 
2.1.7 Antibodies  
Anti-Phospho-S6K1 
(T389/T412) 
St John’s Laboratory (UK) STJ91045 
Anti-Phospho-S6K1 Cell Signalling (UK) #9234 
Anti-Phospho-S6K1 Thermofisher Scientific (UK) PA1-526 
Anti-S6K1 St John’s Laboratory (UK) STJ31332 
Anti-Phospho-RPS6 Cell Signalling (UK) #2211 
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(Ser235/236) (rabbit) 
Anti-Rheb antibody (goat) Santacruz Biotechnology 
(UK) 
sc-6341 
Anti-Vinculin (mouse) Millipore (UK) MAB3574 
Anti-His (mouse) Qiagen (UK) 34660 
Anti-FLAG (mouse) Sigma-Aldrich (UK) F1804 
Anti-mTOR (rabbit) Cell Signalling (UK) #2983 
Anti-myc (mouse) Thermofisher Scientific (UK) MA1-980 
Anti-raptor (rabbit) Cell Signalling (UK) #2280 
Anti-rabbit Alexa Fluor 
405/ 488/ 555 
Abcam (UK) ab175649/ ab150073/ 
ab150074 
Anti-mouse Cy3 Jackson Immunochemicals 
(Europe) 
715-165-151 
Ant-rabbit Cy5 Chemicon International 
(U.S.A.) 
AP187S 
Anti-rabbit HRP Cell Signalling (UK) #7074 
Anti-mouse AP Promega (UK) S372B 
Anti-rabbit AP Promega (UK) S3731 
Anti-goat AP Abcam (UK) ab6742-1 
2.2 Methods 
2.2.1 Amplification of cDNA by polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) reactions were setup in 0.2 ml PCR tubes or in an 
8-strip PCR tube (Star Lab) on ice containing both forward (Fwd) and reverse (Rev) 
primers at a 10 µM working concentration, Phusion Flash High-Fidelity PCR Master 
Mix (Thermofisher Scientific), template plasmid DNA (100-200 ng) containing cDNA 
gene to be amplified and sterile water as shown in Table 2.1. The constituents were 
gently mixed by pipetting up and down. 
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Table 2.1: PCR reaction mixture for cDNA amplification  
 Amount for one reaction  
Phusion Flash Master Mix (2X) 25 µl 
Forward primer (10 µM) 
Reverse primer (10 µM) 
1.5 µl  
1.5 µl 
Template DNA plasmid 1 µl 
Sterile water 21 µl 
Total volume 50 µl 
 
The PCR tubes were loaded into a VeritiTM 96 well Thermal Cycler (Thermofisher 
Scientific) and the thermal cycles listed in Table 2.2 were used. 
Table 2.2: Parameters of thermal cycles used for PCR 
Step Temperature  Time Cycle 
Initial 
Denaturation 
98ºC 10 seconds 1 
Denaturation 
Annealing 
Extension 
98ºC 
60ºC 
72ºC 
1 second 
5 seconds 
 
15 sec/kbp 
29 
Final Extension 72ºC 2 minutes 1 
Hold 4ºC Hold  
 
2.2.2 Agarose gel electrophoresis of PCR products 
Upon completion of the PCR reaction, 10 µl of filtered DNA loading buffer (0.25% 
w/v bromophenol in 30% v/v glycerol) was added to each PCR tube and mixed 
gently by pipetting up and down. A volume of 40 µl of the PCR-dye mix was then 
loaded into a pre-cast 1.0% agarose/ Tris-borate-EDTA (TBE) gel, commonly used 
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for DNA gel electrophoresis, containing SYBRSafe stain (Thermofisher) as listed in 
Table 2.3. Adjacent to the samples, 5 µl of HyperladderTM 1 kb (BioLine) was loaded 
and run in a 10 x 8 gel tank (MiniRapide) filled with TBE for 120 minutes at 70 Volts 
using a Power Pac 300 (Bio-Rad) power supply until the markers were separated 
sufficiently. After marker bands were separated, the gel was viewed with a blue light 
illuminator (Jencons-PLS) to both visualise and verify PCR bands at their respected 
correct base pair lengths.  
Table 2.3: Composition of 1.0% TBE agarose gel 
Composition Amount 
Agarose (Sigma-Aldrich) 0.5 g 
TBE (1X) (Sigma-Aldrich) 50 ml 
SYBRSafe (Thermofisher Scientific) 5 µl 
 
2.2.3 DNA PCR product extraction from agarose and clean up 
PCR DNA bands of correct base pair lengths were excised out of the agarose gel 
using a sterile surgical scalpel (Swann-Morton) whilst under blue light illumination 
and placed into a 1.5 ml microcentrifuge tube (Eppendorf). A microbalance (Mettler 
Toledo) was used to determine the weight of the excised band by blanking with an 
empty microcentrifuge tube. In order to purify the DNA, the agarose gel DNA 
extraction and PCR clean-up kit (Machinery-Nagel), contents of kit given in 
Appendix A.1, was used. For every 100 mg of agarose gel, 200 µl of NTI buffer 
was added to the tube and incubated at 50ºC on a heating block (Grant Instruments) 
for 15-20 minutes with regular mixing every 3 minutes using a vortex (Scientific 
Industries) until the agarose had completely dissolved. Following complete 
dissolution, a 700 µl aliquot was loaded into a NucleoSpin® Gel and PCR Clean-up 
column with a 2 ml collection tube and centrifuged for 30 seconds at 11, 000 x g in a 
microcentrifuge (Beckman Coulter). The flow-through was discarded from the 
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bottom of the collection tube. Any remaining sample was loaded and the 
centrifugation step was repeated. Next, 700 µl of NT3 buffer was added to the 
column, and the centrifugation step repeated with the removal of the flow-through 
after centrifugation. To completely remove any excess buffer the column was 
centrifuged for an additional 1 minute followed by incubation at 70ºC for 5 minutes. 
Finally, the column was placed into a new microcentrifuge tube and incubated with 
12 µl of NE buffer (elution buffer) for 1 minute at room temperature before 
undergoing a final centrifugation. The eluted sample was either used immediately or 
stored at -20ºC until further use.  
2.2.4 Cutting of pOPIN vectors using restriction digestion 
Cut pOPIN vectors were generated by using appropriate restriction enzymes and 
buffers. The appropriate buffer (New England Biolabs) required for double digest 
using a combination of restriction enzymes (New England Biolabs) was selected by 
using the NEBcloner v1.3.4 tool (nebcloner.neb.com/#!/redigest). All pOPINE-3C-
based vectors were cut using PmeI and NcoI restriction enzymes whilst the pOPINN 
based vector was cut using Kpn1 and HindIII. The reaction components listed in 
Table 2.4 were made in a 1.5 ml microcentrifuge tube.  
Table 2.4: Double restriction enzyme digest of uncut vector 
Components Amount for single reaction 
Uncut vector 10 µl 
Restriction enzyme 1 
Restriction enzyme 2 
2.5 µl 
2.5 µl 
Enzyme buffer 1 µl 
BSA 1 µl 
Sterile water 83 µl 
Total volume 100 µl  
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The mixture made from the list in Table 2.4 was incubated for 1 hour on a heating 
block set at 37ºC. Following digestion, cut vector was purified using a NucleoSpin® 
Gel and PCR Clean-up column and the remaining PCR clean-up protocol from after 
sample loading in section 2.2.3 was followed. The cut-vector product was eluted in 
50 µl of elution buffer (Qiagen) into a new clean 1.5 ml microcentrifuge tube. The 
eluted sample was either used immediately or stored at -20ºC for up 24 hours. 
2.2.5 In-Fusion reaction with pOPIN vectors 
Cloning of the PCR products with cut linearised pOPIN vectors were performed 
using a Quick-Fusion cloning kit (Biotool), contents of full kit given in Appendix A.2. 
For a two-way fusion cloning reaction involving one PCR DNA insert and vector, the 
composition in Table 2.5 was made in PCR tubes and mixed gently by pipetting 
action. For a three-way fusion cloning reaction involving two PCR DNA inserts and 
vector, 2 µl of each insert with 2 µl of vector was added and the final volume 
adjusted to 10 µl with sterile water.  
Table 2.5: In-Fusion reaction for a two-way fusion 
Components  Amount for one reaction 
Linearised vector (20-100 ng) 1 µl 
PCR product insert (10-100 ng) 2 µl 
Fusion enzyme  1 µl 
5 x Fusion buffer 2 µl 
Sterile water 4 µl 
Total 10 µl 
 
The in-fusion reaction was run for 30 minutes at a 37ºC step using a VeritiTM 96 well 
Thermal Cycler. Immediately afterwards, the PCR tubes were placed on ice and the 
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reaction stopped with 40 µl of TE buffer (Invitrogen). Fused product was either used 
immediately for cell transformation or stored at -20ºC until further use.  
2.2.6 Transformation using cloning-grade Escherichia coli (E. coli) 
Pre-prepared 50 µl aliquots of competent StellarTM (Takara) or One Shot™ 
OmniMAX™ (Invitogen) E. coli cells were thawed on ice for 15 minutes directly from 
-80ºC. A volume of 2-5 µl of plasmid DNA was pipetted into one aliquot tube of 
competent bacterial cells and mixed gently by pipetting action. Bacterial cells were 
left on ice for 30 minutes followed by heat-shock for 30 seconds at 42ºC by placing 
the tube into a tube holder in a water bath (Grant Instruments). Cells were returned 
to the ice and 400 µl of room-temperature S.O.C (Invitogen) medium was added per 
tube and mixed by pipetting action. Tubes were transferred to an incubator (Binder) 
set at 37ºC for 60 minutes if the antibiotic selection gene in the plasmid contained 
ampicillin or for 90 minutes if the plasmid contained kanamycin. Carbenicillin 
belongs to the penicillin family and therefore can be used as a substitute for 
ampicillin (Bird et al., 2015). During the final 30 minutes of the incubation period, 
warm Luria Broth (LB) agar was supplemented with the mixture listed in Table 2.6 
into a new 50 ml falcon tube for newly in-fused plasmid inside a Class II biological 
safety cabinet (Nuaire) to prevent airborne contamination. For amplification of 
already validated plasmid, only antibiotic was added to LB agar. Details regarding 
making LB agar are given in the Appendix A.3.  
Table 2.6: Making of Luria Broth (LB) Agar plates 
Components  Amount for one plate 
LB agar (warm) 25 ml 
CB or Kan antibiotic 1:1000 dilution 
20% X-gal in DMF (Sigma-Aldrich) 1:1000 dilution 
IPTG (1 M) (Sigma-Aldrich) 1:1000 dilution 
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The warm LB agar mixture, prepared as Table 2.6, was gently mixed by inverting 
the closed falcon tube several times and its contents poured into a sterile 150 mm x 
15 mm petri dish (Thermofisher Scientific) and left to set for 30 minutes inside the 
safety cabinet. After the mixture had set, coinciding with the completion of the 
incubation time of the transformed bacteria, 100 µl of the bacteria were plated by 
spreading the cells using a spreader (VWR) in a smooth continuous circular path 
from one concentrated starting point and allowed to dry for up to 15 minutes before 
turning over. Plated cells were incubated overnight at 37ºC in the incubator.  
2.2.7 Colony selection and starting culture  
For in-fused plasmid that has not been verified by sequencing, the formation of 
negative blue colonies (<10%) indicated re-circulation of linearised parental vector 
whilst formation of white colonies (>90%) indicated successful recombination of the 
DNA into the vector. Several single colonies were picked seperately using an 
inoculation loop and mixed directly into separate 50 ml falcon tubes containing the 
volume of LB listed in Table 2.7 with a 1/1000 dilution of the appropriate antibiotic in 
a biological safety cabinet to reduce airborne contamination of cultures. For verified 
plasmid, only white colonies were formed and a single colony was picked. Tubes 
were left at 37ºC overnight in a shaker (Innova) set at 210-225 RPM. Details 
regarding making Luria Broth (LB) is described in Appendix A.4.  
Table 2.7: Volume of LB used for each prep 
Prep Starting culture volume per prep 
Miniprep 5-10 ml 
Maxiprep 100-130 ml 
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2.2.8 Transformed bacterial glycerol stock preparation 
Glycerol stocks of starting cultures were prepared by transferring 100 µl of culture 
into a microcentrifuge tube containing 100 µl of filter-sterilised LB-glycerol (30%) 
using a 0.2 μm pore size filter, see the Appendix A.5. The tubes were sealed with 
Parafilm M and stored at -80ºC for long term storage.  
2.2.9 Miniprep of plasmid DNA 
The QIAprep Spin Miniprep kit (contents given in Appendix A.6) was used to purify 
DNA from the small starting cultures. 2 ml of starting bacterial culture per purification 
was spun down in a 2 ml microcentrifuge tube (Eppedorf) at 6800 x g for 3 minutes 
at room temperature. The supernatant was discarded and the pellet was re-
suspended in 250 µl of cold P1 buffer with added LyseBlue (1:1000) and RNase A 
solution (see Appendix A.6). A volume of 250 µl P2 buffer (lysis) was added and 
the tubes mixed several times by inversion until the solution turned blue. The 
bacteria were lysed for 5 minutes at room temperature and 350 µl of N3 buffer was 
immediately added to neutralise the lysis, followed by inversion of the tube several 
times until the solution turned colourless. The reacted tube was centrifuged for 10 
minutes at 17,900 x g in a table-top microcentrifuge at room temperature. The 
supernatant (800 µl) was added to a QIAprep 2.0 spin column with a collection tube 
attached and centrifuged for 30 seconds. The flow-through was discarded and 500 
µl of PB buffer was added to the column followed by another centrifugation and 
removal of the flow-through. The spin column was washed with 750 µl of PE buffer 
(with added ethanol) and centrifuged for 30 seconds. Following the removal of the 
flow-through, the column was centrifuged for a further 1 minute to remove any 
residual buffer. The column was placed in a new 1.5 microcentrifuge tube and 
incubated with 25 µl of EB buffer for 1 minute before a final minute centrifugation 
step to elute the DNA. The concentration of eluted DNA was determined using a 
NanoDropTM 800 Spectrophotometer that provided DNA concentrations (ng/µl) as 
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well as purity of the DNA indicated by the 260/280 nm ratio. A ratio of 1.8 is the 
accepted value for a pure quality of DNA whilst lower values indicate impurities or 
contaminations such as remaining guanidine, phenol or other chemicals from the 
purification kit.  
2.2.10 DNA plasmid construct verification by PCR screening 
PCR reactions were setup in dedicated PCR tubes or in an 8-strip PCR tube (see 
section 2.2.1) on ice with the following components where a working concentration 
of pOPIN forward primer or NeoRev2 reverse primer (see Appendix A.7) was used 
with the appropriate gene specific reverse primer, the in-fused DNA plasmid and 
Phusion Flash (Table 2.8). As the volume of primers required is small, a mastermix 
containing 10X the volume of primers and Phusion Flash was prepared and used to 
minimise any errors associated with pipetting smaller volumes. 
Table 2.8: PCR reaction for screening in-fused clones 
 For one reaction  
Phusion Flash Master Mix (2X) 12.5 µl 
Forward primer (10 µM) 
Reverse primer (10 µM) 
0.1 µl  
0.1 µl 
Template DNA plasmid (100 ng) 1 µl 
Sterile water 11.3 µl 
Total volume 25 µl 
 
DNA was amplified using the PCR procedure described in section 2.2.1 and the 
PCR products were separated using gel electrophoresis as described in section 
2.2.2 with the modification of adding 5µl DNA loading dye to the sample and loading 
5-30 µl of sample into agar wells. Following separation of PCR products, the 
agarose gels were imaged and captured using a Bio-Rad Chemidoc™MP Imaging 
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system (UV standard filters and 302 nm excitation) with ‘auto’ imaging parameters to 
select for the best exposure. 
2.2.11 Construct verification using Sanger sequencing 
The DNA inserts in plasmid clones were verified by Sanger sequencing. A volume of 
5 µl at 100 ng/µl of plasmid DNA was prepared in sealed 1.5 microcentrifuge tubes 
and sent to Source Bioscience (UK) for sequencing. T7F primers, appropriate 
reverse primers at Source Bioscience (UK) or custom primers synthesised by 
Source Bioscience were used. Sequencing results were performed overnight and 
analysis was performed using SnapGene viewer 4.2.1. Sequences were manually 
aligned or ran through the BLAST: Basic Local Alignment Search Tool (NCBI) and 
matches between the insert with the original cDNA sequence was indicative of 
successful cloning or mismatches indicated possible mutagenesis.   
2.2.12 Maxiprep of plasmid DNA 
For larger yields of purified plasmid DNA (in the µg-mg range), the QIAGEN Plasmid 
Plus Maxi Kit was used (contents given in Appendix A.8). The starting culture was 
poured into a 500 ml centrifuge bottle (Corning®) and centrifuged at 6000 x g for 15 
minutes at 4ºC using a centrifuge (Beckman Coulter) with a JS.5.3 rotor. The 
supernatant was discarded and the pellet of bacteria was re-suspended in 8 ml of 
P1 buffer (containing LyseBlue and RNAse A; see section 2.2.7) by pipetting up and 
down with a 10 ml Stripette (Corning). An equal volume (8 ml) of P2 buffer was 
added and the lysate was mixed gently by inverting the tube 4-6 times until the 
lysate turned blue. Cells were lysed for 3 minutes and the solution was neutralised 
with 8 ml of S3 buffer by inverting the tube 3-4 times until the solution became 
colourless. The solution was then poured into a QIAfilter cartridge and incubated for 
10 minutes at room temperature to allow density separation of the lysate from the 
cell debris. A plunger was inserted into the cartridge and pushed to filter the lysate 
into a new 50 ml falcon tube. BB buffer (5 ml) was added to the cleared lysate and 
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mixed by inverting the tube several times before loading the entire volume into a 
tube extender attached to a QIAGEN Plasmid Plus Spin column mounted onto a 
QIAvac 24 Plus, QIAvac connecting system and QIAGEN vacuum pump. Vacuum 
(-300 mbar) pressure was applied to draw the lysate through the column. ETR buffer 
(700 µl) was added and vacuum applied followed by 700 µl of PE (containing 
ethanol) solution. The column was placed into a 2 ml collection tube and centrifuged 
at 10,000 x g for 1 minute in a table-top microcentrifuge. The column was finally 
placed into a new 1.5 ml microcentrifuge tube and incubated with 400 µl of EB buffer 
(elution) for one minute before a final 1 minute centrifuge to elute the DNA. The 
concentration and quality of the DNA was determined as described in section 2.2.9. 
2.2.13 Generation of single amino acid mutations in plasmids 
The QuikChange Lightening Site-Directed Mutagenesis Kit (Agilent), see Appendix 
A.9 for contents of kit, was used to generate genetic mutations. The composition 
listed in Table 2.9 was prepared in a PCR tube followed by the addition of 1 μl of 
QuikChange Lightning Enzyme (supplied with kit) and gentle mixing by pipetting 
action.  
Table 2.9: QuikChange Site-Directed mutagenesis PCR reaction composition 
 For one reaction  
Reaction buffer (10x) 5 µl 
Primers (10 µM) 1.5 µl of each (Fwd and Rev) 
Template DNA plasmid (100 ng) 1 µl 
dNTP mix 1 µl 
QuikSolution reagent 1.5 µl 
Sterile water 13.5 µl 
Total volume 25 µl 
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The tube was then placed in a VeritiTM 96 well Thermal Cycle and the DNA 
amplified using the thermal cycle parameters listed in Table 2.10 
Table 2.10: Thermal cycling parameters for QuickChange PCR reaction 
Step Temperature  Time Cycle 
Initial 
Denaturation 
95ºC 2 minutes 1 
Denaturation 
Annealing 
Extension 
95ºC 
60ºC 
68ºC 
20 second 
10 seconds 
 
30 sec/kbp 
18 
Final Extension 68ºC 5 minutes 1 
Hold 4ºC Hold  
 
Upon completion of the PCR reaction, Dpn I restriction enzyme (1 μl) was added 
directly into the PCR tube and incubated at 37°C for 5 minutes to digest any parental 
DNA. An aliquot (45 μl) of pre-prepared XL10-Gold ultracompetent cells (Agilent) in 
a microcentrifuge tube was thawed on ice straight from the -80°C freezer. Whilst still 
on ice, 2 μl of β-mercaptoethanol (β-ME) was added to increase transformation 
efficiency. The tube was mixed gently by tapping the tube and left to incubate on ice 
for 2 minutes. The DNA treated with Dpn I was then transformed into the XL10-
Gold-β-ME treated cells and plated as described in section 2.2.6. Single colonies 
were picked (section 2.2.7) and mini-prep DNA purification performed (section 
2.2.9). Constructs were validated by Sanger sequencing (section 2.2.11).  
2.2.14 Cloning of EGFP-S6K1 
The EGFP-S6K1 construct was made by in-fusing the full length S6K1 PCR product 
from the S6K1-GFPSpark plasmid into a cut pOPINN-EGFP vector (see full uncut 
vector map in Appendix A.10.1) using the primers in Table 2.11.  
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Table 2.11: Primers for EGFP-S6K1. Read from 5’  3’ 
EGFP-S6K1 Fwd AAGTTCTGTTTCAGGGCCCGAGGCGACGAAGGAGGCGG
G  
EGFP-S6K1 Rev ATGGTCTAGAAAGCTTTA 
TAGATTCATACGCAGGTGCTCTG  
 
The final in-fused construct is shown below in Figure 2.1.  
 
Figure 2.1: Plasmid map of EGFP-S6K1. Full vector map of S6K1 cloned into the pOPINN-
EGFP vector. Map generated in SnapGene® (Version 3.2.1) software.  
2.2.15 Cloning of S6K1-mCherry and S6K1-mTurquoise2 
Both S6K1-mCherry and S6K1-mTurquoise2 constructs were made by in-fusing the 
full length S6K1 PCR product from the S6K1-GFPSpark plasmid into cut pOPINE-
3C-mCherry or pOPINE-3C-mTurquoise2 vectors (see full uncut vector maps in 
Appendix A.10.2 and A.10.3) using the primers in Table 2.12. The vectors for both 
pOPINE-3C-mCherry and pOPINE-3C-mTurquoise2 originated from the pOPINE-
3C-EGFP vector (Bird et al., 2015), see Appendix A.10.4 and thus contained same 
primer overhangs for cloning. 
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Table 2.12: PCR primers for S6K1-mCherry and S6K1-mTurq2. Read from 5’  3’ 
S6K1-mCherry/ 
mTurq2 Fwd 
AGGAGATATACCATGAGGCGACGAAGGAGGCGG 
S6K1-mCherry/ 
mTurq2 Rev 
CAGAACTTCCAGTTTTAGATTCATACGCAGGTGCTCTG  
 
Final in-fused constructs are shown below in Figure 2.2.  
 
 
Figure 2.2: Plasmid maps of S6K1-mCherry and S6K1-mTurq2. A) Full vector map of 
S6K1 cloned into the pOPINE-3C-mCherry vector. B) Full vector map of S6K1 cloned into 
the pOPINE-3C-mTurq2 vector. Map generated in SnapGene® (Version 3.2.1) software. 
A 
B   
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2.2.16 Cloning of raptor-YFP 
The raptor-YFP construct was made by in-fusing full length raptor PCR product from 
the mDsRed-raptor plasmid into cut pOPINE-3C-YFP vector (see full uncut vector 
maps in Appendix A.10.5) which also originated from the pOPINE-3C-EGFP vector 
using the primers in Table 2.13.  
Table 2.13: PCR primers for raptor-YFP. Read from 5’  3’ 
raptor-YFP Fwd AGGAGATATACCATGGAGTCCGAAATGCTGCAATCG 
raptor-YFP Rev CAGAACTTCCAGTTTTCTGACACGCTTCTCCACCG 
 
The final in-fused construct is shown below in Figure 2.3.  
 
Figure 2.3: Plasmid map of raptor-YFP. Full vector map of raptor cloned into the pOPINE-
3C-YFP vector. Map generated in SnapGene® (Version 3.2.1) software. 
2.2.17 Cloning of mutant (ΔN) mTOR-mCherry 
The truncated mTOR-mCherry construct was originally made by in-fusing the full 
length mTOR PCR product from the EGFP-mTOR plasmid into cut pOPINE-3C-
mCherry vector using the primers in Table 2.14. Sequencing revealed that the full 
length mTOR sequence was not present but instead a truncated sequence of mTOR 
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was cloned into the vector. This could be most likely due to internal repeats or 
sequence similarity with primers from the mTOR sequence.  
Table 2.14: PCR primers for truncated mTOR-mCherry. Read from 5’  3’ 
ΔmTOR-mCherry 
Fwd 
AGGAGATATACCATGCTTGGAACCGGACCTGCC 
ΔmTOR -mCherry 
Rev 
CAGAACTTCCAGTTTCCAGAAAGGGCACCAGCC 
 
The final in-fused construct is shown below in Figure 2.4.  
 
Figure 2.4: Plasmid map of ΔmTOR-mCherry. Full vector map of truncated mTOR cloned 
into the pOPINE-3C-mCherry vector. Map generated in SnapGene® (Version 3.2.1) 
software. 
2.2.18 Cloning of mCherry-S6K1-EGFP (SensOR) 
The mCherry-S6K1-EGFP FRET sensor construct was made by in-fusing the full 
length S6K1 PCR product from S6K1-GFPSpark and the mCherry PCR product 
from ΔmTOR-mCherry into cut pOPINE-3C-EGFP vector using the primers in Table 
2.15.  
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Table 2.15: PCR primers for mCherry-S6K1-EGFP. Read from 5’  3’ 
mCherry-S6K1 
Fwd 
GACGAGCTGTACAAGATGAGGCGACGAAGGAGGCG 
mCherry-S6K1 
Rev 
CCTTCGTCGCCTCATCTTGTACAGCTCGTCCATGC 
mCherry-S6K1-
EGFP Fwd 
AGGAGATATACCATGGCCATCATCAAGGAGTTCATG 
mCherry-S6K1-
EGFP Rev 
CAGAACTTCCAGTTTTAGATTCATACGCAGGTGCTC 
 
The final in-fused construct is shown below in Figure 2.5. 
 
Figure 2.5: Plasmid map of mCherry-S6K1-EGFP. Full vector map of mCherry-S6K1 
cloned into the pOPINE-3C-EGFP vector. Map generated in SnapGene® (Version 3.2.1) 
software. 
2.2.19 Cloning of mCherry-S6K1-EGFP-2STREP 
The mCherry-S6K1-EGFP FRET sensor construct with a STREP tag for purification 
was made by in-fusing the mCherry-S6K1 PCR product from mCherry-S6K1-EGFP 
and EGFP from EGFP-S6K1 into cut pOPINEneo-3C-2STREPStop vector (see full 
uncut vector maps in Appendix A.10.6) using the primers in Table 2.16.  
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Table 2.16: PCR primers for mCherry-S6K1-EGFP-2STREP. Read from 5’  3’ 
mCherry-S6K1 
Fwd 
AGGAGATATACCATGGCCATCATCAAGGAGTTCATG 
mCherry-S6K1 
Rev 
CACTAGATTCATACGCAGGTGCTCTGGCCGTTTGGAG 
mCherry-S6K1-
GFP Fwd 
CGTATGAATCTAGTGAGCAAGGGCGAGGAGCTGTTCACCG
GG 
mCherry-S6K1-
GFP Rev 
CAGAACTTCCAGTTTCTTGTACAGCTCGTCCATGCCGA 
 
The final in-fused construct is shown below in Figure 2.6. 
 
Figure 2.6: Plasmid map of mCherry-S6K1-EGFP-2Strep. Full plasmid map of mCherry-
S6K1 and EGFP cloned into the pOPINEneo-3C-2STREPStop vector. Map generated in 
SnapGene® (Version 3.2.1) software. 
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2.2.20 Generation of EGFP-F29A S6K1 mutant 
The TOS motif of S6K1 was mutated by altering the phenylalanine position at 29 to 
alanine in the EGFP-S6K1 construct using the primers in Table 2.17.  
Table 2.17: PCR primers for EGFP-F29A S6K1. Read from 5’  3’ 
EGFP-F28A-S6K1 
Fwd 
AGGACATGGCAGGAGTGGCTGACATAGACCTGGACC 
EGFP-F28A-S6K1 
Rev 
GGTCCAGGTCTATGTCAGCCACTCCTGCCATGTCCT 
 
2.2.21 Generation of EGFP- S6K1 T389A mutant 
The phosphorylated motif of S6K1 was mutated by altering the threonine position at 
389 to alanine in the EGFP-S6K1 construct using the primers in Table 2.18.  
Table 2.18: PCR primers for EGFP-F29A S6K1. Read from 5’  3’  
EGFP-S6K1 
T389A Fwd 
CAGGTCTTTCTGGGTTTTGCATATGTGGCTCCATCTG 
EGFP-S6K1 
T389A Rev 
CAGATGGAGCCACATATGCAAAACCCAGAAAGACCTG 
 
2.2.22 Cloning of raptor-His (EV5831) 
All constructs were designed, codon optimised for insect expression, cloned 
and sequence-verified by GenScript. The raptor cDNA was cloned into the 
pBAC4x-1 vector (Appendix A.10.7) from the mCherry-raptor plasmid. The 
addition of the His epitope tag was added to the C-terminus of raptor to 
prevent any protein-protein disruption or tag interference during pull-down. 
The final vector map of the construct is shown in Figure 2.7.  
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Figure 2.7: Plasmid map of raptor-His (EV5831). Full vector map of raptor-His cloned into 
the pBAC4x-1 vector. Map generated in SnapGene® (Version 3.2.1) software. 
2.2.23 Cloning of S6K1-FLAG and raptor-His (EV5832_EV5831) 
The raptor-His from section 2.2.22 was cloned with full length S6K1 from S6K1-
GFPSpark with the addition of a FLAG epitope tag to S6K1 into the pBAC4x-1 
vector. The final vector map of the construct is shown in Figure 2.8. 
 
Figure 2.8: Plasmid map of S6K1-FLAG (EV5832) and raptor-His (EV5831). Full vector 
map of S6K1-FLAG and raptor-His cloned into the pBAC4x-1 vector. Map generated in 
SnapGene® (Version 3.2.1) software.  
2.2.24 Cloning of FLAG-S6K1 and raptor-His (EV5830_EV5831)  
A variant construct of S6K1-FLAG and raptor-His (EV5832_EV5831) (section 
2.2.23) was made by tagging the N-terminus gene of S6K1 with the FLAG epitope. 
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This was designed in mind for testing the best purification conditions. The final 
vector map of the construct is shown in Figure 2.9.  
 
 
Figure 2.9: Plasmid map of FLAG-S6K1 (EV5830) and raptor-His (EV5831). Full plasmid 
map of FLAG-S6K1 and raptor-His cloned into the pBAC4x-1 vector. Map generated in 
SnapGene® (Version 3.2.1) software. 
2.2.25 Cloning of TOS-ΔS6K1-FLAG and raptor-His (EV5834_EV5831) 
A truncated form of S6K1 (Wang et al., 2013) with the addition of a FLAG motif to 
the C-terminus was cloned into a pBAC4x-1 vector with raptor-His. A TOS motif was 
purposely engineered onto the N-terminus of the truncated S6K1 to allow binding 
onto mTORC1 through raptor binding. The final vector map of the construct is 
shown in Figure 2.10. 
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Figure 2.10: Plasmid map of TOS-ΔS6K1-FLAG (EV5834) and raptor-His (EV5831). Full 
vector map of TOS-ΔS6K1-FLAG and raptor-His cloned into the pBAC4x-1 vector. Map 
generated in SnapGene® (Version 3.2.1) software. 
2.2.26 Cloning of mTOR-myc and mLST8 (EV5827_EV5828) 
Full length mTOR was cloned into the pBAC4x-1 vector from FLAG-mTOR(wt) with 
a myc purification tag. The mLST8 gene (see Appendix A11) was optimised and 
cloned into the vector for maintaining the stability of the complex (Yang et al., 2013) 
without a purification tag.  The final vector map of the construct is shown in Figure 
2.11. 
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Figure 2.11: Plasmid map of mTOR (EV5827) and mLST8 (EV5828). Full vector map of 
myc-mTOR and untagged mLST8 were cloned into the pBAC4x-1 vector. Map generated in 
SnapGene® (Version 3.2.1) software. 
2.2.27 Cloning of N-truncated mTOR-myc and mLST8 (EV5833_EV5828) 
A variant construct of that prepared in section 2.2.26, known to express and purify 
more efficiently than the full length mTOR construct, was made with a truncated N-
terminus of mTOR (Yang et al., 2013) tagged with a myc tag. The final vector map 
of the construct is shown in Figure 2.12. 
 
Figure 2.12: Plasmid map of N-terminus truncated mTOR (EV5833) and mLST8 
(EV5828). Full vector map of myc-ΔNmTOR and untagged mLST8 cloned into the pBAC4x-1 
vector. Map generated in SnapGene® (Version 3.2.1) software. 
2.2.28 Cloning of mTOR-myc, S6K1-FLAG and mLST8 (EV5827_ 
EV5832_EV5828) 
Another variant construct of mTOR-myc and mLST8 (EV5827_EV5828) (section 
2.2.26) was made with the addition of S6K1 with its FLAG tag from section 2.2.23. 
The final vector map of the construct is shown in Figure 2.13. 
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Figure 2.13: Plasmid map of S6K1 (EV5832), mTOR (EV5827) mLST8 (EV5828). Full 
vector map of S6K1-FLAG, myc-mTOR and untagged mLST8 into the pBAC4x-1 vector. 
Map generated in SnapGene® (Version 3.2.1) software. 
2.2.29 Cloning of mTOR-myc, S6K1-FLAG, raptor-His and mLST8 (EV5827_ 
EV5832_EV5831_EV5828) 
A final variant combining the genes from the plasmids constructed in sections 2.2.26 
and 2.2.23 together was also made. This “mega-construct” was designed in order to 
help purify an intact mTOR complex with all the proteins of interest complexed 
together from one expression and one-step purification. The final vector map of the 
construct is shown in Figure 2.14. 
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Figure 2.14: Plasmid map of raptor (EV5831), S6K1 (EV5832), mTOR (EV5827) mLST8 
(EV5828). Full plasmid map of raptor-His, S6K1-FLAG, myc-mTOR and untagged mLST8 
cloned into the pBAC4x-1 vector. Map generated in SnapGene® (Version 3.2.1) software. 
2.2.30 Mammalian cell culture  
HEK293 and HeLa cells were cultured in Minimum Essential Media (MEM) 
supplemented with 10% Foetal Bovine Serum (FBS), 2 mM L-glutamine (L-glut) and 
1% Penicillin-Streptomycin (Pen-Strep) for HEK293. FreeStyle 293 (HEK293F) cells 
were grown in serum-free media (Gibco/Life Technologies, UK). MCF-7, A431 and 
U2OS cells were cultured in DMEM supplemented with 10% FBS, L-glut and Pen-
Strep. Cells were incubated at 37°C with 5% CO2 humidified air in T25 or T75 
culture flasks (ThermoFisher Scientific) or in 50 mL tubes (Corning®).  
Cells were passaged three times a week once confluency had reached ~80% 
exponential growth. Adherent cells were washed once with 10 ml of PBS (1X) after 
the removal of media using sterile Stripettes (Corning®). The PBS wash was 
removed and 2 ml of trypsin-EDTA (1X) added to cover the entire monolayer. Cells 
were placed inside an incubator at 37°C for 3-5 minutes to allow the cells to detach. 
Following the incubation period, 8 ml of pre-warmed growth medium was added to 
minimise the trypsin effect and cells were re-suspended several times by pipette 
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action. Cells were counted directly from the flask by taking a 10 μl sample of cell 
suspension and diluting it with an equal volume of trypan blue (Bio-Rad). A final 
volume of 10 μl of the mixture was then loaded into a chamber of a counting slide 
(Bio-Rad) and cells were counted using a TC20 automated cell counter (Cell 
counter) for seeding or the stock suspension was diluted 1:20 with the remaining 
volume made up with pre-warmed growth medium in a new sterile flask. The flask 
was swirled gently from side to side and incubated at 37°C with 5% CO2 humidified 
air. 
For suspension cells, flasks were swirled gently to re-suspend any settled cells from 
keeping the flasks stationary. Cells were directly split (1:20) and seeded after 
counting as described above using a Countess Automated Cell Counter 
(Thermofisher Scientific) into a new sterile tube with pre-warmed growth medium. 
Tubes containing cell and growth medium were incubated at 37°C with 5% CO2 
humidified air at 110 RPM on an orbital shaker placed inside the incubator. 
2.2.31 Long-term mammalian cell storage 
All cell lines were passaged as described in section 2.2.30 following centrifugation in 
a 50 ml falcon tube at 1200 RPM. The supernatant was removed and the cell pellet 
re-suspended in 10 ml freezing media (complete growth media containing 10% 
dimethyl sulfoxide (DMSO). Aliquots (1 ml) of cells diluted to (1 x 106 cell/ml in the 
freezing media) were pipetted into sterile cryotubes (VWR). Tubes were placed in a 
CoolCell (BioCision) cooling container and placed at -80°C overnight before transfer 
into liquid nitrogen for long-term storage.  
2.2.32 Trypan blue exclusion test of cell viability 
To accurately determine the cell viability of mammalian cells during passaging or 
insect cells during infection (see section 2.2.31 onwards) or the effect of varying 
concentrations of AZD2014 on trypsinised HEK293 cells, 10 µl of cells were mixed 
102 
 
with 10 µl of trypan blue (Bio-Rad). A final 10 µl of the mixture was then loaded into 
counting slide chamber and number of live cells determined by a TC20 (Bio-Rad) or 
Countess II (Thermofisher Scientific) automated cell counter.  
2.2.33 Insect cell culture 
Sf9 cells were cultured in Sf 900 III media supplemented with 1% Pen-Strep. Sf21 
cells were cultured in Sf 900 II or III media supplemented with gentamicin (5 μg/ 
mL). Cells were incubated in Erlenmeyer shake flasks (Corning®) or 24-deep well 
blocks (Qiagen) at 27°C.  
Stock Sf9/Sf21 cells were counted as described in section 2.2.30 using a Countess 
Automated Cell Counter (Thermofisher Scientific) and cell viability determined (see 
section 2.2.32). Cells were sub-cultured into Erlenmeyer shake flasks with pre-
warmed growth media or seeded in 6-well plates (Thermofisher Scientific). Cells 
were often sub-cultured at 5 or 6 x 105 cells/ml every 2-3 days and incubated at 
27°C with shaking at 120 RPM. 
2.2.34 Long-term storage of insect and baculovirus infected insect cells 
(BIICs)  
Insect cells were centrifuged in 50 ml falcon tubes at 12,000 x g for 12 minutes and 
the supernatant removed. Cells were counted as described in sections 2.2.30 and 
2.2.32. They were then re-suspended to a density of 2 x 107 cells/mL in freezing mix 
(Sf900-II SFM containing 5 μg/mL gentamicin + 10% heat inactivated FBS + 10% 
DMSO) and aliquoted in 1 mL volumes into cryovials (Nalgene # 5001-0020). The 
vials were then frozen at -80°C (Mr Frosty) or frozen slowly from 4°C to -20°C 
before being placed at -80°C for 24 hours and transferred to liquid nitrogen. P1 and 
P2 liquid virus was stored in the dark at 4°C.  
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Baculovirus infected insect cells (BIICs) were made as described above with a 2 x 
107 cells/ml concentration. Volume of freezing media required was calculated by 
Equation 2.1:  
𝑽𝑽𝟏𝟏 =
𝑪𝑪𝟏𝟏×𝑽𝑽𝟐𝟐
𝟐𝟐𝟐𝟐
 
where the volume (V1) of freezing medium (ml) used is related to the concentration 
(C1) of the cells (cells/ml), final volume of culture (V2) and a correction factor of 20, 
to factor in a final titre concentration of the virus as 2 x 109 cells/ml.  
2.2.35 Thawing mammalian and insect cell /BIICs  
Cryovials containing mammalian cells were returned from low temperature storage 
in liquid nitrogen and placed into a CoolCell. Cryovials were then placed into a vial 
holder in a 37°C water bath (Ultrawave) for 1-2 minutes before being cultured inside 
a flask with pre-warmed growth medium. 
Cryovials containing insect cells and frozen BIICs were placed in a Mr. Frosty 
container and thawed in a plastic vessel containing warm (27°C) water for 2-3 
minutes with gently swirling of the tube before use for culture or infection.  
2.2.36 Growing mammalian spheroids  
HEK293 cells were passaged and seeded as described in section 2.2.30 into a 96- 
U-well bottom plate at a cell density of 10,000 cells per well with a final volume of 
100 µl in complete growth media. Each well was pre-cast with 100 µl of autoclaved 
1.5% low melting point agarose (Sigma-Aldrich) in water prior to seeding. 200 µl of 
PBS (1X) was added to the outer wells of the 96-well plate to maintain humidity due 
to evaporation losses from inner wells. The plate was incubated at 37°C with 5% 
CO2 humidified air for 3-4 days until spheroids were formed in suspension above the 
agar layer.  
(2.1) 
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2.2.37 Mammalian cell transfection using plasmid DNA 
HEK293 cells were transfected after 24 hours following cell seeding at a density of 1 
x 105 or 1.5 x 105 cells/ml on uncoated 35 mm number 1.5 glass bottom dishes 
(MatTek, U.S.A.) or seeded and transfected straightway in shake flasks. For 
adherent HEK293 cells transfected with FuGENE HD (Promega, UK), the 
composition in Table 2.19 was prepared in a sterile 1.5 ml microcentrifuge tube. For 
co-transfections, the amount of FuGENE and the final volume remained the same 
but two quantities of DNA were added, one for each plasmid.   
Table 2.19: Composition of DNA-FuGENE transfection complex 
Components  Amount per transfection  
DNA plasmid 500 ng 
FuGENE HD 6 μl 
Opti-MEM Final volume made to 100μl 
 
20 ml of HEK293F cells in 50 ml falcon tubes were transfected with polyethylenimine 
(PEI) Max (Polysciences). The DNA: PEI MAX ratio of 1:3 was used where 1 μg of 
sterile DNA plasmid and 3 μg of PEI Max (1 mg/ml) were used per ml of suspension 
cells. DNA was mixed with 300 μl of Opti-PRO (serum free medium) by pipette 
action in a sterile 1.5 ml microcentrifuge tube. The mixture of PEI MAX and 300 μl of 
Opti-PRO was also prepared in an additional tube. The contents of one tube was 
pipetted into the other, mixed by gentle re-pipetting, and incubated at room 
temperature for 15 minutes. Following the incubation period, the DNA-transfection 
mixture was added to cells drop-wise. Sodium butyrate (10 mM) added 24 hrs later. 
2.2.38 Insect cell baculovirus-plasmid preparation infection 
The baculovirus system was used to infect insect cells using the flashBAC GOLD 
bacmid (Oxford Expression Technologies) or using a combined bacmid consisting of 
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the Autographa californica nucleopolyhedrovirus (AcMNPV) genome with deletions 
of the ORF 1629, baculovirus chitinase (chiA) protease, cathepsin (v-cath) protease 
genes and insertion of the DsRed marker for verifying protein expression (Berrow et 
al., 2007; Osz-Papai et al., 2015). 1 ml of antibiotic-free insect cell medium was 
aliquoted into a sterile 7 ml bijou tube (Medfor) and 100 ng per reaction of linearised 
flashBAC GOLD bacmid (stock 20 ng/ µl) or AcMNPV-DsRed bacmid was added to 
the medium with gentle mixing by pipette action. 500 ng of sterile plasmid DNA with 
10 μl of Cellfectin II Reagent or FuGENE HD (Promega) with the bacmid was 
added. The transfection mixture was left to incubate at room temperature for 30-35 
minutes. Media from insect cells following 24 hours of seeding in 6-well plates was 
removed and recombinant baculovirus mixture added drop-wise to generate 
recombinant baculovirus P0 stock. Plates were incubated for 6-7 days at 27°C with 
the addition of 1ml of antibiotic-free insect cell medium after the first 24 hours of 
incubation. Control (GFP plasmid) was also used for expression to determine the 
success of the transfection process. 
The P0 stock was amplified to make P1 stock by pipetting 300 μl of the supernatant 
media containing the recombinant baculovirus from a 6-well plate into a 125 ml 
shaker flask (Thermofisher Scientific) containing a 30 ml volume of cells at 1.3 x 106 
and medium supplemented with antibiotic. Flasks were incubated at 27°C on a 
shaker (Infors HT) for 72 hours. Expression was determined by fluorescence or by 
cell size where successful infection resulted in an increase in cell size (typically by 3 
or more microns). P1 stock was harvested and frozen as described in section 
2.2.34.  
P2 BIICs were amplified from P1 BIICs. 250 ml shaker flasks containing a final 
volume of 100 ml of Sf21 cells at ~1.3 x 106 cell density were infected at MOI 0.1 in 
antibiotic-medium using Equation 2.2. The infected shake cultures were incubated 
for 72 hours at 27°C on an orbital shaker at 110 rpm and cells were then observed 
106 
 
under an inverted microscope and compared to a non-infected control culture using 
a Cell Countess to confirm infection. P2-BIICs were harvested and frozen as 
described in section 2.2.34. The volume of BIICs depended on the multiplicity of 
infection (MOI), the average number of virus particles that can infect an individual 
insect cell. The MOI used for P2 was 0.2.  
𝑽𝑽𝟏𝟏 =
𝑪𝑪𝟏𝟏 ×𝑽𝑽𝟐𝟐 ×𝑴𝑴
𝑻𝑻𝟏𝟏
 
where the volume (V1) of BIICs (ml) used is related to the concentration (C1) of the 
cells (cells/ml), final volume (V2), MOI (M) and the titre concentration (T1) of frozen 
BIICs  
P2 BIICs (calculated from Equation 2.2) were used for “scouting” best protein 
expression conditions in Sf21 cells by pipetting BIICs into 3 ml wells of a 24-deep 
well block at 0.2, 1 and 5 MOI test conditions. The block was centrifuged at 2000 
RPM for 10 minutes, the supernatant decanted and the pellets stored at -20°C. 
Insect cells (passage 5-30) were prepared from cultures in logarithmic phase growth 
and >98% viable. Cells were seeded into 2.5 L of SF900II medium (containing 
5µg/ml Gentimicin) in 5L Thomson flasks at 0.65 x 106 cells/mL and allowed to grow 
overnight on orbital shaker (110 RPM, 27°C). The overnight cultures were counted 
and then infected at MOI-5 with P2 BIICs. Following 53 hours of expression (Sf21) 
or 73 hours of expression (Sf9), cell suspension was divided into 500 ml tubes 
(Corning) and centrifuged at 6,000 g for 15 minutes at 4°C. The supernatant was 
removed and the pellets were pooled into a single tube by swirling one pellet with 
100 ml of supernatant and transferring it into the next pellet with further swirling until 
all the pellets were collected for Sf21 cells. The combined pellet was transferred into 
a 500 ml tube and centrifuged again at 6,000 g for 15 minutes 4°C. The supernatant 
was discarded and the final pellet was stored at -80°C. 
(2.2) 
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2.2.39 SensOR purification from insect cells 
Expression test and protein production in insect (Sf9) for large scale production was 
performed as described in (Nettleship et al., 2010). Following 72 hours of infection to 
obtain 90% infection rate, 2.5 litres of Sf9 cells were aliquoted into 6 x 500 ml 
centrifuge tubes and harvested by centrifugation for 15 minutes at 6000 x g and 4°C. 
Cell pellets were frozen at -80°C prior to cell lysis. Pellet were lysed in 50 ml of lysis 
buffer (containing 50 mM HEPES, 150 mM NaCl, 3 mM DTT, 0.1% (w/v) CHAPS, 
protease inhibitors cocktail and 25 U/ml benzonase) either by passing the lysate 
through a syringe needle or by sonication, followed by centrifugation (13,000 g, 30 
minutes, 4°C). The supernatant was filtered using a Nalgene® vacuum filtration 
system capacity 500 mL, with a pore size of 0.2 μm prior to affinity purification using 
a StrepTrap column (GE Healthcare). Protein was eluted in 2.5 mM desthiobiotin 
(Sigma-Aldrich) followed immediately by gel filtration using a Superdex 200 10/300 
(GE Healthcare) on the ÄKTA Express system using manufacturer standard 
protocols (GE Healthcare). Purified protein stability was tested after 48 hrs and 72 
hours for degradation. The protein was aliquoted, flash-freezed in liquid nitrogen and 
stored at -80°C. Purified protein was loaded into gels for western blotting as 
described in section 2.2.43 or for in-gel fluorescence by not boiling the samples and 
imaged directly using the ChemiDoc imager with epi-illumination, 530/28 (green) 
and 605/50 (red) filters.  
2.2.40 mTORC1 purification from insect cells 
Following 72 hours or 53 hours infection of SF21 cells, cell pellets were harvested 
as described in section 2.2.38 from 3 ml, 45 ml or a 5 litre expression. Cell pellets 
were lysed in 1ml (small scale or ‘scouting’) or 300 ml (large scale) of filtered lysis 
buffer (50 mM HEPES (pH 7.4), 150 mM NaCl, 3 mM DTT, protease inhibitor, 10 
U/ml benzonase). Lysates were either sonicated as described later in section 2.2.43 
or were passed through a microfluidizer twice and the lysate was then poured into 
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50 ml centrifuge tubes and spun at 45,000 x g for 45 minutes at 4°C (Beckman 
ultracentrifuge). Supernatant was loaded and protein purified using a HisTrap (1 ml) 
HP column (GE Healthcare) overnight and eluted in 25 ml of elution buffer (50 mM 
HEPES (pH 7.4), 150 mM NaCl, 3 mM DTT, 500 mM imidazole) with gradient 
elution collected in 1.5 ml fractions in a 96-well plate. Elution fractions (positions C9-
D10 of plate) were concentrated in a 50 K concentrator (Millipore) to a final volume 
of 5 ml by centrifugation at 4°C and 4000 RPM for 15-20 minutes. Sample was 
injected using a syringe into a Size-Exclusion Chromatography (SEC) Superdex 200 
pg column (GE Healthcare) performed on the ÄKTA Purifier system overnight using 
standard manufacture protocol. The column was equilibrated with SEC buffer (25 
mM HEPES (pH 7.5), 200 mM NaCl, 1 mM TCEP, 10% glycerol) and fractions were 
collected in a 96-well plate. Eluted samples from SEC were then concentrated on 
nickel resin tips using the Phynexus (see section 2.2.44) and eluted 3 x 150 μl. 
Wash and elution buffer used were the same as that used in the HisTrap purification 
above. All samples were run on gels for western blotting or comassie staining.   
2.2.41 Cell fixation 
Following 48 hours transfection and mock transfection, growth medium from 
HEK293 cells was removed and either 1 ml of 4% paraformaldehyde (Electron 
Microscopy Sciences) was added and placed on a rocker (Stuart) for 15 minutes, or 
1 ml of glyoxal mixture (Richter et al., 2017) (see Table 2.20) was added for 15 
minutes, or 1 ml of ice-cold methanol (Sigma-Aldrich) was added with a 20 minute 
incubation at -20°C. Dishes were washed three times for 5 minutes in cold PBS (1X) 
by placing on a rocker with removal of PBS after each wash. 
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Table 2.20: Glyoxal fixative composition  
Components  Amount for 4 ml solution 
Ethanol (Sigma-Aldrich) 0.789 ml 
Glyoxal 40% (Sigma-Aldrich) 0.313 ml  
Acetic acid (Sigma-Aldrich 0.03 ml  
Sterile water 2.835 ml 
 
2.2.42 Immunofluorescence labelling of fixed cells  
Following fixation, cells were permeabilised with 0.3% Triton X-100/PBS/0.1% 
Bovine Serum Albumin (BSA) solution (Sigma-Aldrich) and washed three times with 
1 ml PBS (1X), each wash lasting 5 minutes with removal of PBS after each wash. 
The fixed cells were blocked with 1 ml of 5% BSA in PBS for 30 minutes to reduce 
non-specific binding. The blocking buffer was removed and cells were incubated for 
1 hour with primary antibody. The primary antibody was diluted 1:200 with 5% 
BSA/PBS in a final volume of 500 μl, with gently vortex mixing before addition. After 
incubation, fixed cells were washed three times as previously and incubated with a 
1:500 dilution of conjugated-fluorescently labelled secondary antibody, made in 
blocking buffer, for 1 hour in the dark (dishes were wrapped with aluminium foil) to 
avoid any photo-bleaching of the conjugated-fluorescently labelled secondary 
antibody. Cells were washed twice and maintained in 1 ml of PBS before imaging. 
Dishes were imaged immediately or stored at 4°C.  
2.2.43 Western blot analysis for phospho-S6K1 and mTORC1 proteins 
Following 48 hours or 72 hours transfection, adherent HEK293 cells were washed 
once with PBS (1X) and detached using 500 μl of trypsin (1X) as described in 
section 2.2.30. Trypsinised cells were transferred into 1.5 ml microcentrifuge tubes 
and cell pellets were obtained by centrifugation using a table-top microcentrifuge at 
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13,000 x g for 3 minutes whilst 5 or 10 ml of 1 x 106 cells/ml of HEK293F 
(suspension cells) treated with and without 200 nM rapamycin for 2 hours (Sigma-
Aldrich) in 50 ml mini bioreactor tubes were spun down at 1200 RPM for 5 minutes 
at 4°C. Pellets were re-suspended in 125 µl of Cellytic M lysis buffer (Sigma-Aldrich) 
or in 1 ml of lysis buffer (50 mM HEPES (Teknova) pH 7.4, 150 mM NaCl, 3 mM 
dithiothreitol (DTT) and 0.4% CHAPS (all from Sigma-Aldrich)) containing 1:1000 
dilution of protease inhibitor cocktail (Thermo Fisher Scientific) with added 1:1000 
sodium fluoride (NaF) and 1:5 sodium orthovanadate (Na3VO4) (Sigma-Aldrich). 
HEK293F pellets were re-suspended in lysis buffer and suspension transferred into 
a cold 2 ml microcentrifuge tube. Samples were vortexed for 2 minutes and then 
incubated on ice for 20 minutes or lysed by ultrasonication (30 sec on/off cycle) 
(Sonic Vibra Cell) for 4 minutes on ice. Total protein was quantified by Bradford 
reagent (Sigma-Aldrich) with known BSA standards (Sigma-Aldrich) using a 
microplate (Thermofisher Scientific) and SpectraMax plate-reader (Molecular 
Devices). Samples were diluted to 50 μg with cold lysis buffer and 50 μl of sample 
was pipetted into cold microcentrifuge tubes. Equal volumes of 2X Laemmli buffer 
containing β-ME (Bio-Rad) or 2X LDS sample buffer (Thermofisher Scientific) was 
added and boiled for 5 minutes in a heating block. 10 μl of sample was loaded into 
each well of a NuPAGE Novex Bis-Tris protein gel (Thermofisher Scientific) with a 
Novex Sharp pre-stained protein standard marker (Thermofisher Scientific) and run 
with MES (1X) buffer (Thermofisher Scientific) for 35 minutes at 200 V (voltage) 
using a XCell SureLock™ mini-cell tank (Thermofisher Scientific) or run in Mini-
PROTEAN® TGX precast gels (Bio-Rad) with a PageRuler prestained protein 
ladder (Thermofisher Scientific) in a Mini-PROTEAN tank (Bio-Rad) filled with 1X 
tris/glycine buffer (Bio-Rad). Gels were transferred to Polyvinylidene Difluoride 
(PVDF) membranes using the iBlot I or II Gel transfer device (Thermofisher 
Scientific) or with a Trans-Blot® Turbo™ Transfer System (Bio-Rad) with 
appropriate transfer stacks (Bio-Rad/ Thermofisher Scientific). The membranes 
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were placed into sealed plastic pouches or containers and incubated with 10 ml of 
blocking buffer (5% milk powder (Sigma-Aldrich) in tris buffered saline with Tween 
20 (TBST) (see Appendix A.12)) or Blocker™ Casein in water (Thermofisher) for 1 
hour. Following blocking, the pouches were opened using a sterile scalpel and re-
sealed in new plastic pouches or kept in a container with 10 ml blocking buffer with a 
1/1000 dilution of primary antibodies pipetted and mixed into it. The sealed pouches 
were gently shaken by hand and incubated at 4°C overnight on a rocker (VWR). The 
membrane was removed out of the pouch and washed three times with 10 ml TBST 
(1X) or phosphate buffered saline with Tween 20 (PBST) (1X), each wash lasting for 
5 minutes. The blots were re-sealed in plastic pouches and incubated with a 1:3000 
dilution of HRP-linked or AP-linked secondary antibody in blocking buffer for 1 hour 
at room temperature. The blots were washed three times with TBST or PBST and a 
final wash in deionised water was performed. The blot was removed from the pouch 
or from the container and placed into a dark container. Blots were developed in a 
final volume of 5-10 ml of Pierce™ ECL Western blotting substrate (Thermo Fisher 
Scientific) for 5 minutes prior to chemiluminescent imaging or with 5 ml of 5-Bromo-
4-Chloro-3-Indolyl-Phosphate with Nitro Blue Tetrazolium (BCIP /NBT) substrate 
solution (Thermofisher) for 5 minutes before washing the blot twice in water and 
imaging. ECL developed blots were “stripped” using Restore Western Blot Stripping 
Buffer (Thermo Fisher Scientific) for 15 minutes at 37°C and re-blotted using other 
antibodies such as S6K1 and vinculin to determine loading of protein for 
normalisation. All gels were imaged using the Bio-Rad Chemidoc™MP Imaging 
system. Standard factory settings for Western blot image acquisition were used and 
set to ‘auto-detection’ in order to obtain best contrast and gain. Bands in captured 
images of the blots were quantified using densitometry in Image J (version 1.48) and 
the levels of normalised phospho-S6K1 levels from each sample was determined 
using Equation 2.3: 
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% 𝑷𝑷 =  �
𝑰𝑰𝒑𝒑
𝑰𝑰𝒕𝒕
� × 𝟏𝟏𝟐𝟐𝟐𝟐 
Where the percentage of phosphorylation (%P) is equal to the intensity of the band 
for phosphorylated protein (Ip) divided by the intensity of the total protein (It).  
2.2.44 Pull-down assays of S6K1-mTORC1 interactions 
Following 72 hours of transfection, 5 or 10 ml of 1 x 106 cells/ml were centrifuged 
and lysed as stated in section 2.2.43. Following lysis on ice, tubes containing lysates 
were spun-down by centrifugation for 45 minutes at 20,000 x g and 4°C. 50 µl 
samples of total and soluble fractions were collected. 1 ml of the supernatant 
(soluble fraction) was loaded onto a 10 µl Ni-NTA resin PhyTip using a robot 
(PhyNexus) at 4°C, washed (wash buffer: lysis buffer + 20 mM imidazole) and 
eluted (elution buffer: lysis buffer + 500 mM imidazole) in a 40 µl final volume. The 
robot was programmed using the PhyNexus operating software and standard 
manufacture protocol was used. Eluted proteins and complexes were separated 
using midi-gels (Bio-Rad, UK) for western blotting as described in section 2.2.43 or 
for coomassie staining by transferring the gel onto pads soaked in equal volumes 
(~10 ml) of stain and de-stain solutions (Thermofisher Scientific) and stained using 
the Power Blotter (Thermofisher Scientific). Stained gels were kept in deionised 
water and left on the rocker for at least an hour to remove any excess stain before 
imaging. 
2.2.45 Cell starvation, amino acid activation and inhibition studies 
Following 48 hours transfection, HEK293 cells were washed once with 1 ml of pre-
warmed PBS (1X) and then incubated in 1 ml of pre-warmed serum-free medium 
overnight for serum starvation. Afterwards, cells were amino acid starved for 1-2 
hour prior to imaging by washing the cells once with 1 ml of pre-warmed Dulbecco's 
(2.3) 
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phosphate-buffered saline (DPBS) containing magnesium and calcium and 
incubated in 1 ml DPBS prior to imaging. DPBS was used as it prevents cells from 
detaching over long period incubations compared to PBS. Leucine (1 mM) and 
serine (500 mM) (Sigma-Aldrich) were made in full serum media and added 
dropwise directly onto cells already in 1 ml media using a pipette to initiate 
activation. Rapamycin (200 nM or 250 nM) (Sigma-Aldrich) and AZD2014 (200 nM 
or 7 μM) (MedChem Express) were also made in full serum media and added in a 
dropwise manner to initiate inhibition.  
2.2.46 Confocal imaging of live and fixed cells 
Confocal images were acquired using either an inverted Nikon TE2000-U or Ti-E 
microscope with a Nikon C1 or C2 confocal scanning unit with a GFP (488 nm 
excitation) or mDsRed/mCherry/Alexa Fluor 555 (543 or 561 nm excitation) and 
mTurquoise2/Alexa Fluor 405 (405 nm excitation) filter set, or by using a Leica TCS 
SP8X confocal microscope using internal GFP, mCherry software settings and 
filters, or using a Zeiss LSM 880 microscope with Airyscan with a 405 nm excitation 
laser and internal Alexa405 Fluor filter.  
2.2.47 Quantifying percentage of cytoplasmic or nuclear fluorescence in cells 
Levels of GFP/RFP in live cells or fluorescence intensity from conjugated-
fluorescent secondary antibodies in fixed cells were determined in the nucleus and 
the cytoplasm per cell by masking sub-cellular regions in ImageJ (version 1.48) and 
incorporating extracted mean intensity values to Equation 2.4 or Equation 2.5:  
 
% 𝑪𝑪 =  �
𝑰𝑰𝑐𝑐
𝑰𝑰𝒕𝒕
� × 𝟏𝟏𝟐𝟐𝟐𝟐 (2.4) 
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% 𝑵𝑵 =  �
𝑰𝑰𝑁𝑁
𝑰𝑰𝒕𝒕
� × 𝟏𝟏𝟐𝟐𝟐𝟐 
where percentage in the cytoplasm is % C, percentage in the nucleus is % N, mean 
intensity in the cytoplasm is IC, mean intensity in the nucleus is IN and mean total 
intensity in both the cytoplasm and nucleus is It.  
2.2.48 UV-Vis and fluorimeter studies 
Inhibitor concentrations of rapamycin (10 µM), AZD2014 (7 µM or 11 µM) and 
INK128 (7 µM or 16 µM) were prepared in 2 ml of DMSO (Thermofisher Scientific) 
or in other solutions such as 0.5-1 mM BSA, water or PBS. Purified GFP was 
prepared in water. The solutions were vortexed mixed and the tubes wrapped in 
aluminium foil to protect the drugs from photo-bleaching or photo-damage by 
ambient light. Using a UV quartz glass cuvette (Hellma) measurements were taken 
using a UV-Vis spectrometer (Shimadzu) or fluorescence spectrometer (Agilent 
Technologies). 
2.2.49 Determining quantum yields of AZD2014 in solution 
The quantum yields of AZD2014 in DMSO and PBS were calculated using 
standards, Coumarin-1 (Exciton, UK) in ethanol (Sigma-Aldrich), Quinine (Sigma-
Aldrich) in 0.5 M sulphuric acid and Rhodamine 6G (Exciton, UK) in ethanol with 
known quantum yields of 0.73, 0.55 and 0.94 in ethanol, respectively. Quantum 
yields were determined by measuring the absorbance of AZD2014 and standard 
solutions at concentrations with similar ODs below 0.1 (absorbance) using a UV-Vis 
spectrometer and then converting these to fraction of light absorbed (1-10-OD). 
Relative fluorescence intensities see section 2.2.48, at a single excitation (393 nm) 
under the same detection settings were also measured. The relative and 
comparative methods were used to extract the quantum yield using Equation 2.6.  
(2.5) 
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𝑄𝑄 = 𝑄𝑄𝐹𝐹
𝐼𝐼
𝐼𝐼𝐹𝐹
𝐴𝐴𝐹𝐹
𝐴𝐴
𝑛𝑛2
𝑛𝑛𝐹𝐹2
 
where Q is the unknown quantum yield of the sample, QR is the quantum yield of the 
standard, I is the integrated fluorescence intensity of the sample, IR is the integrated 
fluorescence intensity of the reference standard, AR is the absorbance of the 
standard, A is the absorbance of the sample (scatter considered), n2 is the refractive 
index of the sample and n2R is the refractive index of the standard.   
The comparative method was used to determine quantum yields by plotting the 
absorbance and integrated fluorescence intensities of three different dilutions of the 
sample and standards. The slope of the line obtained could be substituted for both [I 
/IR] and [ODR /OD] in the equation above. 
2.2.50 Two-photon FRET-FLIM setup for interaction and spectroscopy studies 
Principles of FRET and FLIM are briefly covered in Chapter 1: Introduction. For 
multiphoton FLIM acquisition, the settings and instrument setup used has been 
described previously (Yadav et al., 2013). Briefly, multiphoton excitation using 910 ± 
5 nm or 600 ± 5 nm from a tuneable mode-locked titanium sapphire (Ti:Sapphire) 
laser (Mira 900, Coherent Lasers, UK) that generated 180 fs pulses at 76 MHz 
pumped by a 532 nm solid-state Neodymium Vanadate  laser source (Verdi, 
Coherent Lasers) was used. Alternatively, the wavelength range of the MIRA-900 
was extended using Optical Parametric Oscillators (Mira-OPO, Coherent Lasers, 
UK). FLIM images of 256 x 256 pixels were acquired. Collected fluorescence 
emission was passed through a BG39 bandpass filter (Comar) for laser excitation 
rejection and GFP collection or through 460/60 nm (Semrock) for selective AZD2014 
collection before reaching a high speed hybrid detector (HPM-100) for Time-
Correlated Single Photon Counting TCSPC (Becker-Hickl, GmbH). The laser power 
(2.6) 
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was controlled using a circular Neutral Density (ND) filter and the setup is depicted 
in Figure 2.15.  
 
 
Figure 2.15: Schematic of multiphoton FRET-FLIM system. The above figure was 
adapted from (Schoberer and Botchway, 2014) 
The high repetition femtosecond pulsed excitation beam from the Ti:Sapphire  was 
focussed onto the sample on the microscope stage by using a high numerical 
aperture (1.2) x60 water immersion (WI) objective (Nikon). The TCSPC PC module 
SPC830 (Becker-Hickl) was synchronised to the Nikon scanning unit (x,y and pixel 
clock signals). The synchronisation or ‘sync’ signal was derived from the pulses of 
the Ti:Sapphire laser in order to have a reference for the timing of the  fluorescent 
photons arrival after the excitation pulses. This allowed for the detection and 
measurement time of single fluorescent photon arrival time from the sample relative 
to the excitation pulse enabling the build-up of a histogram of photons emitted over 
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time in picoseconds. This information was built up in the TCSPC PC card or in the 
computer memory to store fluorescent photon distributions both temporally (t) and 
spatially, pixel by pixel (x,y). A Constant Fraction Discriminator (CFD) following the 
detector signal was used as a stop signal in a forward ready mode. A Time-to-
Amplitude Converter (TAC) was used to record the time of a detected photon with 
respect to the ‘sync’ and CFD by generating an output voltage that ended with the 
start of the next detected photon. An Analog-Digital Converter (ADC) was used to 
convert the electrical TAC signal into a digital signal to be stored on the memory of 
the TCSPC unit.  
As the Instrument Response Function (IRF) of the detector was 31 picoseconds (ps) 
(measured using KDP crystals) and the electrical response was 6.8 ps with an 
electrical timing jitter of 3 ps RMS, very accurate and short lifetimes could be 
measured with high precision using this setup. For protein-protein interaction 
studies, cells equally expressing EGFP and mCherry tagged proteins were selected 
and imaged in First-In-First-Out (FIFO) Imaging mode where the photon data was 
sent directly onto the memory of the computer rather than the TCSPC card. FLIM 
images were acquired using 0.25-6 mW of laser power for the sample excitation 
depending on the intensity of the fluorescence. The acquisition times were 60-120 
seconds or until the final counts collected were at least 100 counts per pixel in the 
first peak channel from the rise time. The files were imported into the SPC Image 
(version 6.0) software and fitted to mono-exponential decay models convoluted with 
the IRF by an algorithm to extract model parameters such as lifetime, amplitude and 
chi-square (goodness of the fit). The fluorescence lifetime (τ) of a molecule is the 
average time it spends in the excited state following excitation and emission of a 
fluorescence photon. The weighted average (τm) of the different lifetime components 
in each pixel of a multi-exponential decay profiles can be extracted from Equation 
2.7: 
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∑ 𝑎𝑎𝑖𝑖𝜏𝜏𝑖𝑖
2𝑁𝑁
𝑖𝑖=1
∑ 𝑎𝑎𝑖𝑖𝑁𝑁𝑖𝑖=1 𝜏𝜏𝑖𝑖
 
where the mean lifetime (τm) corresponds to the total number of fluorophores (N), ai 
and τi are respectively amplitude and lifetime respectively for the (i) fluorophore. 
The goodness of the fit was evaluated through the reduced chi-square (χ2) value, 
defined in Equation 2.8:  
𝑥𝑥2 = 1
𝑁𝑁−𝑝𝑝
∑ (𝑑𝑑𝑖𝑖−𝑓𝑓𝑖𝑖)
2
𝑑𝑑𝑖𝑖
𝑁𝑁
𝑖𝑖=1  
where di represents real data points and fi the corresponding points from the fit-
model. N represents the total number of time sample points and p is the number of 
fitting parameters. The reduced chi-square can be calculated from the fitted lifetime, 
1 being indicative of a “perfect fit”, a value >1 or <1 indicates that the model is over-
fitting or under-fitting the data. 
Where the counts were insufficient to give a good chi-square, pixels were binned to 
a factor of 2 where surrounding pixels were summed to give a better statistics per 
pixel. A final FLIM image matrix is obtained where each pixel is colour-coded 
accordingly to its lifetime and chi-square value, and a histogram showing the lifetime 
distribution (number of pixels vs lifetime values) of the complete imaged area is 
produced. To statistically determine differences between lifetime distributions of 
donor alone and donor with acceptor, distributions were fitted to a Gaussian model 
and Full Width at Half Maximum (FWHM) was obtained. As well as cell based 
imaging studies, TCSPC measurements (O’Connor and Phillips, 1984) were also 
performed for in-solution studies where drops of samples (e.g. inhibitors) in solution 
or purified protein solutions were placed on open coverslips (VWR) to determine 
fluorescence lifetime changes. Purified GFP and AZD2014 were prepared in ethyl 
(2.7) 
(2.8) 
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glycol (Sigma-Aldrich) with water and mixed 1:1 to make solutions for in solution 
FRET.  
2.2.51 One-photon FRET-FLIM setup for interaction and spectroscopy studies 
A similar system to the one described above, where one-photon pulsed excitation 
sources, namely a 405 nm pulsed laser (405BDL, Becker-Hickl) or a pulsed NKT 
supercontinuum laser set to 488 nm laser was used to perform one-photon FRET-
FLIM. The laser pulses were synchronised with the TCSPC PC module SPC150 
(Becker-Hickl). The fluorescence emission was passed through a 515/30 (Thorlabs) 
filter or through a 460/60 nm (Semrock) before reaching the hybrid detector.  
2.2.52 Lightsheet setup for monitoring AZD2014 uptake in spheroids  
A commercial light sheet fluorescence microscope, the Leica TCS SP8 DLS (Digital 
Light-Sheet), was used to acquire 3D time-lapse images of spheroids after 
administration of AZD2014. The basic principle of this technique is that the detection 
of the sample is acquired perpendicularly to the illumination axis. The illumination 
consists of a beam of light, shaped into the so-called “sheet”, exciting in one shot 
only the fluorescence of the sample at the focal plane of the detection objective. 
This technique produces fast imaging of wide fields of view with subcellular detail in 
a less phototoxic way compared to confocal and multiphoton microscopy, allowing 
for long-term time-lapse imaging. The use of a CMOS camera for the detection 
enables the fast volumetric imaging, allowing collection of quasi-real time data for 
longer periods of time. 
With the commercial Leica TCS SP8 DLS, stacks of images were acquired using a 
10X/0.3 NA detection objective, with a field of view of 735 µm x 735 µm. For the light 
sheet generation, a laser emitting at 405 nm wavelength was used, focused with a 
2.5X/0.07 NA objective and scanned by galvanometric mirrors, digitally creating a 
light sheet with a thickness of 3.7 µm and a Rayleigh length of 240 µm. Two 
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counter-propagating light sheets were also used in order to reduce blur, reduce 
striping effect and improve the image quality of the acquired sample, and were 
automatically merged into a single image. 
HEK293 cell spheroids, following 72 hours of seeding in agarose-coated 96 U-well 
plates, were pipetted into a custom 3D printed agarose holder (capable of hosting 
up to 5 spheroids) that was placed inside a 35 mm glass bottom dish and filled with 
7 ml of complete growth media. The samples were placed inside the Leica TCS SP8 
DLS box, with the temperature set at 37°C and CO2 set to 5%. The compound 
AZD2014 was administrated in the media, and uptake into spheroids was monitored 
for 2 hours by recording stacks of 780 µm x 780 µm x 300 µm volume composed of 
44 planes taken every 15 seconds. 
2.2.53 Quantifying uptake of AZD2014 in cellular models   
The fluorescence intensities of AZD2014 or INK128 in either monolayer HEK293 or 
multi-cellular spheroids over time from point of administration were extracted using 
ImageJ and then modelled using Michaelis–Menten type kinetics where K constant, 
Kuptake in this case, can be used to determine rate of uptake as given in Equation 
2.9:  
 
𝐹𝐹𝐼𝐼 =
𝐹𝐹𝑚𝑚𝑎𝑎𝑚𝑚 ×  𝑡𝑡
𝐾𝐾𝑢𝑢𝑝𝑝𝑡𝑡𝑎𝑎𝑘𝑘𝑒𝑒 + 𝑡𝑡
 
where FI is fluorescence intensity, Fmax is the maximum fluorescence intensity, t is 
time and Kuptake is the time at half maximum fluorescence intensity saturation. 
2.2.54 Lambda scan for multiphoton excitation of AZD2014 
Series of confocal images were taken using the Leica TCS SP8 in xyλ acquisition 
mode, steps of 5 nm using a defined wavelength range (from 680-1300 nm) with an 
(2.9) 
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InSight® DS ultrafast (120 fs pulse width) laser system (Spectra-Physics, UK) for 
multiphoton imaging. This laser system is more advantageous than Ti:Sapphire 
ultrafast lasers as it offers double the tuning range and gap free tuning. 
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3.0 S6K1 interaction and phosphorylation 
with mTORC1 in living cells 
 
3.1 Brief introduction 
The interactions of the S6K1 kinase protein with mTOR and its subunit binding 
proteins has been implicated using fixed cells and pulled down techniques. Despite 
current knowledge on S6K1 function as a major effector in regulating protein 
synthesis and cellular growth, live cell studies are lacking. This chapter seeks to 
develop the understandings of S6K1 localisation, interaction, regulation and 
phosphorylation in relation to the mTORC1 pathway in live cells. In particular, this 
programme of work aims to develop experimental methods to identify the direct sub-
cellular location and regions of mTOR activity. Ultimately, it is hoped this work will 
aid the development of novel treatments against mTOR disease states including 
cancer where targeting S6K1 interaction with mTORC1 may result in more selective 
and potent therapy.  
The working hypothesis of this chapter is that:  
• The S6K1 (mTOR substrate) is recruited onto mTORC1 via the TOS motif of 
S6K1. Physical interaction between S6K1 and the raptor in the cytoplasm is 
aided by mTOR initially in the nucleus. The combination of these steps leads 
to the phosphorylation of S6K1 by mTOR which is assisted by S6K1 
conformational changes. 
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3.2 Results 
3.2.1 PCR screening of EGFP-S6K1, S6K1-mCherry and S6K1-mTurq2 
constructs  
In order to observe the live cell localisation of S6K1, fluorescently tagged S6K1 
constructs were made by in-fusion cloning as described in Chapter 2: materials 
and methods. Full length S6K1 cDNA was cloned into the pOPINN-EGFP, 
pOPINE-3C-mCherry and pOPINE-3C-mTurquoise2 backbone vectors to produce 
constructs with S6K1 tagged on either the N- or C- terminus. A PCR screen using a 
pOPIN T7 forward primer and reverse S6K1 primer was performed to assess the 
success of the cloning prior to sequencing. PCR bands of the insert product 
corresponding to correct base pair lengths (~2522 and ~1741 bp) were observed 
corresponding to EGFP-S6K1 and S6K1 only respectively from EGFP-S6K1 and 
S6K1-mCherry/S6K1-mTurq2 plasmids shown in the gel of Figure 3.1. Constructs 
were Sanger sequenced and results showed a positive match to the original S6K1 
sequence, indicating that S6K1 was successfully cloned into the pOPINN-EGFP and 
pOPINE-3C-mCherry/ pOPINE-3C-mTurquoise2 vectors.  
 
Figure 3.1: Reverse PCR screen of S6K1 constructs. Analysis of PCR products ran using 
agarose gel electrophoresis. Marker is shown on the left (bp) with insert products on the right 
with bands corresponding to EGFP with S6K1 in the pOPINN-EGFP vector and S6K1 only in 
both the pOPINE-3C-mCherry/ mTurquoise2 (mTurq2) vectors.  
bp 
10037 
6000 
4000 
3000 
2500 
2000 
1500/17 
1000 
800 
EGFP + S6K1 (~2522 bp) 
S6K1 (~1741 bp) 
125 
 
3.2.2 Expression and imaging of tagged S6K1 in live mammalian cells 
Upon the verification of the fluorescently tagged S6K1 constructs, HEK293 cells 
were transfected as described in Chapter 2: materials and methods, and the 
subcellular localisation of overexpressed S6K1 was imaged using single-photon 
confocal microscopy after 24 or 48 hours of transfection as shown in Figure 3.2. 
Overall, EGFP-S6K1, S6K1-mCherry, S6K1-mTurq2 and commercially available 
S6K1-GFPSpark constructs all localised in near equal amounts in both the 
cytoplasm and the nucleus. Fluorescence intensity ratios of 48 ± 2% in the nucleus 
and 52 ± 2% in the cytoplasm for EGFP-S6K1 and S6K1-mTurq2, 47 ± 2% in the 
nucleus and 53 ± 2% in the cytoplasm for S6K1-GFPSpark and 43 ± 2% in the 
nucleus and 57 ± 2% in the cytoplasm for S6K1-mCherry were determined. The 
tagging of S6K1 with the fluorescent protein mTurquoise2 did not disrupt nor 
interfere with S6K1 localisation. However, the use of the mCherry tag resulted in a 
more cytoplasmic localisation evident by an increase in the intensity ratio of 9.3%. 
This may be due to mislocalisation issues related to the leaking of mCherry tagged 
proteins into other cellular compartments (Ghodke et al., 2016).  
Different cell lines were also tested with EGFP-S6K1 transfected in HeLa or U2OS 
cells and similar nucleocytoplasmic localisations was observed by confocal 
microscopy after 24 or 48 hours of transfection, results are shown in Figure 3.3.  
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Figure 3.2:  Live cell localisation of both N and C-terminally tagged S6K1 in HEK293 
cells. Confocal images of A) EGFP-S6K1, B) S6K1-GFPSpark, C) S6K1-mCherry), D) 
S6K1-mTurq2 and E) graph showing % of nuclear and cytoplasmic intensities in HEK293 
cells expressing EGFP-S6K1, S6K1-GFPSpark, S6K1-mTurq2 and S6K1-mCherry (n=10 in 
each construct) from three independent experiments. Relative intensities quantified in 
ImageJ 1.48V. Error bars show the standard deviation. Scale bar = 10 μm in all images. 
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Figure 3.3:  Nucleocytoplasmic localisation of EGFP-S6K1 in other mammalian cell 
lines. Confocal images of EGFP-S6K1 expressed in A) HeLa and B) U2OS cells. Scale bar 
= 10 μm in all images. Imaging was representative of three independent experiments.  
3.2.3 Western blot validation of tagged S6K1 constructs  
After confirming the expression of EGFP-S6K1, S6K1-mTurq2 and S6K1-mCherry 
presented in Figure 3.2 and 3.3, these constructs were validated by Western 
blotting and probed for mTOR activity using antibodies. As described in Chapter 2: 
materials and methods, following 48 hours of transfection of EGFP-S6K1, S6K1-
mTurq2 and S6K1-mCherry in HEK293 cells, lysates were subjected to Western blot 
analysis and probed for mTOR mediated phosphorylation using anti-phospho-S6K1 
(T412/T389) primary antibodies and for S6K1 activity by using anti-phospho-RPS6 
(Ser235/236) antibodies. As shown in Figure 3.4, bands at 110 kDa (combined 
molecular weight of S6K1 and GFP) for phosphorylated S6K1 were observed in 
overexpressed samples compared to non-transfected control samples. Endogenous 
phospho-S6K1 bands were not detected in HEK293; see Appendix B.1. Western 
blot analysis of S6K1-mTurq2 functionality is shown in section 3.2.14. However, 
basal levels of phospho-RPS6 were detected, with a 6-fold increase when EGFP-
S6K1 was overexpressed. In summary, the combination of the Western blots 
confirms fully functioning S6K1 (i.e. capable of being phosphorylated by mTORC1) 
and validates the expression observed in sub-chapter 3.2.2.  
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Figure 3.4: Validation of fluorescently tagged S6K1 using Western blot analysis. 
Western blots of A) transfected (EGFP-S6K1) and non-transfected HEK293 cells labelled 
with anti-phospho-S6K1 (Thr389/412), as well as anti-vinculin (loading control) antibodies. B) 
Transfected (S6K1-mCherry) and non-transfected HEK293 cells labelled with anti-phospho-
S6K1 and anti-vinculin antibodies. C) Transfected (EGFP-S6K1) and non-transfected 
HEK293 cells labelled with phospho-RPS6 (Ser235/236) and anti-S6K1 antibodies.  
3.2.4 Live cell translocation of fluorescently tagged S6K1 from the nucleus to 
the cytoplasm 
EGFP-S6K1 was co-transfected with fluorescently tagged raptor to investigate the 
co-localisation and interaction between S6K1 and raptor in live HEK293 cells. 
Confocal imaging was used to determine the relationship between the two proteins. 
A novel change to a predominately cytoplasmic localisation, similar to that of raptor 
alone, of EGFP-S6K1 was observed upon mCherry-raptor co-expression with the 
movement of S6K1 out of the nucleus (Figure 3.5). Furthermore, it was found that 
this movement, termed ‘translocation’ throughout this thesis, correlated with 
increased intensity (levels) of mCherry-raptor co-expression as shown in Figure 
3.5C.      
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Figure 3.5: Translocation of S6K1 out of the nucleus to the cytoplasm with raptor co-
expression. Confocal images of A) EGFP-S6K1 with co-expression of B) mCherry-raptor. C) 
Graph of fraction of mean cytoplasmic/nuclear (C/N) S6K1 intensities against fraction of 
mean C/N raptor intensities. Data has been taken from three independent experiments. 
Intensities quantified in ImageJ 1.48V. Scale bar = 10 μm in all images. 
This observed translocation of S6K1 was further validated by co-transfecting 
HEK293 cells with different fluorescently tagged S6K1 and raptor constructs. As 
shown in Figure 3.6, the movement of mTurq2 or mCherry labelled S6K1 out of the 
nucleus to the cytoplasm with msDsRed or YFP tagged raptor was similar to that 
observed above with the EGFP and mCherry combination of the proteins; although 
for reasons unknown, the combination with YFP tagged raptor showed less efficient 
translocation in some cells. This inefficiency may be due to steric hindrance or 
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distortion from the bulkiness of the YFP tag (Pedersen, Carmosino and Forbush, 
2008) and thus may block the translocation event.  
 
Figure 3.6: Translocation of S6K1 out of the nucleus with other fluorescently tagged 
raptor proteins. Confocal images of A) S6K1- mTurquoise2 with B) mDsRed-raptor co-
expression. C) S6K1-mCherry with D) raptor-YFP co-expression and E) S6K1-mTurquoise2 
with F) raptor-YFP co-expression in HEK293 cells. Representative data from three 
independent experiments are shown. Scale bar = 10 μm in all images. 
To verify that the translocation was representative amongst other mammalian cell 
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imaged using confocal microscopy. Similar results as seen in HEK293 cells were 
observed in HeLa cells, see Figure 3.7, where S6K1 translocated with raptor co-
expression evident by a lack of GFP intensity in the nucleus. It is worth noting that 
the translocation was less efficient compared to that in HEK293 cells and this may 
be due to differences in transfection efficiency (~60%) and expression levels.  
 
Figure 3.7: Translocation of S6K1 in HeLa cells. Confocal images of A) EGFP-S6K1 and 
B) mCherry-raptor co-expressed in HeLa cells. Scale bar = 10 μm in all images. 
Representative data from three independent experiments are shown.  
3.2.5 S6K1 translocation with serum/AA starvation or inhibitor treatment  
Having identified the subcellular localisation of S6K1 with respect to the raptor 
scaffold protein, the significance of the S6K1 translocation process was next turned 
to. As nutrient regulation of cells is linked to mTOR mediated phosphorylation of 
S6K1, see Chapter 1, depriving HEK293 cells of nutrients was investigated to test if 
the translocation of S6K1 was associated with mTOR mediated phosphorylation. 
The combination of overnight serum and 1 hour of amino acid starvation of HEK293 
cells transiently co-expressing both EGFP-S6K1 and mCherry-raptor did not disrupt 
the translocation of S6K1 as shown by the confocal images in Figure 3.8 where 
EGFP-S6K1 remained predominately localised in the cytoplasm. Furthermore, the 
treatment of live HEK293 cells co-expressing both EGFP-S6K1 and mCherry-raptor 
with mTOR inhibitors such as rapamycin and AZD2014 for up to 17 hours also did 
not disrupt or revert the translocation of S6K1 (Figure 3.8), as mentioned above, 
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further demonstrating that the translocation may be independent of mTOR mediated 
phosphorylation.  
  
Figure 3.8: Effect of serum and amino acid starvation on translocated S6K1. Confocal 
images of live HEK293 cells co-expressing both A) EGFP-S6K1 and B) mCherry-raptor with 
17 hours of serum and 1 hour of amino acid starvation. C) EGFP-S6K1 and D) mCherry-
raptor with 17 hours of 200 nM rapamycin treatment. E) EGFP-S6K1 and F) mCherry-raptor 
with 17 hours of 200 nM AZD2014 treatment. Representative data from three independent 
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experiments are shown. Scale bar = 10 μm in all images. Any visual differences in 
translocation efficiency compared to previous figures are due to different contrast settings.  
3.2.6 S6K1 translocation with S6K1 TOS and phospho-domain mutations  
Having found that the S6K1 translocation process may not be dependent on mTOR 
phosphorylation, the S6K1 sequence was mutated to test if the S6K1 translocation 
was directly related to raptor binding. An S6K1 mutant construct (EGFP-F28A-
S6K1) was generated where phenylalanine at amino acid position 28 of the TOS 
motif known to mediate interaction with raptor was mutated to an alanine from the 
EGFP-S6K1 construct (see Chapter 2: materials and methods) and expressed 
either alone or co-expressed with mCherry-raptor in live HEK293 cells. Figure 3.9 
shows that the translocation of S6K1 out of the nucleus was inhibited in all cells with 
EGFP-F28A-S6K1 and mCherry-raptor co-expression as GFP intensity levels 
remained equally distributed in both the nucleus and cytoplasm, indicating that the 
translocation of S6K1 may be linked to raptor binding. Furthermore, the 
phosphorylation site on S6K1 in the EGFP-S6K1 construct was mutated to generate 
another mutant construct (EGFP-S6K1-T389A), where threonine at amino acid 
position 389, the target for mTOR phosphorylation, was mutated to an alanine. 
Confocal imaging results showed that when EGFP-S6K1-T389A was co-expressed 
with mCherry-raptor in HEK293 cells, no effect on S6K1 translocation was observed 
as well as no change in cytoplasmic S6K1 GFP distribution (Figure 3.9). From the 
experiments with the two mutant S6K1 forms it is concluded that the translocation of 
S6K1 event is independent of mTOR phosphorylation and rather may be related to 
an initial raptor interaction.  
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Figure 3.9: Effects of S6K1 mutations on S6K1 translocation with raptor. Confocal 
images of A) EGFP-F28A S6K1 (TOS motif mutant), B) EGFP-S6K1 T389A (phosphorylation 
mutant), C) EGFP-F28A S6K1 with D) mCherry-raptor co-expression, E) EGFP-S6K1 T389A 
with F) mCherry-raptor co-expression. Representative data from three independent 
experiments are shown. Scale bar = 10 μm in all images. 
3.2.7 mDsRed acceptor unsuitability for multiphoton FRET-FLIM  
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out of the nucleus with raptor co-expression may be related to S6K1 directly binding 
to raptor in the cytoplasm. To investigate whether S6K1 and raptor underwent a 
direct physical interaction, FRET-FLIM were performed on HEK293 cells co-
expressing EGFP-S6K1 (donor) and mDsRed-raptor (acceptor). Cells expressing 
equal intensities of both fluorescently tagged molecules were selected and imaged 
as described in Chapter 2: materials and methods. Figure 3.10 gives the results 
for the fluorescence lifetime measurements of EGFP-S6K1 in the presence of 
mDsRed-raptor. Whilst the value of 2.40 ± 0.03 ns is lower than the natural lifetime 
of EGFP-S6K1 (2.60 ± 0.01 ns), suggests an interaction between the two proteins, 
this however requires further analysis and is discussed below. In order to establish 
the assembly of S6K1 onto the complex, HEK293 cells were co-transfected to 
express both EGFP-S6K1 and mDsRed-Rheb. FRET-FLIM imaging showed 
quenching of the lifetime of EGFP-S6K1 (stated above) to 2.40 ± 0.05 ns (Figure 
3.10). Whilst a reduction of 200 ps normally indicates a direct interaction, before any 
conclusions may be drawn from FRET-FLIM measurements, it is necessary to 
perform a few validation checks.  
HEK293 cells expressing mDsRed alone were excited at 910 nm, the same 
wavelength used to excite the GFP donor. An emission of mDsRed using filters to 
collect GFP emission was found indicating an evoked green emission upon 
multiphoton excitation. The decay of this emission was short with a lifetime of 435 ± 
11 ps. However, the decay fitted best to a multi-exponential in comparison to the 
mono-exponential decay of EGFP (Figure 3.11). The importance of this result 
means a skewed lifetime measurement towards shorter values. This is discussed at 
the end of the chapter in 3.3 Discussion. In comparison, another acceptor 
fluorescent protein, mCherry was imaged at the same settings and no photon count 
was collected, evident by no image in the FLIM (Figure 3.11). This showed that 
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mCherry is a more suitable acceptor for multiphoton FRET-FLIM and does not give 
any green emission upon multiphoton excitation.  
 
Figure 3.10: Live cell S6K1 interaction with mDsRed-mTORC1 acceptor proteins. A) 
Confocal image of EGFP-S6K1 in HEK293 cells. B) FLIM image of the fluorescent lifetimes 
of EGFP-S6K1. C) Corresponding lifetime distribution map of each pixel lifetime value with a 
lifetime mean (τm). D) Confocal images of EGFP-S6K1 with E) mDsRed-raptor co-
expression. F) FLIM image of the fluorescent lifetimes of EGFP-S6K1 with G) Corresponding 
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lifetime distribution map. H) Confocal images of EGFP-S6K1 with I) mDsRed-Rheb co-
expression. J) FLIM image of the fluorescent lifetimes of EGFP-S6K1 with K) Corresponding 
lifetime distribution map. All FLIM images generated by the FLIM analysis software and 
distributions exported (B&H SPCImage version 6.0). Representative data from three 
independent experiments are shown. Error bars show the standard deviation. Scale bar = 10 
μm in all images.  
 
Figure 3.11: mDsRed unsuitable for multiphoton GFP-RFP (protein-protein) FRET-
FLIM studies. A) Confocal image of mDsRed only in HEK293 cells. B) FLIM image of the 
fluorescent lifetimes of mDsRed at 910 nm excitation. C) Corresponding lifetime distribution 
map of each pixel lifetime value with a lifetime mean (τm). D) Confocal image of mCherry 
only in HEK293 cells. E) FLIM image of the fluorescent lifetimes of mCherry at 910 nm 
excitation. F) Corresponding lifetime distribution map of each pixel lifetime value. All FLIM 
images generated by the FLIM analysis software and distributions exported (B&H SPCImage 
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version 6.0). G) Fitted mono-exponential decay of EGFP on a y-axis log scale. H) Fitted 
multi-exponential decay of mDsRed on a y-axis log scale. Scale bar = 10 μm in all images.  
3.2.8 S6K1 interaction with raptor in live cells using FRET-FLIM 
Having confirmed the suitability of mCherry as an acceptor for multiphoton FRET-
FLIM with GFP tagged proteins, FRET-FLIM was then performed on live HEK293 
cells co-expressing EGFP-S6K1 and mCherry-raptor. As shown in Figure 3.12, the 
lifetime of EGFP-S6K1 (2.6 ± 0.01 ns) was quenched to 2.4 ± 0.05 ns when co-
expressed with mCherry-raptor. The quenching of the EGFP-S6K1 lifetime 
appeared to be stronger in the cytoplasm with a lifetime of 2.3 ± 0.03 ns where 
raptor is predominately localised, compared to the lifetime (2.4 ± 0.05 ns) of whole 
cells (Figure 3.12H). This indicates direct physical interaction between S6K1 and 
raptor in living cells. The change in donor lifetime was statistically determined by 
fitting to a gaussian function as shown in Figure 3.12J, and a difference of 200 ps in 
the peak profile identified, a value considered to be significant as discussed in sub-
chapter 3.3: Discussion. These interaction studies provide strong evidence to 
support the notion that the translocation of S6K1 to the cytoplasm with raptor co-
expression is related to its interaction.  
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Figure 3.12: Direct interactions between S6K1 and raptor in living cells. Confocal image 
of A) EGFP-S6K1 expressed in HEK293 cells. B) FLIM image of the fluorescent lifetimes of 
EGFP-S6K1. C) Corresponding lifetime distribution map of each pixel lifetime value with a 
lifetime mean (τm). Confocal images of D) EGFP-S6K1 with G) mCherry-raptor co-
expression. E) FLIM image of EGFP-S6K1. F) Corresponding lifetime distribution map of 
each pixel lifetime value. H) Graph of FRET changes between cytoplasm and whole cell 
lifetimes. I) Schematic of proposed interaction. J) Graph showing lifetime separation of 
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EGFP-S6K1 (donor) with EGFP-S6K1 and mCherry-raptor (acceptor) fitted in MATLAB 
V.R2013A in conjunction with ezyfit software (V.2.42)  to a Gaussian distribution 'a*exp(-((x-
x_0)^2)/(2*sigma^2))’ where x_0 = mean and 2*sigma is Full Width at Half Maximum 
(FWHM). All FLIM images generated by the FLIM analysis software and distributions 
exported (B&H SPCImage version 6.0). Experiments performed minimum of three 
independent times. Error representative of standard deviation. Scale bar = 10 μm in all 
images. 
3.2.9 S6K1 interaction with mTOR in live cells using FRET-FLIM 
The interaction between S6K1 and the rest of the subunit proteins, including mTOR, 
was also investigated to obtain a spatial understanding of S6K1 binding onto the 
complex. Figure 3.13 gives the donor lifetime of EGFP-mTOR alone (2.60 ± 0.01 
ns) in HEK293 cells and the lifetime of EGFP-mTOR co-expressed with S6K1-
mCherry (2.50 ± 0.04 ns). This lower lifetime change, 100 ps, in comparison to the 
200 ps interaction (found between S6K1 and raptor) suggests a weaker interaction 
between mTOR and S6K1 and this is discussed further in section 3.3: Discussion. 
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Figure 3.13: Interactions between S6K1 and mTOR in living cells. Confocal image of A) 
EGFP-mTOR expressed in HEK293 cells. B) FLIM image of the fluorescent lifetimes of 
EGFP-mTOR. C) Corresponding lifetime distribution map of each pixel lifetime value with a 
lifetime mean (τm). Confocal images of D) EGFP-mTOR with E) S6K1-mCherry co-
expression. F) FLIM image of EGFP-mTOR. G) Corresponding lifetime distribution map of 
each pixel lifetime value. H) Schematic of possible dynamic or long distance interaction that 
could be masked in lifetime collection. Black dashed arrow shows possible dynamic 
movement/conformational change. Experiments performed a minimum of three independent 
times. Error representative of standard deviation. Scale bar = 10 μm in all images. 
3.2.10 Lack of S6K1 interaction with Rheb in live cells using FRET-FLIM 
FRET-FLIM experiments were also performed between EGFP-Rheb and S6K1-
mCherry, co-expressed in living HEK293 cells. As shown in Figure 3.14, no 
interaction between S6K1 and Rheb was observed as evident by lack of change in 
the natural lifetime of EGFP-Rheb (2.5 ± 0.01 ns). In addition, the lack of 
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interactions between Rheb and S6K1 were supported by co-localisation studies 
using high resolution imaging. The results obtained showed poor co-localisation of 
S6K1 and Rheb when EGFP-S6K1 was co-expressed with mDsRed-Rheb in live 
HEK293 cells. An absence of S6K1 fluorescence in the ER/Golgi/peri-nuclear 
regions was observed whilst Rheb fluorescence was higher in these sub-cellular 
regions (Appendix B.2). 
 
Figure 3.14: Interactions between S6K1 and Rheb in living cells. Confocal image of A) 
EGFP-Rheb expressed in HEK293 cells. B) FLIM image of the fluorescent lifetimes of 
EGFP-Rheb. C) Corresponding lifetime distribution map of each pixel lifetime value with a 
lifetime mean (τm). Confocal images of D) EGFP-Rheb with E) S6K1-mCherry co-expression. 
F) FLIM image of EGFP-Rheb. G) Corresponding lifetime distribution map of each pixel 
lifetime value. H) Schematic of proposed long distance interaction. Representative data from 
three independent experiments are shown. Error representative of standard deviation. Scale 
bar = 10 μm in all images. 
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3.2.11 S6K1 pull-down with raptor, mTOR and Rheb 
To further validate the FRET-FLIM findings, pull-down (co-immunoprecipitation) 
assays were performed in HEK293F cells expressing the following constructs alone 
or in combination: EGFP-S6K1, mCherry-raptor, FLAG-mTOR and mDsRed-Rheb. 
Experimental detail of this technique is given in Chapter 2: materials and 
methods. Complexes were bound to nickel resins and eluted. As summarised in 
Figure 3.15 from the compilation of Western blots and coomassie gels; pulled-down 
results were in line with the FRET-FLIM data where strong interaction between 
S6K1 and raptor was observed while a weak interaction between S6K1 and mTOR 
and no interaction with Rheb were detected. Furthermore, S6K1 with both mTOR 
and raptor were all pulled-down together indicating S6K1 is bound onto the complex.  
3.2.12 S6K1 interaction with FKBP12 in live cells using FRET-FLIM 
Having placed S6K1 onto mTORC1, the assembly and relative orientation of S6K1 
binding onto the complex as a whole was investigated by determining the interaction 
between S6K1 and the FKBP12-rapamycin complex, known to bind to mTOR 
(Sabers et al., 1995). HEK293 cells co-expressing both mCherry-FKBP12 and 
EGFP-S6K1 were treated with rapamycin for 30 minutes and then imaged using 
FRET-FLIM. The natural lifetime of EGFP-S6K1 (2.6 ± 0.01 ns, as stated in 3.2.8) 
was quenched to 2.50 ± 0.02 ns in the presence of mCherry-FKBP12-rapamycin, 
shown in Figure 3.16. This 100 ps change in lifetime was similar to that observed 
between mTOR and S6K1 (see 3.2.9) and falls outside the 200 ps confidence for a 
direct interaction, suggestive of long distance interactions with S6K1 binding 
equidistantly to both FKBP12-rapamycin and mTOR.  
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Figure 3.15: Pull-down interactions between S6K1 and mTORC1 in mammalian cells. 
A) Western blots of denatured (by SDS) eluted complexes (from 40 µL of eluted sample) of 
S6K1 + raptor, S6K1 + mTOR, S6K1 + raptor + mTOR and S6K1 + Rheb are shown from 
HEK293F cells. Presence of all expected interacting proteins + His-EGFP-S6K1 (“bait” 
protein) shows interaction in the co-IP blots whilst absence of expected binding protein + 
presence of His-EGFP-S6K1 (“bait” protein)  indicates no interaction. Summary of 
interactions are shown and assigned (yes/no) Y/N. B) Lysates are shown (input) of lysed 
soluble sample before pull-down (from 1 mL of sample). HA-mCherry-raptor was blotted for 
using anti-raptor antibodies, His-EGFP-S6K1 was blotted for using anti-His antibodies, 
mDsRed-Rheb was blotted using anti-Rheb antibodies and FLAG-mTOR was blotted for 
using anti-FLAG antibodies. Full-length gels and blots are presented in Appendix B3. 
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Figure 3.16 Interactions between S6K1 and FKBP12-rapamycin in living cells. Confocal 
images of A) EGFP-S6K1 with B) mCherry-FKBP12 co-expressed and treated with 
rapamycin (1 µM) for 30 minutes in HEK293 cells. C) FLIM image of the fluorescent lifetimes 
of EGFP-S6K1. (D) Corresponding lifetime distribution map of each pixel lifetime value with a 
lifetime mean (τm). E) Predicted schematic of S6K1 interaction with mTOR and the FKBP12-
rapamyin complex. Representative data from three independent experiments are shown. 
Error representative of standard deviation. Scale bar = 10 μm in all images. 
3.2.13 PCR screen of ΔmTOR-mCherry and sequencing of raptor-YFP 
Multi-colour tagging of mTORC1 sub-unit proteins for studying the mTOR complex, 
its assembly and dynamics in living cells was addressed in light of the findings 
above where the expression of the raptor component was seen to be critical in the 
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recruitment of S6K1 onto the mTOR complex. To this end, other fluorescently 
tagged mTORC1 constructs were made. Full length mTOR cloned with a mCherry 
tag was attempted using in-fusion cloning (see Chapter 2: materials and 
methods). A PCR screen using a pOPIN T7 forward primer and reverse mTOR 
primer was carried out to verify the plasmid. However, unexpectedly as shown in 
Figure 3.17A, a PCR band of the insert product corresponding to a truncation 
(~2323 bp) was seen. This was further validated by sequencing. In addition, full 
length raptor was cloned with a YFP tag. Due to the large nature of the insert 
product (~4000 bp), a PCR screen was simulated using the pOPIN T7 forward 
primer and the reverse raptor primer using software (Figure 3.17B). After 
successfully simulating the PCR screen, the final construct was sent for sequencing 
and positively matched with the original raptor sequence as shown in Figure 3.17C.  
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Figure 3.17: PCR screen for ΔNmTOR-mCherry and sequencing of raptor-YFP. A) 
Analysis of PCR products ran by agarose gel electrophoresis with marker shown on the left 
(bp) and insert product on the right indicating a band corresponding to truncated mTOR in 
the pOPINE-3C-mCherry vector. B) Simulated analysis of PCR products by agarose gel 
electrophoresis using the SnapGene software. A band corresponding to full length raptor 
was predicted. C) Sequence alignment of sequencing results with original raptor sequence 
using Basic Local Alignment Search Tool (NCBI) (date generated 30_07_18). 
3.2.14 Imaging S6K1 translocation with mutated (ΔN) mTOR 
Having confirmed that the translocation of S6K1 in the living cell is a process driven 
by raptor binding and thus recruitment onto mTORC1, the mechanism of this event 
in relation to mTOR was investigated with the non-functional mTOR mutant 
generated in 3.2.13. Imaging multiple fluorescently tagged mTORC1 subunit 
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mCherry) in HEK293 cells by confocal microscopy showed that although S6K1 
translocation was present in wildtype (YFP-mTOR) triple-expression, S6K1 
translocation with the mutant was repressed (Figure 3.18). In addition, the 
expression of raptor yielded an increase in S6K1 phosphorylation determined by 
Western blot analysis while expression of the mutant mTOR resulted in an inhibition 
in phosphorylation, indicating that mTOR, particularly the N-terminus (Figure 3.18), 
may have an involvement in a secondary recruitment mechanism which may be 
required to stabilise S6K1 onto the complex.  
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Figure 3.18: Secondary recruitment mechanism involving functioning mTORC1. 
Confocal images of triple expression of A) YFP-mTOR, B) mCherry-raptor and C) S6K1-
mTurquoise2. Confocal images of D) N-terminal truncated mTOR-mCherry, E) raptor-YFP 
and F) S6K1-mTurquoise2. G) Structure of N-terminal truncated mTOR-mCherry construct 
showing domains and numbered amino acid sequence. H) and I) Western blots for phospho-
S6K1 with either raptor or ΔNmTOR-mCherry co-expression with S6K1. J) Schematic of 
proposed sequence of recruitment and interaction of S6K1 onto mTORC1. Representative 
data from three independent experiments are shown. Scale bar = 10 μm in all images. 
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3.2.15 Imaging S6K1 translocation with PRAS40 and 4EBP1 
Next, the relationship between other mTORC1 substrates such as PRAS40 and 
4EBP1 with S6K1 was investigated. Live HEK293 cells co-expressing fluorescently 
tagged 4EBP1 (4EBP1-GFPspark) with mCherry-raptor also showed a translocation 
effect with 4EBP1 moving out of the nucleus, giving a cytoplasmic localisation as 
shown in Figure 3.19. These results suggest that 4EBP1 could compete with S6K1 
for binding onto mTORC1 and this is presented below.  The PRAS40 protein, known 
to bind to both raptor and mTOR was expressed with a fluorescent tag (YFP-
PRAS40). YFP-PRAS40 localisation alone was cytoplasmic. When S6K1-mTurq2 
was expressed with mCherry-raptor and either 4EBP1-GFPSpark or YFP-PRAS40, 
a 2-times decrease in S6K1 translocation to the cytoplasm was observed as 
interpreted by the presence of mTurq2 intensity in the nucleus (Figure 3.19) 
indicating that the translocation/binding to raptor can be dynamically manipulated in 
living cells with other mTORC1 binding substrates.  
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Figure 3.19: Inhibition of S6K1 translocation with PRAS40 and 4EBP1 competitive 
binding. Confocal images of A) 4EBP1-GFPSpark only, B) YFP-PRAS40 only, C) 4EBP1-
GFPSpark with D) mCherry-raptor co-expression, E) graph showing cytoplasmic/nuclear 
intensity of S6K1 with raptor +/- 4EBP1 or PRAS40 expression (n=10) taken from three 
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independent experiments where the error represents the standard deviation. Confocal 
images of triple expression of F) YFP-PRAS40 with G) mCherry-raptor and H) S6K1-
mTurquoise2. Confocal images of triple expression of I) 4EBP1-GFPSpark with J) mCherry-
raptor and K) S6K1-mTurquoise2. L) Schematic of proposed dynamic interactions of other 
mTORC1 substrates. Yellow arrows show translocation of 4EBP1. Experiments performed a 
minimum of three independent times. Scale bar = 10 μm in all images. 
3.2.16 4EBP1 interaction with raptor using FRET-FLIM 
The interaction between 4EBP1 observed with mCherry-raptor was investigated 
using FRET-FLIM to support the hypothesis that just like with S6K1, the 
translocation event is related to direct physical interaction with the raptor scaffold 
protein. Figure 3.20 gives the natural lifetime of 4EBP1-GFPSpark in living HEK293 
cells as 2.40 ± 0.05 ns. Upon co-expressing with mCherry-raptor in HEK293 cells, 
the donor lifetime was quenched to 2.20 ±0.06 ns. These results show that 4EBP1 
directly interacts with raptor and may also be recruited onto mTORC1 in live cells.  
 
Figure 3.20: Interactions between 4EBP1 and raptor in living cells. Confocal image of A) 
4EBP1-GFPSpark. B) FLIM image of the fluorescent lifetimes of 4EBP1-GFPSpark. C) 
mTOR 
Rheb 
4EBP1-GFPSpark 
1800 2050 2300
Lifetime distribution 
τm =2.40 ± 
0.05 ns 
4EBP1-GFPSpark 
mCherry-raptor 
FLIM 
FLIM 
1800 2050 2300
Lifetime distribution 
τm =2.20 
± 0.06 ns 
A B C 
D 
E 
F G 
raptor 
4EBP1 
H 
FLIM 
153 
 
Corresponding lifetime distribution map of each pixel lifetime value with a lifetime mean (τm). 
D) Confocal image of mCherry-raptor co-expressed with E) 4EBP1-GFPSpark. F) FLIM 
image of the fluorescent lifetimes of 4EBP1-GFPSpark. G) Corresponding lifetime 
distribution map of each pixel lifetime value with a lifetime mean (τm). H) Proposed schematic 
of 4EBP1 interaction with mTORC1. Experiments performed a minimum of three 
independent times. Scale bar = 10 μm in all images. 
3.2.17 Phospho-S6K1 inhibition with rapamycin and Rheb 
As Rheb is known to activate mTORC1 (see Chapter 1), the regulation of S6K1 and 
the effect by Rheb was next examined. The overexpression of EGFP-S6K1 with 
mDsRed-Rheb in HEK293 cells resulted in a 128% induction in S6K1 
phosphorylation quantified by Western blot analysis as shown in Figure 3.21. 
Inhibition of S6K1 phosphorylation with rapamycin treatment was only observed 
when both EGFP-S6K1 and mDsRed-Rheb were co-expressed together (71% 
decrease in phosphorylation). This highlights Rheb to be sensitive to rapamycin 
treatment and may function in a role beyond upstream mTOR activation.  
 
Figure 3.21: S6K1 phosphorylation with Rheb expression and rapamycin treatment. 
Quantified western blot data showing % phospho-S6K1 of EGFP-S6K1 (phosphorylated 
S6K1/ total S6K1 x 100) with and without rapamycin (200 nM for 2 hour treatment) as well as 
with Rheb co-expression, with and without rapamycin treatment. Data representative of three 
independent experiments where error shows standard deviation. Red dotted line = baseline.  
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3.2.18 Imaging S6K1 translocation with both Rheb and rapamycin 
Using the information from section 3.2.17, studies were performed in HEK293 cells 
transfected with YFP-Rheb, S6K1-mTurqouise2 and mCherry-raptor and treated 
with and without rapamycin (1 µM) treatment (Figure 3.22). No effect was observed 
on the translocation of S6K1 as shown by no change in S6K1 nuclear fluorescence 
localisation, cementing the idea that the translocation of S6K1 is not triggered by 
mTOR mediated phosphorylation. The translocation of S6K1 to the cytoplasm may 
however be required for mTOR to function efficiently for S6K1 phosphorylation and 
this will be presented next. 
 
Figure 3.22: Effect of rapamycin on translocated S6K1 with Rheb expression. Confocal 
images of A) S6K1-mTurq2 co-expressed with B) mCherry-raptor. C) S6K1-mTurq2 triple 
expression with D) mCherry raptor and E) YFP-Rheb. F) S6K -mTurq2 triple expression with 
S6K1-mTurq2 mCherry-raptor 
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G) mCherry raptor and H) YFP-Rheb with 2 hour rapamycin (1 μM) treatment. Experiments 
performed a minimum of three independent times. Scale bar = 10 μm in all images. 
3.2.19 Immunofluorescence labelling of p-S6K1 in fixed cells   
The localisation of mTOR mediated phosphorylation of S6K1 was then investigated 
as follow-on from the interaction studies to study the mechanism of mTOR 
phosphorylation in the cell. The use of cell fixation with immunofluorescence 
labelling (see Chapter 2: materials and methods for details) was first turned to as 
a means to investigate the localisation of phospho-S6K1. Cells expressing EGFP 
tagged S6K1 were fixed with paraformaldehyde (formaldehyde), methanol (alcohol) 
or glyoxal (dialdehyde) fixatives. After permeabilisation, primary anti-phospho-S6K1 
and secondary fluorescently-conjugated antibodies were introduced and imaged as 
shown in Figure 3.23. Paraformaldehyde (PFA) fixation caused loss of soluble 
EGFP-S6K1 from the cytoplasm and this was evident by a loss of 37.3% GFP 
distribution in the cytoplasm. It was also observed that EGFP-S6K1 leaked into the 
nucleolus of the cells and that cells generally had more GFP in the nucleus which 
was not seen prior to PFA fixation. EGFP intensities were quantified to be 67.5 ± 4% 
in the nucleus and 32.5 ± 4% in the cytoplasm (Figure 3.24A). Imaging phospho-
S6K1 labelling in PFA fixed cells showed a similar localisation with 60 ± 2% in the 
nucleus and 40 ± 2% in the cytoplasm (Figure 3.24B). 
On the other hand, methanol fixation caused loss of EGFP-S6K1 mostly from the 
nucleus, as evident by the lack of green fluorescence with cytosolic membrane like 
the peri-nuclear region exhibiting high EGFP-S6K1 intensity. EGFP intensities were 
quantified to be 39.8 ± 4% in the nucleus and 60.8 ± 4% in the cytoplasm (Figure 
3.24A). Imaging phospho-S6K1 labelling in methanol fixed cells showed a similar 
localisation with 41 ± 8% in the nucleus and 59 ± 8% in the cytoplasm (Figure 
3.24B). 
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Interestingly, imaging glyoxal fixed EGFP-S6K1 cells provided the best localisation 
results close to live cell imaging as GFP distributions in both the nucleus and 
cytoplasm were maintained in almost equal amounts. EGFP intensities were 
quantified to be 49.5 ± 6% in the nucleus and 50.5 ± 6% in the cytoplasm (Figure 
3.24A). Imaging phospho-S6K1 in glyoxal fixed cells showed 40 ± 3% staining in the 
nucleus and 60 ± 3% staining in the cytoplasm (Figure 3.24B). The relative higher 
amounts of phospho-fluorescence in the cytoplasm show that mTOR mediated 
phosphorylation may be occuring in the cytoplasm. The studies performed with 
glyoxal fixation were not pursued further as the potential for the reagent as a fixative 
was not known at the start of the research project and only discovered towards the 
end.   
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Figure 3.23: Imaging the localisation of phospho-S6K1 in fixed EGFP-S6K1 expressing 
cells. Confocal images of paraformaldehyde fixed HEK293 cells expressing (A) EGFP-S6K1 
labelled with (B) anti-phospho-S6K1 and Alexa555 antibodies. Methanol fixed HEK293 cells 
expressing (C) EGFP-S6K1 labelled with (D) anti-phospho-S6K1 and Cy3 antibodies. 
Glyoxal fixed HEK293 cells expressing (E) EGFP-S6K1 and labelled with (F) anti-phospho-
S6K1 and Alexa555 antibodies. Experiments performed a minimum of three independent 
times. Scale bar = 10 μm in all images 
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Figure 3.24: Nuclear and cytoplasmic distributions of S6K1 and phospho-S6K1 in 
various fixatives. A) Bar graph of nuclear and cytoplasmic distributions of EGFP-S6K1 in 
live, paraformaldehyde, methanol and glyoxal fixed cells. B) Bar graph of nuclear and 
cytoplasmic distributions of phospho-EGFP-S6K1 (Cy3/ Alexa555) in paraformaldehyde, 
methanol and glyoxal fixed cells (number of cells = 10 for each sample) with error bars 
showing standard deviation. Representative data from three independent experiments are 
shown. 
3.2.20 S6K1 and p-S6K1 artefacts from immunofluorescence labelling 
In addition to the results found above, it was also observed that the PFA fixation 
process caused extraction of EGFP-S6K1 from the cytoplasm as evident by leaving 
areas or holes where protein was absent (Figure 3.25B). Furthermore, inefficient 
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labelling was observed at times in some cells where antibodies were unable to 
reach the nucleus of the cell, leaving a gradient effect staining appearance only in 
the cytoplasm (Figure 3.25). The differences in distribution of EGFP-S6K1 observed 
for the different fixation methods could hinder and compromise any conclusions 
regarding phospho-S6K1 localisation. It is also worth noting that PFA fixation of 
HEK293 cells caused a change in its natural lifetime of EGFP; see Appendix B.4, 
thus demonstrating the need for live cell FRET-FLIM imaging.  
 
Figure 3.25: Artefact generation from PFA fixation. Confocal images of HEK293 cells 
expressing A) EGFP-S6K1 with B) zoom-in area of yellow box. C) EGFP-S6K1 labelled with 
D) anti-phospho-S6K1 and Cy5 secondary antibody labelling. Experiments performed a 
minimum of three independent times. Scale bar = 10 μm in all images. 
3.2.21 p-S6K1 immunofluorescence labelling of translocated S6K1 
The localisation of phosphorylated S6K1 upon translocation of S6K1 was 
investigated using immunofluorescence staining. HEK293 cells expressing both 
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EGFP-S6K1 and mDsRed-raptor were fixed in PFA and labelled for anti-phospho 
S6K1. The translocated EGFP-S6K1 and labelled phospho-EGFP-S6K1 with 
Alexa405 showed similar levels of fluorescence in the cytoplasm, Figure 3.26, 
indicating that phosphorylation follows after the translocation of S6K1 and occurs in 
the cytoplasm. Although some soluble EGFP-S6K1 extraction from the cytoplasm 
may still have occurred as found in the previous subchapters, the more diffused 
localisation of S6K1 with raptor in the cytoplasm suggests that S6K1 may be 
tethered to sub-cellular structures preventing it from being extracted.  
 
Figure 3.26: Phospho-S6K1 labelling of translocated S6K1. Confocal images of A) 
EGFP-S6K1 with B) mDsRed-raptor co-expression with C) anti-phospho-S6K1 and Alexa405 
secondary antibody labelling. All cells fixed in PFA. Experiments performed a minimum of 
three independent times. Scale bar = 10 μm in all images. 
3.2.22 Quantification of overexpressed p-S6K1 with Rheb in fixed cells   
As overexpression of Rheb induces a dramatic increase in S6K1 phosphorylation, 
found earlier in section 3.2.17, it was hypothesised that higher expression of Rheb 
would lead to higher phospho-S6K1 staining levels in fixed cells co-expressing 
fluorescently tagged S6K1. Using transient overexpression as a useful tool to 
observe differing expression levels of Rheb, cells were fixed in PFA. Given in 
Appendix B.5, no clear correlation between highly expressing Rheb cells and 
phospho-S6K1 levels was observed, most likely owing to the fixation method. This 
was apparent by the findings that brighter Rheb cells did not show brighter phospho-
S6K1 fluorescence. However, the levels of phospho-S6K1 did appear to correlate to 
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the levels of S6K1 overexpressed (i.e. brighter GFP S6K1 cells showed brighter 
phospho-S6K1 fluorescence) and thus no conclusions could be made.   
3.2.23 Variation in endogenous p-S6K1 with antibody labelling  
A recognised hurdle to overcome in immunofluorescence staining is the lack of 
specificity and sensitivity of commercially available antibodies which are required to 
bind to the target of interest. This means non-specific antibody binding may lead to 
discrepancies in the localisation of phospho-S6K1 indicating that different antibodies 
to the same target could produce artefacts other than that induced by cell fixation 
shown in section 3.2.19. Although Western blot analysis, was unable to detect 
endogenous phospho-S6K1 levels (section 2.2.3), immunofluorescence labelling for 
determining the localisation of endogenous phospho-S6K1 was relied on using 
several commercial primary antibodies. When using the Cell Signalling antibody 
(#9234) homogenous levels of endogenous phospho-S6K1 fluorescence in the 
cytoplasm and nucleus were stained in both PFA fixed HEK293 and HeLa cells, 
whilst the Millipore (MABS82) antibody stain appeared more cytoplasmic in PFA 
fixed HEK293 cells, and to some degree in PFA fixed HeLa cells (Appendix B.6). A 
phospho-S6K1 antibody from Thermofisher Scientific (PA1-526) was also trialled in 
PFA fixed A431 and MCF-7 cells known to have inherit constitutive mTOR activity 
and thus higher phospho-S6K1 levels in those cell lines are expected, and the 
labelling stained the cytoplasm with higher fluorescence between cell junctions 
(Appendix B.6). Labelling with only secondary antibodies did not provide any 
labelling (controls) and these results are shown in Appendix B7.  
3.2.24 Localisation of endogenous p-S6K1 with Rheb in fixed cells   
After further trialling and validation, antibodies from St John’s Laboratory were used 
to label phospho-S6K1 and total S6K1 in PFA fixed HEK293 cells. Confocal imaging 
provided endogenous phospho-S6K1 and S6K1 localisation labelling results more in 
line with the current literature compared to that presented before. Endogenous anti-
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S6K1 labelling provided similar localisation staining to that observed with GFP 
tagged S6K1 overexpression by showing fluorescence staining in both the nucleus 
and cytoplasm in equal amounts. These results may be due to more specific 
labelling of this antibody compared to previously trialled antibodies for phospho-
S6K1. Interestingly, fluorescent punctate structures were observed with endogenous 
phospho-S6K1 staining and overall the majority of the fluorescence was localised in 
the nucleus of HEK293 cells (Appendix B.8). In order to investigate the 
translocation of phospho-S6K1 in fixed cells following the stimulation of S6K1 
phosphorylation, HEK293 cells with fluorescently labelled Rheb or raptor co-
expression were stained for phospho-S6K1. No change in endogenous phospho-
S6K1 localisation was observed as seen by a lack of change in fluorescence 
staining of sub-cellular distributions between transfected and non-transfected cells 
(Appendix B.8) demonstrating that phospho-S6K1 localisation may not be 
regulated by phosphorylation.  
3.2.25 Quantification of endogenous p-S6K1 with Rheb in fixed cells   
In order to obtain more insight into Rheb’s mechanism of activation in cells, the 
quantification of Rheb intensity against endogenous phospho-S6K1 levels in 
HEK293 cells fixed in PFA were carried out similar to that performed with 
overexpressed S6K1 in section 3.2.22. As seen with overexpressed S6K1, high 
Rheb levels (red fluorescence) did not correlate with higher phospho-S6K1 levels 
(green fluorescence) by cell-cell analysis as shown in Appendix B.9. These results 
suggest that poor fixation may affect S6K1 as a whole and that extraction of soluble 
proteins may also extend to endogenous proteins.  
3.2.26 PCR screen of mCherry-S6K1-EGFP 
Having faced issues with fixed cell imaging of S6K1 phosphorylation, attempts were 
made to determine S6K1 phosphorylation in living cells. Two fluorescent labels were 
tagged to either end of the S6K1 protein to make a donor-acceptor pair bio-sensor 
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that would undergo a FRET process following an induced conformational change 
post mTOR mediated phosphorylation (Komatsu et al., 2011; Zhou et al., 2015), see 
Figure 3.28A. The biosensor should ideally function in living cells and with this in 
mind was achieved by cloning mCherry and S6K1 together into the pOPINE-3C-
EGFP vector (see Chapter 2: materials and methods). A PCR screen was 
performed using the pOPIN T7 forward primer with a reverse S6K1 primer to confirm 
successful incorporation of insert product. Figure 3.27 shows a band at around 
2256 bp which equates to a mCherry combined with S6K1 PCR insert. Sequencing 
of both the join ends of the two insert products and vector ends further showed 
successful cloning. The construct was named S6K1 sensing of mammalian Target 
Of Rapamycin (SensOR).  
 
Figure 3.27: Reverse PCR screen of mCherry-S6K1-EGFP. Analysis of PCR product ran 
by agarose gel electrophoresis. Marker is shown on the left (bp) with insert product on the 
right with a band corresponding to mCherry combined with S6K1 in the pOPINE-3C-EGFP 
vector. 
3.2.27 S6K1 live cell FRET bio-sensor western blot validation 
A key goal of this thesis is to show that mCherry-S6K1-EGFP (SensOR) does 
undergo conformational changes upon phosphorylation and such changes can be 
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monitored using FRET-FLIM in living cells. An initial validation step for SensOR 
functionality was to perform Western blot studies on HEK293 cells expressing the 
construct and probing for mTOR mediated phosphorylation. A band at 130 kDA (MW 
of mCherry, S6K1 and EGFP combined) was detected by chemiluminescence using 
anti-S6K1 antibodies as well as a corresponding band using anti-phospho-S6K1 
antibodies at the same molecular weight, suggesting that the construct was 
functional (i.e. could be phosphorylated in the mTORC1 pathway), see Figure 3.28.  
 
Figure 3.28: Western blot validation of SensOR. A) Schematic diagram showing 
mechanism of biosensor. B) Western blots showing S6K1 and phospho-S6K1 labelling in 
mCherry-S6K1-EGFP (SensOR) transfected and non-transfected HEK293 cells.  
3.2.28 Phospho-S6K1 localisation in living cells using SensOR 
When SensOR was expressed in HEK293 cells and imaged, it was noticed that in 
highly expressing cells, the localisation of the SensOR appeared to be more 
cytoplasmic. Using FRET-FLIM, the fluorescence lifetime was measured of the bio-
sensor and a shorter lifetime (2.1 ± 0.06 ns) in the cytoplasm compared to the 
nucleus (2.3 ± 0.01 ns) was found (Figure 3.29). This difference in lifetime was less 
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pronounced in low to moderate expressing cells, HEK293 cells expressing the 
SensOR, but still observable (Figure 3.30). These lifetime changes mentioned 
above between the nucleus and cytoplasm were not observed with the singly tagged 
S6K1 construct (EGFP-S6K1) which showed a lifetime of 2.6 ns in both cellular 
compartments, indicating that the shorter lifetime in the cytoplasm may be linked to 
the phosphorylated state of S6K1; highlighting the importance of targeting S6K1 to 
the cytoplasm.  
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Figure 3.29: Localisation of phospho-S6K1 in living cells using SensOR. A) and B) 
Confocal images of biosensor alone in HEK293 cells. C) FLIM of SensOR with lifetime scale 
bar below in nanoseconds (ns). D) Cytoplasmic versus nuclear lifetime distributions of 
EGFP-S6K1. E) Graph showing cytoplasmic against nuclear lifetime distributions of 
SensOR, selected by masking and obtaining the mode lifetime in SPCImage V6.0 software. 
Data representative of three independent experiments. Scale bar = 10 μm in all images. 
Error represents standard deviation.  
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Figure 3.30: Localisation and cellular lifetimes of SensOR. A) and B) Confocal images 
showing S6K1-FRET construct. C) FLIM image of SensOR with lifetime scale. D) Graph 
comparing lifetime of SensOR between cytoplasm and nucleus in low to moderate SensOR 
expressing HEK293 cells. Data representative of three independent experiments. Scale bar 
= 5 μm in all images. Error represents standard deviation.  
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3.2.29 Imaging p-S6K1 with activation and inhibition in living cells  
To investigate the sub-cellular localisation of mTOR activity, the SensOR construct 
was tested by serum (overnight) and then amino acid (1-2 hours) starving 
expressing HEK293 cells to de-activate the mTOR pathway. The lifetime of the bio-
sensor was measured under these conditions and found to be 2.5 ± 0.03 ns (Figure 
3.31). This increase in lifetime, from 2.3 ns in SensOR expressed in cells with 
complete growth medium, is indicative of a subtle environment and/or 
conformational change of SensOR in living cells showing that the biosensor may not 
be in a phosphorylated form. Amino acids including leucine and arginine were then 
subsequently added to re-activate the mTOR pathway and the fluorescence 
immediately monitored. Within a few minutes lower lifetimes of 2.3 ± 0.02 ns were 
observed in the cytoplasm. These lifetimes were similar to those observed with 
untreated cells and indicative of phosphorylation. When these cells were then 
treated with rapamycin, lifetimes returned to 2.5 ± 0.04 ns (dephosphorylation), it 
was noted that the FLIM images showed such changes within the cytoplasm (Figure 
3.31). Taking all these findings together it was concluded that the cytoplasmic region 
is important for phosphorylation of S6K1. 
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Figure 3.31: mTORC1 activation and inhibition using SensOR. A) FLIM of serum and 
amino acid starved HEK293 cells expressing SensOR. B) FLIM at 10 minutes following 
serine and leucine activation. C) FLIM at 40 minutes after subsequent rapamycin treatment 
of AA activated cells for 30 minutes. D) Summary of lifetime changes of SensOR with serum 
starvation, amino acid addition and rapamycin treatment from mean lifetimes and also pixel 
by pixel analysis of image (n=10). Opening and closing of sensor also shown via schematics. 
Data representative of three independent experiments where two experiments were treated 
with leucine and the third treated with the combination of leucine and serine. Error 
represents standard deviation. 
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3.2.30 In vitro and in vivo temperature studies of purified SensOR  
Temperature dependence of the protein folding kinetics has been studied using 
FRET to show conformational changes within a kinase structure with temperature 
(Guo, Xu and Gruebele, 2012). Therefore, SensOR in live HEK293 cells was 
investigated in order to correlate lifetime values observed with phosphorylation in 
vivo with the opening and closing of the SensOR in vitro with temperature changes. 
To do this, mCherry-S6K1-EGFP was re-cloned with a STREP tag and expressed in 
insect cells and purified, see Chapter 5 for details regarding cloning, expression and 
purification. TCSPC measurements were performed on drops of purified SensOR, 
as described in Chapter 2: materials and methods. Preliminary data showed that 
the lifetime of the SensOR decreased (closing of sensor) with increasing 
temperature as shown in Figure 3.32. When compared to FLIM of in vivo work 
expressing the construct in live HEK293 cells, similar results were observed with 
lower lifetimes related to hotter temperature (Figure 3.32).  
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Figure 3.32: Temperature dependence study on SensOR folding. A) Graph showing 
lifetime of purified SensOR (60 μg) with temperature (°C) in vitro, fitted to polynomial order 2. 
Measurements taken from 6 repeats. B) FLIM of HEK293 cells expressing SensOR at 4°C. 
C) FLIM of HEK293 cells expressing SensOR at 45°C. Mean lifetime (τm) is shown with 
lifetime scale bar in nanoseconds (ns). Error represents standard deviation. 
3.2.31 In vitro activation of SensOR with ATP 
Using the temperature dependence study of SensOR as a calibration for the 
opening and closing of the biosensor with respect to lifetime, purified SensOR was 
incubated on ice to force the biosensor into the open confirmation. TCSPC 
measurements were performed at room temperature and a lifetime of 2.7 ± 0.01 ns 
was observed. An equal volume of ATP solution was mixed with the purified 
SensOR and a quenched lifetime of 2.0 ± 0.01 ns was determined as shown in 
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Figure 3.33. These results show that the phosphorylated state of S6K1 is linked to 
the closed form, i.e. such as the lower lifetime values (2.1-2.3 ns) observed in the 
cytoplasm by FRET-FLIM throughout these set of studies. These findings do not rule 
out the nucleus as a home for the phosphorylated state of S6K1 as fully unfolded 
SensOR is expected to show much longer lifetimes, thus indicating a form of 
phosphorylated S6K1 could reside in the nucleus.  
 
Figure 3.33: ATP activation of SensOR. Graph showing lifetime of purified (60 μg) before 
addition and after addition of ATP containing Mg2+ (2.4 mM). Data taken from 3 repeats. 
Error represents standard deviation. 
3.3 Discussion 
The transient overexpression of EGFP, mCherry and mTurquoise2 (mTurq2) tagged 
S6K1 showed localisation of S6K1 in near equal amounts in both the nucleus and 
the cytoplasm of living mammalian cells using confocal microscopy. These findings 
support both cell fractionation studies (Coffer and Woodgett, 1994; Rosner and 
Hengstschläger, 2011) that detected S6K1 in both cytoplasmic and nuclear fractions 
as well as immunofluorescence work where anti-S6K1 antibodies stained both 
cellular compartments in fixed HEK293 cells (Skorokhod, Khoruzhenko and 
Filonenko, 2013). Interestingly, fluorescence imaging of GFP-S6K1 expressing live 
plant cells also shows an equal nucleocytoplasmic localisation of S6K1 (Mahfouz, 
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2006), in agreement with the live mammalian cell localisation of fluorescently tagged 
S6K1 determined in this thesis. Whilst recognising these agreements, the results do 
however differ with previous studies where cell fractionation of HEK293 cells (Zhang 
et al., 2002) showed detection of S6K1 predominately in the cytoplasm and imaging 
of fixed HEK293T cells expressing GFP tagged S6K1 (Lun et al., 2017) has shown a 
predominately cytoplasmic localisation of GFP-S6K1. The live cell work in this thesis 
provides an improved method for better understanding of S6K1 function in living 
cells through imaging its real time cellular dynamics. The live cell application applied 
here to the imaging of tagged proteins is more advantageous compared to 
conventional methodologies such as those mentioned above, namely cell 
fractionation and cell fixation due to lesser susceptibility to experimental artefact 
generation stemming from maintaining cellular integrity (Huber, Pfaller and Vietor, 
2003; Say and Hooper, 2007; Schnell et al., 2012). In context with the present-day 
literature, the use of S6K1 live cell imaging validates the functions of S6K1 in 
relation to its sub-cellular localisation as S6K1 in the nucleus is involved in histone 
phosphorylation (Lee et al., 2016; Yi, Han and Han, 2016) whilst in the cytoplasm, 
S6K1 is associated with cell growth and survival that involves S6K1 in the 
mitochondria (Djouder et al., 2007).    
Although the overexpression of a gene within a cell provides a useful tool for 
determining pathway components that could stay undetected using traditional 
detection methods used for ectopic expression, it must not be forgotten that 
overexpression could lead to artefacts as such high levels of one protein may lead 
to cells promoting abnormal behaviour (Prelich, 2012). Protein production in mass 
quantities within the cell could be toxic to the cell leading to the leakage of protein 
into other cellular compartments (Lowder et al., 2000). In addition, inaccurate 
findings may be deduced where the overexpression system forces non-interacting 
proteins together (Taipale, 2018). Equally, it must be noted that both the choice of 
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fluorescent protein used to tag a protein of interest as well as the terminus to which 
it is added to, is important and could lead to differences in localisation in living cells 
(Fritz et al., 2008). In the case of S6K1 neither the EGFP, mCherry nor mTurquoise2 
tags or addition of them on either terminus end of S6K1 significantly disrupted 
localisation although S6K1-mCherry appeared slightly more cytoplasmic. Problems 
with using mCherry as fluorophore for protein tagging have been reported before 
(Shemiakina et al., 2012; Huang et al., 2014; Costantini et al., 2015). Unlike EGFP 
and mTurqouise2, mCherry is a coral derived FP and although this effect may also 
appear to affect the FRET biosensor, SensOR (mCherry-S6K1-EGFP), this is not 
the case as a later developed version of SensOR (mTurq2-S6K1-EGFP) localised 
similarly to its predecessor.  
A unique translocation of S6K1 was identified when co-expressed with raptor using 
several fluorescent constructs (YFP, mCherry, mTuq2 and mDsRed) in living 
mammalian cells, and the results support the current thinking that raptor acts as a 
scaffold protein in recruiting downstream mTOR substrates (Schalm and Blenis, 
2002; Nojima et al., 2003; Schalm et al., 2003; Yonezawa et al., 2004; Oshiro et al., 
2007). The translocation of S6K1 to the cytoplasm may embody the first steps in 
S6K1 recruitment onto the mTORC1 complex as live cell imaging of fluorescently 
labelled mTORC1 subunit proteins such as raptor, mTOR and Rheb are 
predominately cytoplasmic in live cells (Qian et al., 2010; Yadav et al., 2013; 
Manifava et al., 2016). Since raptor does not localise in the nucleus (Yadav et al., 
2013), a novel sensing mechanism could be involved. The notion that raptor is 
directly involved with substrate recruitment is further supported by the observation 
that S6K1 phosphorylation was increased with raptor co-expression and adds 
strength to similar findings from others (Yadav et al., 2013; Jain et al., 2014; Martin 
et al., 2014).  
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Whether S6K1 phosphorylation is an effect of its translocation is still unresolved. 
The work reported has also identified that the S6K1 translocation was not triggered 
by mTOR mediated phosphorylation, firstly by serum and amino acid starvation of 
wildtype EGFP-S6K1 and secondly by the generation of a non-phosphorylated 
EGFP-S6K1 (T389A) construct, in line with fractionation work (Kim et al., 2009). 
Interestingly, no large punctate structures were formed of EGFP-S6K1 upon nutrient 
starvation compared to previous live HEK293 cell imaging studies where punctates 
of EGFP-mTOR were observed under starvation conditions (Yadav et al., 2013). 
Also no punctate structures were observed with mCherry-raptor under nutrient 
starvation similar to previous findings (Yadav et al., 2013). However, smaller 
punctate structures have been identified with nutrient starved HEK293 and HAP-1 
cells expressing raptor-GFP (Manifava et al., 2016). The discrepancy between these 
results could be explained by the fact that the latter work knocked-in GFP to 
endogenous raptor protein whilst the work reported in this thesis used 
overexpression. Thus, combining gene editing tools such as CRISPR-Cas9 
technology (Lackner et al., 2015) with microscopy may overcome some of the 
disadvantages of using overexpression where the balance of components within a 
signalling pathway may be better controlled.  
The translocation of S6K1 has been recognised to be dependent on S6K1 binding to 
raptor as the expression of a mutated TOS S6K1 construct (EGFP-F28A S6K1) with 
mCherry-raptor, resulted in a lack of translocation. This finding supports previous 
pulled-down studies where TOS motif mutated S6K1 was unable to co- 
immunoprecipitate with raptor  (Nojima et al., 2003; Ali and Sabatini, 2005). S6K1 
TOS mutants have also shown diminished phosphorylation by pull-down assays 
(Schalm and Blenis, 2002; Nojima et al., 2003) indicating that S6K1 and raptor 
binding is essential to the mTOR mediated phosphorylation of S6K1. The lack of 
evidence for raptor localisation in the nucleus begs the question as to whether raptor 
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actively recruits and binds S6K1 onto mTORC1 complex and if so what is the 
recruitment mechanism? This is discussed next.  
A secondary mechanism for S6K1 translocation has been identified in results 
section 3.2.14 involving a fully functioning mTOR protein. Shuttling of mTOR to the 
nucleus has been reported for maximal S6K1 phosphorylation (Kim and Chen, 2000; 
Bachmann et al., 2006), both hypothesised that mTOR may be involved in 
recruitment and this was made apparent in the results of this chapter when the 
translocation of S6K1-mTurq2 with raptor was inhibited with an N-terminal truncated 
mTOR construct (ΔN-mTOR-mCherry). These results lead to the deduction that 
mTOR itself may be involved in a primary or secondary recruitment mechanism 
involving the N-terminus (presumably the HEAT repeat domains) other than the 
reported FRB domain of mTOR in mediating recruitment (Yang et al., 2017). If 
mTOR dimerisation plays an active role in secondary recruitment of S6K1, an 
obvious experiment is to test whether a mutated mTOR construct engineered to 
prevent formation of the mTOR (N-to C-terminus) dimer (Jain et al., 2014) would 
inhibit translocation, assuming formation of the mTORC1 dimer is required for S6K1 
translocation and subsequent phosphorylation.  
The belief that S6K1 is recruited onto the complex is supported by the direct 
interactions found between EGFP-S6K1 and mCherry-raptor in live HEK293 cells in 
this chapter, as evident by a ~200 picosecond change in the fluorescence lifetime of 
the EGFP-S6K1 donor and also with previous live cell EGFP-mTOR and mDsRed-
raptor interaction studies (Yadav et al., 2013). The ~200 picosecond change in 
lifetime has been previously shown to be statistically significant for protein-protein 
interaction studies based on comparisons with protein-protein mass spectrometry 
(Stubbs et al., 2005; Kriechbaumer et al., 2015; Kriechbaumer, Botchway and 
Hawes, 2016). The FRET-FLIM results from this chapter confirms several studies 
that have pulled-down S6K1 and raptor together using cell disruptive pulled-down 
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assays (Schalm and Blenis, 2002; Nojima et al., 2003; Yonezawa et al., 2004; 
Schalm, Tee and Blenis, 2005). The requirement of S6K1 to dock onto the complex 
through raptor recruitment leading to mTOR mediated phosphorylation is made 
more apparent through the evidence presented by previous raptor-knockout studies 
that observed abolishment in S6K1 phosphorylation (Ali and Sabatini, 2005). The 
disassembly of S6K1 on the complex by either targeting the recruitment mechanism 
or raptor binding has potential as a novel method to inhibit mTOR activity by 
pharmaceutical involvement.   
It was previously found that Rheb and raptor both directly interact with mTOR in live 
HEK293 cells whilst no interaction between Rheb and raptor was determined 
(Yadav et al., 2013). In this thesis, only a ~100 ps change in the natural EGFP-
mTOR lifetime was observed with S6K1-mCherry. This change in lifetime is smaller 
than expected compared to the 200 picosecond change mentioned above for an 
interaction. As mTOR has been reported to phosphorylate S6K1 (Brown et al., 
1995), one would expect a direct and physical interaction between the two proteins. 
However, this smaller magnitude of FRET may reflect a weak long distance 
interaction (>10 nm) between S6K1 and mTOR, owing to the large geometry of the 
complex. Also, the interaction observed could be one of a fast and dynamic nature 
which due to averaging events over several tens of seconds during FLIM acquisition 
may provide a bias lifetime favouring the dominate lifetime. Alternatively, a lack of 
interaction observed may be masked due to the lack of the raptor component, in 
excess of endogenous levels, needed to dock S6K1 onto the complex. The SPC 
instrument response of the FLIM detection is 31 picoseconds and thus any changes 
in lifetime beyond this value can be accurately measured and can be considered 
significant with good time resolution. Taken together, these FRET-FLIM data would 
support pulled-down studies that have failed to pull-down full length S6K1 and 
mTOR together (Ben-Hur et al., 2013; Brown et al., 2017). In the cases where S6K1 
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has been pulled down with mTOR (Brown et al., 1995; Ali and Sabatini, 2005), the 
finding from this thesis that showed EGFP-S6K1 pulled down with both mCherry-
raptor and FLAG-mTOR together from HEK293F cells provides plausible evidence 
for endogenous raptor acting as a tertiary component to bridge subunits together on 
the complex in other works.  
Similarly, only a 100 ps change in EGFP-S6K1 lifetime was observed with mCherry-
FKBP12 in cells supplemented with rapamycin. The FKBP12-rapamycin complex 
has been shown to bind to the FRB domain of mTOR (Choi et al., 1996) and a 
peptide sequence of S6K1 has been shown to bind with the same mTOR domain 
(Yang et al., 2017), thus an interaction within near proximity between S6K1 and 
FKBP12 is plausible. The FRET-FLIM result presented in this chapter does support 
such an interaction as the mTOR protein would be sandwiched between S6K1 and 
the FKBP12–rapamycin complex resulting in less FRET efficiency. However, whilst 
this is an attractive interpretation, the 100 ps lower lifetime could also be due to the 
binding of S6K1 on the complex at an interface opposite to where Rheb and 
FKBP12-rapmaycin bind, such positioning would lead to a long distance interaction 
and a falloff in quenching efficiency.    
Interestingly, no change in the unquenched lifetime of EGFP-Rheb was observed 
with S6K1-mCherry co-expression, indicating a lack of direct interaction despite a 
129% induction in S6K1 phosphorylation with Rheb overexpression. Although no 
change in donor EGFP-Rheb lifetime was observed, the probability that the 
fluorophores could be in an unfavourable orientation or beyond the 10 nm distance 
for FRET should be considered. The interaction between S6K1 and Rheb has not to 
date been investigated. The newly resolved structure of mTORC1 with Rheb 
determined using cryoEM indicates that Rheb and raptor do not interact (Yang et al., 
2017) and thus if mTOR substrates are recruited by raptor interaction, they are 
expected not to interact with Rheb. In addition, if the TOS motif of S6K1 is involved 
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in mediating the interaction with raptor, a belief heavily supported by previous 
structural studies that have shown the N-terminus of raptor is within close proximity 
to mTOR (Aylett et al., 2016; Yang et al., 2016), then S6K1 is expected to be within 
close proximity to the active site of mTOR. In summary, combining the FRET-FLIM 
data and the pull-down work with the previously reported mTOR interactions (Yadav 
et al., 2013), provides an assembly of S6K1 that can be modelled in 3D and is 
shown in Figure 3.34 with the summary of the main lifetime interactions from this 
chapter.  
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Figure 3.34: Summary of mTORC1-S6K1 interactions. A) Graph summarising FRET-FLIM 
interactions. B) 3D model of S6K1 and raptor interaction. C) 3D model of S6K1 docked onto 
mTORC1. Made in Swiss PDB Viewer V4.10 software using PDB files: 3a62, 1xts, 5h64 
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The choice of fluorescent acceptor for FRET-FLIM studies has also been shown to 
be important in this results chapter. The green emission observed from the mDsRed 
acceptor evoked by multiphoton excitation has been reported previously and has 
been termed the ‘greening’ effect stemming from emission between 510–550 nm 
(Marchant et al., 2001; Nifosı and Yi, 2007; Kremers et al., 2009; Subach and 
Verkhusha, 2012). It has been proposed that this phenomenon is due to photo-
conversion where an immature ‘green’ intermediate of the chromophore is formed. 
Although DsRed has been used in FRET studies (Erickson, Moon and Yue, 2003) 
and FRET-FLIM studies (Peter et al., 2005; Stubbs et al., 2005; Yadav et al., 2013) 
to determine protein-protein interactions, the collection of the ‘green’ component of 
the mDsRed acceptor with the EGFP donor can lead to a shorter average lifetime as 
reported here resulting in false conclusions regarding interactions. It has been 
reported that mCherry on the other hand does not have any multiphoton evoked 
green emission (Kim et al., 2012). With this in mind, experiments between mTOR 
with raptor were re-performed using EGFP-mTOR and mCherry-raptor (see 
Appendix B.10) and direct interactions were observed with a similar change in 
lifetime of 200 picoseconds as reported previously (Yadav et al., 2013).  
Another important finding in this chapter has been identifying the involvement of 
Rheb in both phosphorylation and dephosphorylation (Inoki et al., 2003; Yonezawa 
et al., 2004; Long et al., 2007). A ~72% decrease in S6K1 phosphorylation was only 
observed with the combination of both Rheb and S6K1 overexpression with 
rapamycin treatment whilst no effect was observed with S6K1 overexpression alone. 
Although there is no direct explanation for this difference, possible explanations are 
that the role of Rheb may go beyond what was originally thought of as a GTPase 
activator of mTOR or that the endogenous levels of FKBP12 may be too low to 
compensate for the overexpressed S6K1.  
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The mechanism of Rheb in activating the mTOR kinase protein and drastically 
inducing S6K1 phosphorylation without directly interacting with S6K1 raises the 
questions of how mTOR induces hyperphosphorylation and how the combined effect 
of rapamycin and Rheb leads to a reduction in S6K1 phosphorylation. Advanced 
confocal imaging using deconvolution to go beyond the diffraction limit showed poor 
co-localisation between EGFP-S6K1 and mDsRed-Rheb suggesting that the two 
proteins are not within the same localisation site. The recent cryoEM structure of 
mTORC1 with Rheb has shed light on its mechanism of activation by proposing that 
the binding of Rheb to the mTORC1 complex results in a conformation change in 
mTOR that primes its active site for substrate phosphorylation (Yang et al., 2017). 
Other than structural studies, computational modelling has been used to simulate 
the dynamics of the complex, in particular to predict Rheb’s mechanism of action. It 
has been suggested that Rheb may function to increase mTORC1 substrate 
phosphorylation by increasing mTORC1 substrate binding to raptor (Rahman and 
Haugh, 2017; Sulaimanov et al., 2017). Although this model is supported by 
previous experimental data where Rheb overexpression increased 4EBP1 binding to 
raptor (Sato et al., 2009) by pulled-down assay, no translocation of S6K1 was 
observed with both Rheb and raptor expression in this results chapter.  
It has also been shown from other work that S6K1 phosphorylation levels remain 
heightened after nutrient activation, evaluated by Western blot analysis, after 
mTORC1 has detached from lysosomes into the cytoplasm and thus provides a 
spatial understanding for activation as Rheb has been reported to tether the 
complex to the lysosomal membrane (Yao, Jones and Inoki, 2017). This raise 
questions as to whether the entire mTOR1 complex is assembled on the lysosomal 
membrane and then finally rests in the cytoplasm and/or upon mTOR activation is 
Rheb still bound onto the complex? Taken together, this chapter proposes that the 
mechanism of Rheb in S6K1 phosphorylation may be strongly related to dynamic 
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conformational changes within the complex that enhances the dynamic interaction 
between mTOR and S6K1 inevitably leading to the localisation of the complete 
complex in the cytoplasm as a final resting point. It has been suggested that S6K1 
detaches from the complex after phosphorylation (Holz et al., 2005), however this 
does not hold true  with our findings as the translocated S6K1 in the cytoplasm is 
shown to be in the phosphorylated form, as evident by both the lower lifetimes 
observed in the cytoplasm with the live cell S6K1 phosphorylation FRET sensor 
(SensOR) as well as Alexa405 labelling for phospho-S6K1 in fixed cells. However, 
the results obtained from cell fixation must not be ignored as the detrimental effects 
of the fixation process causes artefacts.  
The dynamics of S6K1 binding onto mTORC1 have been shown in relation to other 
raptor binding proteins such as PRAS40 and 4EBP1, also known to contain their 
own TOS motif sequences (Schalm and Blenis, 2002; Beugnet, Wang and Proud, 
2003; Choi, McMahon and Lawrence, 2003; Wang, Rhodes and Lawrence, 2006; 
Oshiro et al., 2007; Lee et al., 2008). Both the confocal and FRET-FLIM microscopy 
results supports the previously stated literature as shown by the translocation and 
interaction of 4EBP1-GFPSpark with mCherry-raptor. This indicates that 4EBP1, 
similar to S6K1, may also be recruited onto the complex. Fluorescently labelled 
PRAS40 did not translocate with raptor co-expression and localised to the 
cytoplasm, in line with the findings that PRAS40 is jointly bound onto the complex by 
mTOR and PRAS40 (Oshiro et al., 2007; Sancak et al., 2007; Wang et al., 2007). 
The results from three colour live cell imaging with expression of 4EBP1-GFPSpark 
or YFP-PRAS40 and fluorescently tagged S6K1 together with raptor indicated the 
S6K1 translocation was inhibited, by up 2-times, a result in agreement with the 
notion that mTOR substrates competitively compete for raptor binding on the same 
site (Hara et al., 2002; Wang et al., 2007; Dennis, Kimball and Jefferson, 2013). In 
the triple colour imaging studies, although not always the case as 4EBP1 did appear 
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slightly translocated in some cells, both S6K1 and 4EBP1 translocation was 
inhibited. This ‘cancelling-out’ effect suggests that raptor does not have specificity 
towards either mTOR substrate. However, the fluorescence levels of a FP is not a 
robust tool for measuring the concentration of tagged proteins as differences in 
quantum yields and extinction coefficients of the FPs may affect quantification. 
However, it has been suggested through the use of in vitro studies, that raptor has a 
higher affinity for 4EBP1 than S6K1 for binding (Schalm et al., 2003), therefore 
4EBP1 may still be expected to possess some translocation.  
The localisation and distribution of the phosphorylated form of EGFP-S6K1 was 
investigated by paraformaldehyde, methanol and glyoxal cell fixation methods, as no 
readily available live cell phosphorylation labelling methods were available at the 
start of this work. It was found that paraformaldehyde caused the extraction and loss 
of soluble EGFP-S6K1 from the cytoplasm, movement of EGFP-S6K1 into the 
nucleoli and masking of the epitopes of S6K1 for sufficient antibody labelling. These 
observations have been previously investigated using GFP expressed protein or 
quantum dots (Williams et al., 2008; Schnell et al., 2012). Methanol fixation also 
resulted in mis-localisation of EGFP-S6K1 with higher fluorescence intensities found 
in the peri-nuclear region (Williams et al., 2008). However, glyoxal fixation provided 
the least amount of mis-localisation, indicating its superior suitability for fixed cell 
immunofluorescence labelling (Richter et al., 2017). Taken together, these findings 
show that cell fixation induces artefacts which are likely to influence the localisation 
of a phosphorylated protein. Such detrimental effects of fixation have been reported 
previously for mTORC1 studies (Sancak et al., 2008; Yadav et al., 2013). Variable 
results were also obtained using different phospho-S6K1 antibodies from various 
commercial companies. Thus, the choice of the fixative and antibody used will 
significantly influence the localisation of phosphorylated S6K1.  
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In agreement with previous studies that have shown a dose-dependent effect of 
Rheb (Garami et al., 2003; Inoki et al., 2003; Stocker et al., 2003; Long, Ortiz-Vega, 
et al., 2005; Long et al., 2007; Yadav et al., 2013; Gonzalez et al., 2014; Martin et 
al., 2014), the co-expression of S6K1 with Rheb induced an increase (129%) in 
S6K1 phosphorylation and this was quantified by Western blot analysis in this 
chapter. However, when HEK293 cells were fixed in paraformaldehyde and 
immunofluorescence was used to label both overexpressed and endogenous 
phospho-S6K1, no correlation between high Rheb and high phospho-S6K1 
intensities were observed from single cell-to-cell analysis. The discrepancy between 
these two techniques could be explained by the fact that Western blotting involves 
pooling all the proteins from all the cells together and thus an accumulated increase 
in S6K1 phosphorylation is detected whereas on a cell to cell basis, levels of 
phosphorylation may vary and may be much lower when combined with insensitive 
antibody labelling and poor detection. Furthermore, having covered the obstacles 
faced with cell fixation in the discussion above, it is equally plausible that soluble 
phospho-S6K1 may be lost from the cytoplasm and thus renders the findings from 
the immunofluorescence work inconclusive. Based on the evidence presented in this 
chapter translocation of labelled phosphorylated S6K1 from the cytoplasm into the 
nucleus upon activation is not observed which is contrary to that previously reported 
(Kim and Kahn, 1997; Rhoads et al., 2008; Rosner, Schipany and Hengstschläger, 
2012; Kim et al., 2013). Instead, using the novel real-time live cell S6K1 
phosphorylation FRET bio-sensor (SensOR) activation of S6K1 in the cytoplasm 
was observed, as evident by the mCherry-S6K1-EGFP protein having a significant 
lifetime change (~200 picosecond) mainly in the cytoplasm following a cycle of 
nutrient starvation, nutrient replenishment and rapamycin treatment. It is concluded 
from the SensOR study that S6K1 activity is under mTORC1 regulation. The 
observed reduction in lifetime of SensOR is similar to the ~200 picosecond change 
observed in a study using a similar FRET sensor design to monitor the activity of the 
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aurora kinase protein (Bertolin et al., 2016). Although it has been found that a two-
step amino acid mechanism activates mTOR where a priming amino acid as well as 
an activating amino acid is required (Dyachok et al., 2016), the work in this chapter 
found FRET changes with both the activating amino acid (leucine) alone or with both 
the activating and priming (arginine) amino acid.  
The lifetime changes observed with the phosphorylation events above relate to 
structural changes in the protein which can also be manipulated with temperature 
(i.e. opening and closing) the sensor. The combined dynamics of purified SensOR 
with in vitro temperature kinetic and ATP activation studies validates the use of the 
construct for monitoring mTOR activity. The mechanism of the bio-sensor is 
summarised in the schematic in Figure 3.35. The changes in lifetime observed with 
the FRET bio-sensor support the idea that phosphorylation of S6K1 is linked to a 
conformational change (Magnuson, Ekim and Fingar, 2012) and agree with findings 
of other FRET sensors where S6K1 or mTOR activity has been observed in the 
cytoplasm of living cells (Komatsu et al., 2011, 2018; Zhou et al., 2015). The novel 
FRET sensor developed in this work surpasses previous FRET sensors cited above 
as SensOR directly reports on mTOR activity whilst the Eevee-S6K sensor gives a 
read-out for S6K1 activity and does not locate into the nucleus due to truncated 
rictor and S6K1 sequences (Komatsu et al., 2011). SensOR monitors complete 
rapamycin sensitivity whilst the TORCAR sensor for observing 4EBP1 activity is 
insensitive to rapamycin (Zhou et al., 2015). Furthermore, the steady state FRET 
used in the previous studies by others is unable to determine very small structural 
changes which can be better resolved using time-resolved FRET-FLIM.  
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Figure 3.35: Schematic showing mechanism of SensOR. 3D models of SensOR opening 
and closing are shown. Conditions at which conformational change occurs is also shown. 
Made in Swiss PDB Viewer V4.10 software. PDB codes used: 2Y0G and 4L46. The donor-
to-acceptor separation distance (r) has been calculated from R=R0(3√1/E -1) where the 
Förster distance (R0) is 52.88 Å and the FRET efficiency (E) was determined from the 
lifetime values.  
The fact that highly expressing cells showed translocation of SensOR without any 
co-expression is interesting. Since the amount of endogenous raptor is unknown, 
the translocation of the FRET sensor may be due to enhanced phospho-S6K1 
shuttling based on observations that the FRET was heterogeneous amongst cells, 
which is expected when there are variations in levels of activity. Furthermore, it is 
also possible that the addition of two fluorescent proteins may have caused mis-
localisation as the addition of both GFP and mCherry to the Aurura Kinase FRET 
sensor also showed a translocated localisation although not explicitly reported 
(Bertolin et al., 2016). However, as Western blot analysis of SensOR has shown 
functionality, it is more likely that the translocation of the SensOR is biologically 
related. Nevertheless, the SensOR studies has shown distinct FRET variations in 
the cytoplasm which may be related to sub-cellular regional mTOR activity that 
cannot be resolved using standard diffraction limited confocal based FRET-FLIM 
microscopy. Also, although the nuclear localisation of the SensOR, collected with a 
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high count for accurate model fitting, shows longer lifetimes than its cytoplasmic 
localisation, this doesn’t necessary mean phosphorylation is not occurring in the 
nucleus. Although, the majority of the S6K1 phosphorylation is identified to be in the 
cytoplasm it is plausible that a much lower level of phosphorylation in the nucleus 
may not have been detected if the S6K1 conformational change is inefficient in the 
nucleus or if this closed-state population is too small and masked by surrounding 
pixels that contain the open-state S6K1 during FLIM analysis.  
In summary, the data from this chapter can be combined to produce an updated 
scheme of the mTORC1 pathway showing the recruitment and dynamics of S6K1 
assembly and phosphorylation in living cells, see Figure 3.36.  
 
Figure 3.36: Schematic of updated mTORC1 pathway. Modified and updated schematic 
taken from (Yadav et al., 2013). Red arrows show recruitment. Black dotted arrow shows 
unknown recruitment. Resonance arrows show dynamic exchange.  
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3.4 Conclusions 
S6K1 localises to both the nucleus and cytoplasm in live mammalian cells using 
GFP tagged S6K1. S6K1 is recruited primarily by raptor via a functional S6K1 TOS 
motif resulting in the movement of S6K1 from the nucleus to the cytoplasm. This 
movement (translocation) is not triggered by mTOR mediated phosphorylation. A 
secondary recruitment mechanism involving the N-terminus of mTOR may be also 
involved. S6K1 directly interacts with raptor to allow mTOR substrate docking onto 
mTORC1. Although there is a lack of interaction between S6K1 and Rheb, there is 
an enhancement in S6K1 phosphorylation only with Rheb co-expression. 
Rapamycin appears to only function in the presence of Rheb. Once S6K1 is docked 
onto the complex, phosphorylation occurs and this predominately takes place in the 
cytoplasm as evident by phosphorylation triggered S6K1 conformational changes 
both in vivo and in vitro utilising SensOR.  
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4.0 Directly imaging AZD2014 and INK128 
pan-mTOR inhibitors in living cells 
 
4.1 Brief introduction 
AZD2014 and INK128 are currently referred to as second generation mTOR 
inhibitors that are undergoing pre-clinical and clinical trials (Li et al., 2015; Powles et 
al., 2016). These inhibitors are also known as pan-mTOR inhibitors as they are 
designed to bind to the mTOR kinase domain, competing with ATP binding, and 
thus are suggested to be more selective than rapamycin or rapalogue derivatives. 
AZD2014 and INK128 target mTORC1 and mTORC2 similarly. However, the exact 
localisation and mechanism of these drugs has not been well-studied despite 
advancements in the clinical context (Li et al., 2018).  
This chapter reports the use of advanced microscopies that utilise the natural 
fluorescence from AZD2014 and INK128 without the need for additional fluorescent 
tags (Miller, Fricker and Drewe, 1997; Kozany et al., 2009). In this chapter, their 
fluorescence properties have been characterised as well as their real-time uptake in 
living mammalian cells. Particular focus has been paid to AZD2014 with respect to 
both its localisation and interaction with mTORC1. In general, where and how 
mTOR inhibitors localise is imperative and crucial in drug design and development. 
The hypothesis of this chapter is: 
• The regulation of the mTORC1 pathway by pan-mTOR inhibitors may 
function by targeting mTOR, the complex, or downstream substrates directly  
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4.2 Results 
4.2.1 UV-Vis spectroscopy analysis of rapamycin, AZD2014 and INK128 
In order to obtain information regarding possible luminescent properties of the 
mTOR inhibitors required for imaging in cell studies, the absorption properties in the 
ultraviolet-visible (UV-VIS) spectral region of AZD2014, INK128 and rapamycin were 
investigated. These drugs were dissolved in DMSO as the solvent, per 
manufacturer's recommendation and absorbance measured using a UV-vis 
spectrophotometer. The experimental UV-VIS absorption spectra were deconvolved 
by subtracting the solvent absorbance and are presented in Figure 4.1. AZD2014 
showed two absorbance peaks at 283 nm and 393 nm, respectively. INK128 gave 
absorbance below 330 nm with a peak at 293 nm whilst rapamycin absorbed below 
280 nm. The DMSO solvent alone also showed strong absorbance below 290 nm 
and this is given in Appendix C.1.  
The absorbance information was used to determine their molar extinction 
coefficients, a measure of how strongly a compound is likely to absorb light at a 
specific wavelength. The molar extinction coefficient (ε) of AZD2014 at the 393 nm 
wavelength was determined as 1,166 M−1 cm−1 whilst at 283 nm, it was found to be 
36,790 M−1 cm−1 using Beer-Lambert law. The extinction coefficients of INK128 and 
rapamycin were calculated as 16,215 M−1 cm−1 at 293 nm and 41,425 M−1 cm−1 at 
279 nm respectively (Appendix C.2). In comparison, EGFP has a value of 55,000 
M−1 cm−1 at 488 nm. The high ε values for AZD2014 and INK128 at around 300 nm 
indicate that these inhibitors are good at absorbing this wavelength of light.  
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Figure 4.1: UV-VIS spectra of AZD2014, INK128 and rapamycin. UV-VIS spectrum of A) 
AZD2014 (11 μM), B) INK128 (16 μM) and C) rapamycin (10 μM) in DMSO solvent. Solvent 
(DMSO) only absorbance spectrum was subtracted from raw spectra for deconvolution 
purposes. Data is representative of three independent experiments.  
4.2.2 Fluorescence spectroscopy analysis of AZD2014 in solution 
The UV-VIS absorption data from 4.2.1 was used to determine any fluorescence 
emission of AZD2014 by performing emission spectra at the absorption maxima 
(283 nm or 393 nm). A solution of AZD2014 (7 µM) in DMSO solvent was ran using 
a fluorimeter (see Chapter 2) and an emission peak at 468 nm was obtained 
(Figure 4.2A). Using the emission peak of AZD2014, an excitation spectra using the 
fluorimeter was carried out on a solution of AZD2014 (7 µM) in DMSO. Two 
excitation peaks were determined at 284 nm and 393 nm, respectively (Figure 
4.2A) that matched the UV-VIS data. As both the fluorescence spectra and its 
relative intensities are generally dependent on the molecule environment, the effects 
of solvation by solvents can be used to elucidate possible characteristics of the 
molecule in a cellular system. The fluorescence properties of AZD2014 were 
therefore investigated in a variety of solvents that included: DMSO, PBS and 1 mM 
BSA (a serum protein to mimic the cytosol and nucleosol environment of the cell) 
diluted in PBS. As shown in Figure 4.2B, the fluorescence intensity of AZD2014 
was quenched in both PBS and BSA solutions (by 72%) compared to DMSO 
indicating that the solvent environment has significant effects on the spectral 
emission properties of AZD2014. The optical densities (OD) of these solutions 
remained similar (presented in section 4.2.3) suggesting that the quantum yield may 
be changing. The excitation spectra of these solutions are given in Appendix C.3 
and show a 7 nm shift in the excitation spectrum of PBS compared to DMSO as well 
as a decrease in excitation intensities of 71%. Most notably, the 284 nm excitation 
peak of AZD2014 in 1 mM BSA disappeared showing a single 42% intensity 
reduced excitation peak at 393 nm (Appendix C.3). It is plausible that due to the 
195 
 
reported intrinsic fluorescence properties of BSA (Fujimori et al., 1981), (Ex= ~380 
and ~410 nm; Em= 450 nm), the lack of excitation may be caused by wavelength 
dependent attenuation.  
 
Figure 4.2: Fluorescence spectra of AZD2014 in various solvents. A) Fluorescence 
spectrum of AZD2014 (7 μM) in DMSO showing excitation profile in black and emission 
profile in cyan. Spectra shown on two different axis and were taken at different detector 
settings to provide clean spectrum. B) Fluorescence spectra of AZD2014 (7 μM) in DMSO, 
PBS (1X) and 1 mM BSA in PBS (1X). Colour coded key of spectra solvents is shown in the 
top right hand corner. Data repeated minimum of three independent times. 
4.2.3 Determining the quantum yields of AZD2014 in solution 
Having confirmed AZD2014 fluorescence, the strength of its fluorescence was 
examined. The quantum yield (φF) of a fluorescent molecule gives a measure of its 
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efficiency to convert absorbed photons into emitted photons and is provided as a 
numerical number between 0 and 1 with the latter exhibiting 100% quantum 
efficiency. Using coumarin-1 (φF of 0.73 in ethanol) (Jones et al., 1985) and quinine 
sulphate (φF of 0.55 in sulphuric acid) (Heller et al., 1974) as standards, the φF of 
AZD2014 in both DMSO and PBS was determined using the relative or comparative 
methods (see Chapter 2 for details). The φF of AZD2014 in DMSO was determined 
as 0.47 ± 0.02 (Figure 4.3) at 393 nm excitation. In comparison, the φF of AZD2014 
in PBS at 393 nm was determined as 0.11 ± 0.01. The 74% decrease in quantum 
yield observed in PBS supports the decrease in AZD2014 fluorescence emission in 
section 4.2.2 and indicates AZD2014 may be brighter in environments similar to 
DMSO than PBS. As a control, the φF of coumarin-1 was assumed to be unknown 
and was calculated using quinine sulphate with a value of 0.70 obtained (within 3% 
of the literature value, 0.73) (Jones et al., 1985). In a similar fashion, a third 
standard was also trialled, rhodamine 6G (R6G) in ethanol (φF = 0.95) (Kubin and 
Fletcher, 1982). A lower φF value for R6G to that of the literature was determined 
most likely owing to the inner filter effect where R6G’s fluorescence emission was 
found relatively proportional to the absorbed light, indicating that some emission 
may be re-absorbed, giving inaccurate fluorescence integrations (spectral overlap 
given in Appendix C.4), on this basis R6G was rejected as a suitable standard.  
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Figure 4.3: Quantum yield absorbance and fluorescence spectra of AZD2014 and 
standard. UV-VIS spectra of AZD2014 in DMSO and PBS, coumarin-1 in ethanol, quinine 
sulphate in sulphuric acid (H2SO4) with fluorescence emissions of the same solutions. All 
settings were kept constant for each experiment. AZD2014 and standards were excited at 
393 nm. Absorbance values at 393 nm and integrated fluorescent intensities were used for 
quantum yield calculations. Data repeated two independent times.  
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4.2.4 Multiphoton excitation spectrum of AZD2014 
Having confirmed the fluorescence of AZD2014 using one-photon excitation 
fluorimetry, the multiphoton excitation properties were next investigated by using a 
lambda scan to record a series of confocal images across a series of multiphoton 
excitation wavelengths from a drop of AZD2014 solution (7 μM) in DMSO placed on 
a coverslip. As shown in Figure 4.4, a spectrum was produced from the intensities 
of the confocal images. A two-photon excitation peak at 798 ± 36 nm was 
determined as well as a second peak below 680 nm. The second rising peak could 
be due to the UV absorption at 283 (x2) nm. However, laser tunability stops at 680 
nm and so any peaks below 680 nm could not be defined. Based on UV-VIS results 
from section 4.2.1, a two-photon excitation at around 600 nm and 800 nm could be 
expected as doubling the single photon excitation (~300 nm and ~400 nm) 
wavelength of AZD2014 would meet the requirement of a two-photon excitation. No 
attempts to obtain a two-photon absorption cross section were made as this is not 
the current focus of this study.    
 
Figure 4.4: Two-photon excitation spectrum of AZD2014. Lambda scan of 7 μM 
AZD2014 in DMSO. Data taken from confocal multiphoton images and intensities 
quantified in ImageJ version 1.58. Intensities against wavelength plotted and 
spectrum shown in red.  
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4.2.5 AZD2014 FRET characterisation with EGFP 
To shed further insight into the mechanism of action of AZD2014, attempts to use 
AZD2014 as a donor molecule and GFP an acceptor molecule for FRET-FLIM 
studies were performed as a proof-of-concept for piloting direct drug-protein 
interactions in living cells. First, the fluorescence absorbance of purified GFP in 
water was obtained which showed an overlap with the emission spectrum of 
AZD2014 (Figure 4.5). The spectral overlap percentage for FRET between 
AZD2014 emission and EGFP absorption was determined as 73%. After confirming 
that there was significant overlap for FRET, the fluorescence lifetime of a drop of 
AZD2014 in ethyl glycerol alone was measured as 4.0 ± 0.22 ns using 600 nm 
excitation, since 405 nm excitation was found unsuitable as presented in section 
4.2.14. A 1:1 ratio of AZD2014 and purified GFP was made in ethyl glycerol which 
gave a shortening in AZD2014 lifetime to 2.70 ± 0.24 ns, as shown in Figure 4.5. As 
a control experiment for acceptor bleed-through, no intensity (hence no lifetime) of 
only purified GFP in ethyl glycerol was detected at 600 nm excitation and this will 
become crucial for section 4.2.15 where drug-protein interactions are probed. 
Overall, these findings provide confirmation for using AZD2014 and GFP tagged 
proteins as energy transfer acceptors (FRET pairs) for studying drug-protein 
interactions in the cellular model, see section 4.2.15.  
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Figure 4.5: AZD2014 FRET interaction with EGFP in solution. A) Spectral overlap 
between EGFP absorption and AZD2014 emission by normalisation to the maximum peaks 
of each spectra. B) Bar chart showing lifetimes (ps) of AZD2014, GFP and both mixed (1:1) 
in ethyl glycerol solutions using 600 nm multiphoton excitation. Data repeated minimum of 
three independent times. Error bars show standard deviation. 
4.2.6 AZD2014 TCSPC measurements in solution 
To determine the excited state fluorescence lifetime of AZD2014 in different solvents 
(see Chapter 2: Materials and methods) a drop of AZD2014 placed onto a 
microscope coverslip was excited at 600 nm two-photon or at 405 nm one-photon 
excitation in DMSO, PBS and 1 mM BSA solvents. As shown in Table 4.1, the 
lifetime of AZD2014 was longer with a mono-exponential decay profile (6.6 ± 0.16 
ns) than in PBS (2 ± 0.02 ns). The reason for any lifetime differences to that found in 
section 4.2.5 may be likely due to solvent effects that may enhance or decrease 
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AZD2014 lifetime.  A similar reduced lifetime (3.3 ± 0.18 ns) was observed in 1 mM 
BSA although the data fitted better to a double-exponential decay model. Taken 
together, these results suggest that AZD2014 may be more stable in lipid 
environments as DMSO mimics hydrophobic environments closer to that found in a 
cellular system, particularly lipidic membrane structures. Calibration curves for one-
photon and two-photon excitation of AZD2014 are given in Appendix C5.  
Table 4.1: Various lifetimes and pre-exponential components of AZD2014 in solution 
 
τm (ps) 
(mean) 
SD 
± 
τ1 (ps) 
(mean) 
SD 
± 
a (%)(mean) SD 
± 
τ2 (ps) 
(mean) 
SD 
± 
b (%) 
(mean) 
SD 
± 
AZD2014 
(7 µM) in 
DMSO 
6660 161 - - - - - - - - 
AZD2014 
(7 µM) in 
PBS 
2028 23 - - - - - - - - 
AZD2014 
(7 µM) in 
1mM 
BSA 
3252 181 970 291 46 9 5158 712 54 9 
 
4.2.7 Fluorimetry analysis of INK128 
The fluorescence of INK128 in DMSO was also investigated. A 7 μM solution of 
INK128 in DMSO was ran in a fluorimeter for an emission scan using an excitation 
at 300 nm as a starting point following the UV-Vis spectrometer studies in section 
4.2.1. A broad emission peak at 400 nm was observed indicating that INK128 
exhibits fluorescence properties (Figure 4.6A). Using this information, the emission 
was set at 400 nm and an excitation profile was ran and showed a peak at 308 nm 
Figure 4.6A. The fluorescence emissions of 7 μM INK128 in either DMSO or PBS 
was compared to provide an understanding of the environmental favourability of the 
molecule. As shown in Figure 4.6B, the fluorescence of INK128 was solvent 
quenched in PBS compared to DMSO, evident by a significantly reduced (by 99%) 
emission peak, demonstrating that this mTOR inhibitor may generally favour polar 
aprotic environments.  
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In comparison, no fluorescence excitation or emission was observed (in the region 
of 300- 500 nm) when 7 μM of rapamycin was ran in the fluorimeter using the 
detector at its highest sensitivity setting.  
 
Figure 4.6: Fluorescence spectra of INK128 in various solvents. A) Fluorescence 
spectrum of INK128 (7 μM) in DMSO showing excitation profile in dark blue and emission 
profile in lighter blue. B) Fluorescence spectra of INK128 (7 μM) in DMSO and PBS (1X). 
Colour coded key is shown in the top right hand corner. Repeated minimum of three 
independent times.  
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4.2.8 Fluorescence lifetime and φF of INK128 in solution 
The fluorescence lifetime of INK128 using TSCPC was examined. A concentration 
of 70 µM INK128 exhibited weak fluorescence and thus a higher concentration of 
3.2 mM was used to acquire better meaningful statistical lifetime information. Self-
quenching at this higher concentration needs to be considered but this not known to 
be a problem when using multiphoton excitation. The lifetime of INK128 was 
determined to be 4.7 ± 0.13 ns in DMSO whilst INK128 in PBS showed low counts 
and thus its lifetime could not be accurately determined.  
Similarly to section 4.2.3, the quantum yield of INK128 in DMSO was determined as 
0.33 using quinine sulphate as a standard (spectral data shown in Figure 4.7) at 
300 nm excitation. This value is lower than that obtained for AZD2014 (0.47) 
indicating that INK128 is 30% less efficient at emitting light compared to AZD2014.  
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Figure 4.7: Quantum yield absorbance and fluorescence spectra of INK128 and 
standard. UV-VIS spectra of INK128 in DMSO and quinine sulphate in sulphuric acid 
(H2SO4) with fluorescence emissions of the same solutions. All settings were kept constant 
for each experiment. INK128 and standards were excited at 300 nm. Absorbance values at 
300 nm and integrated fluorescent intensities were used for quantum yield calculations.  
4.2.9 Uptake of AZD2014 in living cells 
Following on from the solution studies, the uptake and imaging of AZD2014 in live 
mammalian cells was investigated. A solution of AZD2014 (7 µM) in complete 
growth media was added to adherent exponentially growing HEK293 cells and the 
uptake determined by acquiring confocal images over a 20 minute time period with 
one minute time intervals using 405 nm excitation (Figure 4.8). Figure 4.8 shows 
that AZD2014 was taken up by cells within 1 minute of addition (kuptake= 1 minute, 
defined by time at 1/2 the maximum intensity saturation) and plateaued at around 4 
minutes. In addition, AZD2014 in HEK293 cells was imaged 15 minutes after 
administration using confocal microscopy and showed localisation in the nucleus, 
the cytosol and peri-nuclear subcellular regions of the cell (Figure 4.8C). Trypan 
blue exclusion test for cell viability was also performed in HEK293 cells in solution 
with varying concentrations of AZD2014. Testing for viability at the concentrations 
similar to that administered in the cell studies, Figure 4.8D, showed at least 80% 
cell viability with 10 µM treatment of AZD2014 at 30 minutes indicating that although 
concentration range used for live cell imaging may have some detrimental effect to 
the cell, it is however still sufficient for obtaining good quality cell data. It is worth 
noting the 7 μM AZD2014 is similar to the concentration using in pre-clinical studies 
(Pike et al., 2013). It is suggested that future use of AZD2014 be carried out below 7 
μM. 
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Figure 4.8: Uptake and imaging of AZD2014 in HEK293 cells. A) Confocal images of 
AZD2014 (7 µM) uptake in HEK293 cells taken over 17 minutes of administration, with one 
minute time intervals using 405 nm excitation. Scale bar = 50 µm. B) Plot of extracted 
confocal intensities of AZD2014 (7 µM) over the 17 minutes with Michaelis–Menten (MM) 
and non-linear (ExpA) fitting. C) Airyscan confocal imaging of AZD2014 in live HEK293 cells. 
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Scale bar = 10 µm. D) Trypan blue exclusion test of HEK293 cell viability with AZD2014 
treatment. Repeated minimum of three independent times. Error bars show standard 
deviation from three experiments.  
4.2.10 Imaging AZD2014 in other living mammalian cell lines 
To verify that the localisation of AZD2014 observed in the HEK293 cell line was 
similar for other mammalian cells, experiments were repeated using CHO and 
MCF7 cells. Figure 4.9A shows treatment of CHO cells with 7 µM of AZD2014 and 
indicates similar localised nuclear and cytoplasmic fluorescence intensities of 
AZD2014 to that observed for the HEK293 cells. Moreover, similar results were 
observed when AZD2014 was administered to MCF7 cells (Figure 4.9B) with 
comparable results to both CHO cells and HEK293 cells. Together, these findings 
demonstrate specificity in localisation of AZD2014 although some differences in 
mammalian cells may be due to simply cell specificity in organelles.  
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Figure 4.9: Imaging AZD2014 in CHO and MCF7 live cells. Confocal images of AZD2014 
(7 µM) in A) CHO and B) MCF7 cell lines with 405 nm excitation. Repeated minimum of three 
independent times. Scale bar = 10 µm 
4.2.11 Quantifying AZD2014 accumulation in living cells 
Having successfully imaged the pan-mTOR inhibitor AZD2014 naturally within its 
physiologically live cell environment, an attempt was made to quantify the 
accumulated AZD2014 within both the nucleus and the cytoplasm. This was 
achieved by measuring the average fluorescence intensity of various concentrations 
of AZD2014 in media solution with 600 nm two-photon excitation under the same 
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settings to generate a calibration line graph, see Figure 4.10. Two-photon excitation 
was chosen over single (405 nm) excitation because of its advantage in inducing 
lower photodamage and so is more suitable for long time-lapse imaging. Under the 
same acquisition settings, the fluorescence intensity of HEK293 cells, treated with 7 
µM of AZD2014 was determined 15 minutes following administration to allow the 
uptake to plateau. These concentration dependent intensities were then used to 
extrapolate concentrations from the solution calibration graph. The accumulated 
concentration of AZD2014 in the nucleus was calculated as 124 µM and in the 
cytoplasm as 213 µM whilst the average concentration in the whole cell was 
determined as 148 µM (Figure 4.10). These findings suggest that even though a 
small dosage (7 µM) may be administered to cells, this does not reflect the final 
concentration within the cell, a finding critical to pre-clinical characterisation and 
toxicity effects of any drug. This may also explain the small (~20%) of cell 
killing observed in the viability studies (section 4.2.9).  
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Figure 4.10: Quantification of AZD2014 in live HEK293 cells. A) Two-photon confocal 
images of AZD2014 in complete growth media using 600 nm excitation at 1 mW. B) 
Calibration line graph of increasing concentrations of AZD2014 in complete growth media 
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with extracted intensities using 600 nm excitation. C) Two-photon confocal image of HEK293 
cells treated with 7 µM AZD2014. D) Extrapolated nuclear, cytoplasmic and whole cell 
concentrations in HEK293 cells administered with 7 µM AZD2014. Repeated minimum of 
three independent times. Error bars show standard deviation. Scale bar = 10 µm 
4.2.12 Uptake of INK128 in living cells 
The localisation of INK128 in live HEK293 cells was also investigated in order to 
correlate any similarities between the second generation mTOR inhibitors. Initial 
attempts were made using one-photon excitation wavelengths, however, due to 
weak INK128 fluorescence, two-photon excitation was turned to for UV excitation 
whilst minimising any unwanted cellular background signals, a key advantage of 
multiphoton microscopy. Seeded HEK293 cells only were initially imaged over time 
with 600 nm excitation. As expected the two-photon excitation gave low levels of 
autofluorescence at 0.9 mW (Figure 4.11). It is expected that at higher laser 
powers, natural indole molecules such as tryptophan and derivatives will also be 
efficiently excited and observed below 380 nm (Guo et al., 1998; Botchway et al., 
2008). Next, 70 µM of INK128 was added to HEK293 cells at room temperature and 
imaged over time with 600 nm excitation. An increase in fluorescence intensity was 
observed illustrating uptake and accumulation of INK128 in living cells (Figure 
4.11A) at these detectable levels. The uptake was fitted to Michaelis–Menten 
kinetics, showing an uptake within 1 minute (kuptake= 42 seconds) and a plateau 
reached within 2 minutes (Figure 4.11B). Multiphoton imaging at 600 nm of INK128 
in live HEK293 cells showed a similar localisation to that of AZD2014, showing 
fluorescence in the nucleus and accumulation of fluorescence in the cytosol with 
similar sub-structure localisation to that observed with AZD2014 (Figure 4.11C). 
Together, these results show in situ detection of pan-mTOR inhibitors in the living 
cell environment using the two-photon microscopy approach.  
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Figure 4.11: Imaging the uptake of INK128 in live HEK293 cells. A) Series of multiphoton 
images of HEK293 administered with INK128 (70 μM) illuminated with 600 nm over time. B) 
Uptake curve of INK128 (70 µM) in HEK293 cells over time by extracting average intensity 
from multiphoton confocal images with a Michaelis–Menten (MM) fitting. Data representative 
of one of three independent repeats where error bars show standard deviation. C) Two-
photon confocal image of INK128 in live HEK293 cells shown both in greyscale and also in 
an intensity map (LUT). Scale bar = 10 μm. D) Series of multiphoton images of HEK293 
without treatment illuminated with 600 nm over time. Scale bar = 50 μm. Data repeated 
minimum of three independent times.  
4.2.13 Uptake and imaging of AZD2014 in living HEK293 spheroids 
Due to the higher concentration required to image INK128, deemed excessively high 
and potentially toxic to the cell, only AZD2014 was taken forward for further 
investigation. The next step was to characterise the uptake of AZD2014 in a 
spheroid tumour model mimicking the three-dimensional physiology and functions of 
living tissues. HEK293 spheroids were formed as described in Chapter 2 using the 
low melting point agarose method. Light sheet fluorescence microscopy was chosen 
to study AZD2014 administration to the spheroids due to its ability to image in real-
time at high speeds with extremely low levels of laser power, making it ideal for 
short or long-term time lapse measurements. As shown in Figure 4.12A, the 
fluorescence of AZD2014 (7 μM) was observed across all depths (z planes) in the 
volume of the spheroid from the surface layer cells to the core planes. The rate of 
uptake into the outer surface of the spheroid was faster (5-times) compared to that 
found in the core of the spheroid, indicating possible diffusion control through to the 
core (Figure 4.12B and C) as the intensity of the drug in the media of the spheroid 
remained relatively constant over time. The uptake of AZD2014 into the 3D spheroid 
was similar to that observed in the monolayer studies with uptake within 1 minute of 
administration supporting the use of the spheroid model for studying cellular 
signalling.  
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Figure 4.12: Uptake of AZD2014 in multi-cellular spheroids. A) AZD2014 (7 µM) was 
administrated (+) in the media and the spheroids imaged using Light sheet microscopy for 2 
hours by recording stacks of 780 µm x 780 µm x 300 µm volume composed of 44 planes 
taken every 15 seconds. Compiled intensity projection images over time are shown with 
increasing depths (z planes). Images without AZD2014 treatment are also shown (-). B) The 
uptake of the AZD2014 fluorescence in the spheroid for the first 25 minutes was studied at 
different depths (z planes in μm). C) The mean rates of uptake, determined as the time at 
half-saturation of the fluorescence, for the various depths are shown. Scale bar = 150 μm. 
Repeated minimum of three independent times. (n=12).  
4.2.14 AZD2014 photo-activated disassembly and cell death of spheroids 
The effect of 405 nm illumination on the HEK293 spheroids with administered 7 μM 
AZD2014 present in surrounding media was investigated to develop an 
understanding of the photochemical properties of the drug. After 30 minutes of 
illumination, a 2.3-times increase in volume of the spheroid was observed (Figure 
4.13). Cellular death was immediately observed in the transmitted light channel as 
well as the expansion of the spheroid and accumulation of drug into the core as 
seen by an increase in fluorescence intensity, most likely due to disruption in cell-
cell contacts that ‘loosen’ the spheroid. Control experiments were also ran with 405 
nm illumination or 7 μM AZD2014 alone without 405 nm excitation. The results 
showed that although the illumination itself gave a 1.2-times increase in volume, this 
was insignificant compared to the combination of both drug and 405 nm excitation 
(Figure 4.13). AZD2014 administration alone without light illumination did not give 
any volume increase supporting a photo-activated effect of AZD2014 (Figure 4.13). 
These results implicate AZD2014 as a potential photosensitizer agent towards 
combined mTOR targeting and photodynamic therapy (PDT) against tumours.  
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Figure 4.13: AZD2014 photo-activation in multi-cellular spheroids. A) 3D renders of 
HEK293 spheroid volumes with AZD2014 (7 μM) imaged over time using Lightsheet 
microscopy. B) Intensity projections of HEK293 spheroid volumes with AZD2014 (7 μM) over 
time. C) Graph showing fold increase of HEK293 spheroid volume with AZD2014 (drug) only, 
405 nm (light) only and both AZD2014 and 405 nm (drug + light) treatments. Repeated 
minimum of three independent times. Error bars show standard deviation. All scale bars = 
150 μm. 
4.2.15 Unsuitability of GFP tagged S6K1 acceptor for one-photon FRET-FLIM 
The application of using AZD2014 to determine mTORC1 interactions was explored 
in living mammalian cells. The S6K1 protein with a GFP tag was first turned to as a 
pilot for this study to test the hypothesis whether AZD2014 functions by interacting 
with downstream mTOR targets. HEK293 expressing fluorescently tagged S6K1 
(S6K1-GFPSpark) were treated with AZD2014 (7 μM). The lifetime of AZD2014 in 
cells was measured using a ~60 ps pulsed 405 nm excitation source and exhibited a 
single exponential decay with a mean lifetime of 4.60 ± 0.05 ns that is shown in 
Figure 4.14. Upon AZD2014 addition to S6K1-GFPSpark expressing cells, a 
change in mean lifetime from 4.60 ± 0.05 ns to 3.70 ± 0.50 ns was observed, as 
given in Figure 4.14. Although this quenching suggests that AZD2014 may be 
directly and physically interacting with S6K1, there may be possible fluorescence 
emission directly from excitation of GFP at 405 nm since certain GFPs have been 
known to be excited at 405 nm. To investigate such interference, S6K1-GFPSpark in 
cells as a control was tested. Figure 4.15 shows that there is indeed some emission 
occurring with a lifetime of 0.9 ± 0.3 ns. This suggests that the measured change in 
AZD2014 lifetime may be due to the presence of this second fast component and 
fitting to a single exponential decay results in an average shortened lifetime. Similar 
results on decay properties using 405 nm excitation of GFP-like fluorescent proteins 
has been reported previously (Habuchi et al., 2005).  Overall this suggests that any 
interactions of AZD2014 with S6K1 using single photon excitation may be 
problematic.  
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Figure 4.14: AZD2014 possible interaction with S6K1-GFPSpark in live cells. A) Photon 
intensity image of AZD2014 in HEK293 cells. B) FLIM image of AZD2014 at 405 nm. C) 
Lifetime distributions of AZD2014 with a lifetime mean (τm). D) Confocal image of S6K1-
GFPSpark. E) FLIM image of AZD2014 with region of interest shown in white dotted line. F) 
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Intensity of AZD2014. G) Lifetime distributions of AZD2014 from selected FLIM region. 
Repeated minimum of three independent times. Error bars show standard deviation. Scale 
bar = 10 μm. 
 
Figure 4.15: GFP acceptor spectral bleed-through with 405 nm excitation. A) Confocal 
image of S6K1-GFPspark expressed in HEK293 cells at 488nm excitation. B) FLIM of S6K1-
GFPSpark at 405 nm excitation. C) Lifetime distributions of S6K1-GFPSpark at 405 nm 
excitation. D) Fitted fluorescence decay of S6K1-GFPSpark to two components. Repeated 
minimum of three independent times. Error bars show standard deviation. Scale bar = 11 
μm. 
4.2.16 AZD2014 interaction with EGFP-mTORC1 using multiphoton FRET-FLIM 
Having resolved the problems with 405 nm single excitation (see section 4.2.5), 
exciting into the 283 nm absorption peak of AZD2014 using multiphoton excitation 
(600 nm) was investigated for live cell drug-protein interactions using GFP tagged 
as acceptors. GFP alone is expected to be minimally excited in this region as found 
by solution studies in section 4.2.5. Seeded adherent HEK293 cells were treated 
with AZD2014 (35 μM) and imaged after 15 minutes of incubation. Using FLIM, 
mono-exponential shorter and longer lifetimes were extracted within subcellular 
regions of the cell (Figure 4.16) with the nucleus showing a lifetime of 3.6 ± 0.42 ns 
FLIM S6K1-GFP Spark A B C 
D 
τm = 0.9 ± 0.3 ns 
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and the cytosol a lifetime of 4.6 ± 0.28 ns from one of three independent 
experiments. Such a large difference in lifetimes between cellular regions advocates 
that AZD2014 favours the cytosol which contain mTOR membrane bound organelles 
and support the in solution studies in section 4.2.6 where longer lifetimes of 
AZD2014 were seen in DMSO and shorter lifetimes were seen in PBS.  
Figure 4.16: Cellular lifetimes of AZD2014 in mammalian cells. A) Confocal image of 
HEK293 cells treated with AZD2014 (35 μM). Scale bar = 5 μm. B) FLIM image with 600 nm 
excitation. Lifetime colour key provided. Regions of interests, nucleus and cytosol shown in 
roman numerals, respectively (i and ii). C) Histogram distributions of region of interest 
lifetimes (i and ii). Experiments performed minimum of three independent times, data shown 
in representative of one the three experiments. Errors = standard error from the mean.  
Other organelles within the cell, as stated in section 4.2.12 can be excited directly at 
600 nm due to co-factors such as NADH, thus a low laser power (0.25 or 0.5 mW) 
FLIMAZD2014 
HEK293 
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i
ii
i ii 
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FLIM 
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was used with a higher concentration of AZD2014, 35 µM or 70 µM, to avoid 
excitation of these cellular molecules and to attain high counts for accurate lifetime 
statistics. No autofluorescence from HEK293 cells was observed under these 
conditions (results given in Appendix C.6). The mean lifetime of AZD2014 (donor) 
across a minimum of three independent experiments was determined in live 
HEK293 cells as 4.0 ± 0.5 ns (Figure 4.17). The error for these and following 
experiments were particularly high as the lifetime of AZD2014 varied across all 
experiments even using new and old stock/batch of the drug. This may suggest that 
the drug could be unstable and unsuitable for long term storage although storing 
conditions are not known to the manufacture. When AZD2014 was added to 
HEK293 cells expressing EGFP-S6K1 a change in average donor lifetime to 3.2 ± 
0.3 ns was observed whilst changes of 3.4 ± 0.5 ns, 3.6 ± 0.4 ns and 3.6 ± 0.6 ns 
was determined in cells expressing EGFP-Rheb, EGFP-raptor and EGFP-mTOR, 
respectively (see Figure 4.17). These results show greater quenching of the excited 
state of AZD2014 beyond the 200 ps changes observed for the EGFP-mCherry 
interactions reported in Chapter 3 due to greater spectral overlap; and indicate that 
AZD2014 is physically interacting with mTORC1 components in living cells. 
Quenches in lifetime between cytoplasm and nucleus could not be accurately 
distinguished as the counts in the nucleus were lower for precise model fitting, thus 
the mean lifetime (τm) of whole cells was integrated to provide an overall lifetime 
value. The change in lifetime of 800 ps observed with EGFP-S6K1 suggests that 
AZD2014 binds strongly with S6K1 or at an interface on mTORC1 that is closer to 
S6K1 and Rheb as the mean quench value with EGFP-Rheb was 600 ps. To test for 
any acceptor bleed-through, EGFP tagged acceptors were imaged alone under the 
same conditions and no significant counts were detected (such as EGFP-S6K1 
alone, result given in Appendix C.7) indicating no other contributing factors 
influenced the lifetime results observed in this study.  
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Figure 4.17: AZD2014 interactions with mTORC1 in living cells. A) Confocal images of 
HEK293 cells treated with AZD2014 (70 μM). B) FLIM image of AZD2014. C) Lifetime 
distribution with x axis showing lifetime in picoseconds and y axis showing number of pixels. 
Scale bar = 20 μm. D) Confocal images of HEK293 cells expressing EGFP-S6K1 treated 
with AZD2014 (70 μM). E) FLIM image of AZD2014. F) Lifetime distribution. Scale bar = 10 
μm. G) Confocal images of HEK293 cells expressing EGFP-Rheb treated with AZD2014 (70 
μM). H) FLIM image of AZD2014. I) Lifetime distribution. J) Confocal images of HEK293 cells 
expressing EGFP-raptor treated with AZD2014 (70 μM). K) FLIM image of AZD2014. L) 
Lifetime distribution. M) Confocal images of HEK293 cells expressing EGFP-mTOR treated 
with AZD2014 (70 μM). N) FLIM image of AZD2014. O) Lifetime distribution. Experiments 
repeated minimum of three independent times. SD= standard deviation. All other scale bars 
= 10 μm. 
4.2.17 Co-localisation of AZD2014 with Rheb in living cells 
Following the interaction studies observed in the section above, the co-localisation 
of AZD2014 with the Rheb mTORC1 was explored firstly due to its similar 
localisation and secondly because of its interaction. AZD2014 (7 μM) was 
administered to HEK293 cells transiently overexpressing mDsRed-Rheb. Steady-
state co-localisation analysis using the Colocalization Colormap plugin for ImageJ, 
between AZD2014 and fluorescently labelled Rheb mapped regions of co-
localisation with strong yellow-red ‘hot-spot’ areas indicating strong co-localisation 
particularly in the ER/Golgi sub-cellular regions of the cell, see Figure 4.18. This co-
localisation analysis is more effective than other intensity dependent types of 
analyses which do not provide accurate pixel-pixel based correlations (Jaskolski, 
Mulle and Manzoni, 2005). The index of correlation (Icorr) value which represents 
the fraction of positively correlated pixels in the image was determined as 0.546, 
indicating that AZD2014 may localise to specific subcellular regions where mTORC1 
localisation sits (i.e. lysosomal, ER/Golgi membranes).   
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Figure 4.18: Specific AZD2014-mTORC1 subcellular targeting. Confocal images of A) 7 
µM AZD2014 with B) mDsRed-Rheb expression in HEK293 cells. Analysis performed in 
ImageJ version 1.48 using Colocalisation Colormap plugin.C) Colour map produced from 
plugin re-presenting co-localisation between AZD2014 and Rheb GTPase protein. 
Distribution of nMDP (normalized   mean deviation product) values (ranging from -1 to 
1) is visualised with a colour scale. Negative indexes are represented by cold colours 
(exclusion). Indexes above 0 are represented by hot colours (co-localisation). d) Respected 
histogram with a normal distribution (dotted) is also shown. Repeated minimum of three 
independent times. Scale bar = 10 μm. 
4.2.18 mTOR inhibition using AZD2014 with SensOR  
To correlate the fluorescence imaging of AZD2014 observed in this chapter to its 
physiological significance interaction with the mTOR signalling pathway, both in vitro 
and in vivo methods to probe for mTOR activity were performed. Western blot 
analysis of HEK293 cells overexpressing EGFP-S6K1 treated with either 7 nM or 7 
µM AZD2014 or no AZD2014 for 2 hours. A decrease in phospho-S6K1 activity (less 
intense chemiluminescent band) with 7 µM AZD2014 treatment was observed but 
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not with the 7 nM treatment (Figure 4.19). The live cell FRET biosensor (mCherry-
S6K1-EGFP), SensOR, developed in Chapter 3 to report directly on mTOR activity, 
was tested using this effective concentration (7 µM) of AZD2014 to validate 
AZD2014 function with respect to the live cell imaging results observed in this 
chapter. To investigate the treatment of AZD2014 in cancer models where mTOR is 
hyperactivated due to aberrant expressed Rheb levels (Liu et al., 2018), a cyan 
tagged fluorescent Rheb protein (CFP-Rheb) was co-expressed with SensOR for 
spectrally separated three colour imaging. As a control, CFP-Rheb was co-
expressed with SensOR and treated with rapamycin under identical conditions to the 
same experiment performed in Chapter 3 without CFP-Rheb expression, and 
similar lifetime changes were obtained. Next, AZD2014 was added to HEK293 cells 
co-expressing SensOR and changes in the fluorescence lifetime of SensOR in the 
cytoplasm from 2.4 ± 0.06 ns (closed configuration of the sensor) to 2.52 ± 0.04 ns 
(open configuration) was observed with AZD2014 (7 µM) treatment using one-
photon FRET-FLIM (Figure 4.19). These changes in lifetime correlate with the 
proposed opening of the FRET biosensor conformation in living cells which 
represents inhibition in mTOR activity (dephosphorylation). The individual values for 
the fluorescence lifetime at each pixel from this data can be presented in a polar 
diagram (Phasor plot) combined with the time-domain FLIM image where pixels with 
similar lifetimes and decay characteristics are clustered together (Figure 4.19). This 
approach is highly efficient in identifying subtle changes in lifetime in the same field 
of view. Shown in Figure 4.19C, the population of SensOR lifetime pixels shifted 
towards longer lifetime (evident by position on semi-circle) after AZD2014 treatment, 
shown in blue pseudo-colouring. In summary, these results validate AZD2014 for 
fluorescent microscopy and highlight its importance for cancer associated 
hyperactivated mTOR mutants that are rapamycin or rapalogue insensitive.  
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Figure 4.19: Phospho-S6K1 inhibition with AZD2014 in cells. A) Western blot showing 
phospho-S6K1 and total S6K1 levels with and without AZD2014 treatment. Concentrations 
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are shown. B) Confocal images showing mCherry-S6K1-EGFP (SensOR) co-expressed with 
CFP-Rheb and FLIM images of SensOR before and after AZD2014 (7 µM) treatment. Scale 
bar = 10 µm. C) Phasor plots of FLIM image pixels before and after AZD2014 treatment with 
phasor coordinates; x-axis =g and y-axis = s. Data was calibrated with fluorescein at pH 9 (4 
ns, monoexponetial). Single-lifetime species are on the semicircle, complex species are 
inside the semicircle and excited-state products are outside the semicircle. D) Box plot of 
SensOR cytoplasmic lifetimes before and after AZD2014 treatment. Number of pixels 
analysed = 17. Data taken from three repeats.  
4.3 Discussion 
Identifying where drugs localise within cancer cells and living tissues is imperative to 
both understanding the mechanism of pharmaceutical drugs and their effectiveness 
in binding to drug targets on a sub-cellular level (Stumpf, 2005; Rutkowska et al., 
2016) as well as to optimise their effect. Although most common ways to study drug 
localisation involve making fluorescent analogues of the drug (Miller, Fricker and 
Drewe, 1997; Kozany et al., 2009), fixing/ablating samples as found in forms of 
mass spectroscopy imaging (Ait-Belkacem et al., 2012; Vismeh et al., 2012), 
stimulated Raman scattering microscopy has been mostly replied upon to directly 
image drug localisation in living cells (Tipping et al., 2016). However, the use of 
natural fluorescence as a tool for live cell drug imaging is largely overlooked. In this 
chapter, the fluorescence properties of two pan-mTOR inhibitors have been 
characterised AZD2014 and INK128. The main mTOR inhibitor, rapamycin, did not 
show useful fluorescence for live cell imaging. During the preparation of this thesis, 
it was also reported that AZD2014 was naturally fluorescent and emitted in the 
483/32 nm region (Conway et al., 2018). The fluorimeter studies from this chapter 
support these findings and have shown that AZD2014 is strongly fluorescent 
(emission peak at 468 nm) with absorption peaks at both 284 nm and 393 nm using 
one-photon excitation and one of the two-photon excitation peaks characterised at 
795 nm. AZD2014 can also be used as fluorophore as its molar extinction 
coefficients (ε) have been determined as 36,790 M−1 cm−1 (284 nm) and 1,166 M−1 
cm−1 (393 nm) with a very good quantum yield (QY) of 0.47 in DMSO. Since the 
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brightness of a fluorophore is related to the product of its molar extinction coefficient 
and its quantum yield, the brightness of AZD2014 can be calculated as 17,291 
M−1cm−1 and 548 M−1cm−1 depending on the excitation wavelength. In comparison, 
the QY of EGFP is 0.6 and its ε is 55,000 M−1cm−1 giving it a brightness of 33,000 
M−1cm−1 (Kaishima et al., 2016). Therefore, AZD2014 can be used as a suitable 
fluorescent marker for studying mTOR inhibitor localisation and uptake within cancer 
cells. The fluorescence of AZD2014 may be attributed to its highly delocalised 
conjugated cyclic aromatic and purine ring structure which appears to be a feature 
of most fluorescent chromophores.  
However, although UV-Vis spectroscopy showed that rapamycin may be excited 
using wavelengths below 300 nm, no fluorescence was observed in this programme 
of work, indicating very low QY. This would support previous studies that have 
needed to conjugate rapamycin to external fluorophores such as 
nitrobenzoxadiazole (NBD) for imaging in killifish renal proximal tubules (Miller, 
Fricker and Drewe, 1997) as well as for in-vitro spectroscopy for studying binding of 
fluorescein-coupled rapamycin analogues to FKBP family proteins (Kozany et al., 
2009). The addition of fluorophores to macrolide structures such as rapamycin and 
rapamycin analogues is unfavourable as the addition of a dye to a compound could 
hinder uptake, solubility, and also function (Snipstad et al., 2017). Furthermore, as 
rapamycin has been shown to have variable and inconsistent results in targeting 
both mTORC1 and mTORC2 (Mukhopadhyay et al., 2016), studying second 
generation mTOR inhibitors provides a more reliable route for studying mTOR 
function.  
This chapter reports that INK128, another pan-mTOR inhibitor, also exhibits 
fluorescence properties with an excitation at 308 nm and an emission at 400 nm 
which is expected as the molecule shares similarity with the nicotinamide moiety of 
nicotinamide adenine dinucleotide (NADH) known to be excited at 340 nm (Blacker 
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et al., 2014) as well as DNA purines such as adenosine and guanine (excitation 
between 240-300 nm) (Kuimova et al., 2006). The ε of INK128 has been determined 
to be 16,215 M−1 cm−1 at 293 nm whist its QY in DMSO is 0.33. The brightness of 
INK128 is therefore 5,350 M−1 cm−1. This indicates that at these excitation 
wavelengths, AZD2014 is 69% brighter than INK128. A summary of the ε and QYs 
for AZD2014 and INK128 are given in Table 4.2.  
Table 4.2: Wavelengths, molar extinction coefficients and quantum yields of AZD2014 
and INK128 
 Wavelength 
(nm) 
ε 
(M−1cm−1) 
QYF (φ) 
AZD2014 (DMSO) 284 36,790 0.47 ± 0.02 
393 1,166 
AZD2014 (PBS) -                                - 0.11 ± 0.01 
INK128 (DMSO) 293 16,215 0.33 
EGFP 488 55,000 0.60 
 
The solution lifetime and spectroscopy studies of AZD2014 and INK128 showed 
longer lifetime and higher fluorescence yields in DMSO compared to PBS, 
supporting the notion that these molecules favour lipophilic rich environments such 
as the ER/Golgi/ peri-nuclear membranes observed in the live cell imaging. 
Similarly, cell work also shows longer lifetimes in the cytoplasm (subcellular organic 
structures) and shorter lifetimes in the nucleus (polar environments) (Asaad, Otter 
and Engberts, 2004). Another interesting result obtained from the experiments 
reported in this chapter was the extrapolation of the accumulated concentration of 
AZD2014 within the live cell which was shown to be 30-times higher than the 
concentration administered. In comparison to human clinical AZD2014 dosages that 
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are given at 25-100 mg (Basu et al., 2015; Powles et al., 2016) and pre-clinical 
doses at 7.5 and 15 mg/kg given to mice (Guichard et al., 2015), accumulation of 
clinically administered AZD2014 at 30x greater concentrations inside human cells 
could explain undesirable side effects such as fatigue (78%) and nausea (51%) 
(Basu et al., 2015). Currently, administered doses for INK128 range between 2-7 mg 
and patients have also exhibited adverse effects such as fatigue (10%) 
thrombocytopenia (15%) and neutropenia (5%) (Ghobrial et al., 2016). This 
accumulation effect could be vital for phase III clinical trials where repeated doses or 
dose intervals on larger populations of test patients could lead to unwanted clinical 
consequences (Brocks and Mehvar, 2010).  
The novelty of this work shows the ability to directly image mTOR inhibitors in living 
cells using both single photon and multiphoton microscopy. The uptake of both 
AZD2014 and INK128 in real-time has been established in monolayer HEK293 cells 
and found to be taken up within one minute with a maximum saturation reached 
within 10-15 minutes of administration. These findings are in line with previous work 
that observed a similar rate of uptake using multiphoton excitation to monitor and 
measure the anti-cancer drug combretastatin uptake in mammalian cells (CHO) 
(Bisby et al., 2012). Furthermore, in this chapter, similar uptake rate of AZD2014 
was found in the outer surface of multi-cellular HEK293 spheroid models with slower 
rates of uptake observed in the core z planes, using Light sheet microscopy. These 
findings are similar to experiments measuring drug uptake of combretastatin (E-
CA4) in C8161 spheroids  using confocal microscopy (Scherer et al., 2015). 
Understanding mTOR inhibitor uptake in a model close to real tumours is imperative 
towards the understanding of mTOR activity in the tumour environment. Other 
studies have shown that spheroids exhibit altered mTOR signalling with a ~50% 
reduction in mTOR activity compared to 2D monolayers (Riedl et al., 2016). Using 
immunofluorescence staining to probe for mTOR activity of downstream substrate 
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phosphorylation, the recent study has shown a fluorescence intensity gradient, 
starting from the outer layers to the inner layers of fixed spheroids (Riedl et al., 
2016). This highlights the significance for mTOR inhibitors to be designed to diffuse 
beyond the outer layers of tumours. However, it is worth noting that this gradient 
staining showing lack of labelling in the core layers of the spheroid could be an 
artefact from antibodies not being able to permeate through the spheroid layers 
(Riedl et al., 2016). 
Intriguingly, the treatment of spheroids with AZD2014 followed by 405 nm excitation 
in this programme of work, led to the possible discovery of a photo-activated effect 
where the spheroid volume increased by 2.3-times as measured by light sheet 
microscopy. Light sheet microscopy provides superior imaging over conventional 
imaging methods due to its ability to rapidly image live cell events in 3D over long 
time periods without inducing significant photo-toxicity owing to low laser power 
illumination (Candeo et al., 2017). The light-induced activation of AZD2014 resulted 
in cells undergoing cell death (apoptosis), a mechanism known to be specific to 
photodynamic therapy (PDT) (Agostinis et al., 2011). Although the involvement of 
reactive oxygen species (ROS) is not always essential in inducing apoptosis 
(Scherer et al., 2016) (Type IV mechanism), their relevance to AZD2014 has not 
been yet identified in the literature. A direct effect, currently unknown, would involve 
the drug itself reacting with some primary component of the cell to cause cell death.  
This work found similar localisations of both AZD2014 and INK128 to sub-cellular 
membrane regions (particularly the ER, Golgi and perinuclear) similar to that 
observed with fluorescently labelled Rheb (Yadav et al., 2013; Hao et al., 2018) 
across HEK293, CHO and MCF7 cells. The strong co-localisation between 
AZD2014 and mDsRed-Rheb established in this chapter supports the notion that 
AZD2014 may inherently target mTORC1 sub-structures and thus the question is 
raised whether mTOR drugs function by targeting proteins upstream of mTOR such 
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as Rheb which functions to activate the mTOR kinase (Long et al., 2007). Both 
AZD2014 and INK128 were also present in the nucleus, where mTOR localisation is 
reported (Yadav et al., 2013) as well as mTOR functionality (Giguère, 2018) and 
thus pan-mTOR inhibitors may automatically target mTOR in the cell.  
The mechanism of AZD2014, in relation to the mTORC1 pathway has been 
investigated in this chapter by advancing the applications of FRET-FLIM technology. 
First, the biological effect of AZD2014 treatment in HEK293 cells was found to inhibit 
mTOR activity by monitoring S6K1 phosphorylation through Western blot analysis 
and also by utilising the live cell FRET SensOR (developed in Chapter 3) with Rheb 
overexpression. The SensOR studies used in this chapter demonstrates the 
effectiveness in using AZD2014 against hyperactivated mTOR cancers that are 
rapamycin or rapalogue insensitive (Xie, Wang and Proud, 2016; Xu et al., 2016). 
The phasor plot approach demonstrated here requires no model fitting and therefore 
benefits from displaying raw FLIM data which can be used to discriminate clusters or 
lifetime changes. Furthermore, in support of the dual-selectivity of AZD2014 against 
both mTOR complexes, live cell mTORC2 inhibition has been detected using a 
Eevee-Akt-mT2 FRET sensor to explore changes in mTORC2 activity with AZD2014 
treatment in KPC cells (Conway et al., 2018).  
The lifetime of AZD2014 alone in HEK293 cells in this chapter was determined to be 
4.0 ± 0.5 ns whilst others have reported its lifetime to be 5.4 ± 0.03 ns in KPC cells 
(Conway et al., 2018). Such differences in observed lifetimes may be due to the 
purity of AZD2014 used or from cell lines differences. Furthermore, the τ of 
AZD2014 in this chapter was obtained at 600 or 405 nm excitation whilst the recent 
study has used 760 nm (Conway et al., 2018). The stability of the drug is yet 
unknown and this may be reliant on the correct storage conditions and time-usage 
of the drug, although storage at -20ºC and use of the drug for more than 2 months 
may not be suitable as found in this study. Nevertheless, direct interactions between 
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AZD2014 and the mTORC1 proteins have been determined in living cells by using 
AZD2014 as a donor and EGFP tagged proteins as an acceptor, yielding changes in 
lifetime greater than the 200 ps found in Chapter 3 between S6K1 and raptor. The 
spectral overlap between AZD2014 and EGFP has been determined to be more 
than 70% making this type of FRET acceptors-donor pairs most suited to observing 
large dynamic range quenching which is similar to modern-day FP FRET pairs 
(Mastop et al., 2017). The FRET changes determined here show selectivity towards 
certain mTORC1 proteins as evident by greater changes in lifetime, in particular for 
S6K1 and Rheb. A summary of these energy transfer (FRET) efficiencies are shown 
in Table 4.3. These findings are not surprising, as AZD2014 has been shown to 
have selectivity against some proteins such as those from the PIKK family as well as 
the Wnk2 kinase protein at similar concentrations (10 µM) used in this chapter (Pike 
et al., 2013; Guichard et al., 2015). 
Table 4.3: FRET Efficiencies of AZD2014 interactions with GFP mTORC1 proteins. 
FRET efficiency (E) obtained from AZD2014 alone lifetime (τD) and AZD2014 lifetime with an 
acceptor (τDA) using E=1- (τDA/ τD) x 100  
Donor +/- acceptor FRET efficiency (%) 
AZD2014 only - 
AZD2014 + EGFP-S6K1 18.70 
AZD2014 + EGFP-Rheb 15.80 
AZD2014 + EGFP-raptor 10.73 
AZD2014 + EGFP-mTOR 10.60 
 
The interaction between S6K1 and AZD2014 could support a working model for an 
indirect involvement of AZD2014 for PDT treatment where directly inhibiting S6K1 
phosphorylation has shown to induce apoptosis (Song et al., 2014). It is also worth 
noting that there are large deviations in the measured lifetime of AZD2014 and the 
average lifetime taken across independent experiments may skew the overall 
magnitude of change in each interaction.  
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4.4 Conclusions 
In conclusion, mTOR inhibitors such as AZD2014 and INK128 display fluorescent 
properties that can be used as markers for determining cellular uptake and 
localisation in living cells using advanced imaging microscopy. It has been observed 
that the inhibitors localise to sub-cellular lipid-rich endomembrane regions within the 
cell known to be associated with the tethering of mTORC1. AZD2014 has a longer 
lifetime and higher quantum yield in DMSO than in PBS. AZD2014 is 69% brighter 
than INK128. Both AZD2014 and INK128 are taken up into 2D monolayer 
mammalian cells within one minute of addition whilst AZD2014 accumulated at a 30-
times higher concentration. AZD2014 uptake rate into 3D cell spheroids was similar 
to that in monolayer cells. Upon light photo-activation, AZD2014 causes expansion 
in the diameter of living spheroids leading to cell death. AZD2014 interacts with the 
mTORC1 subunit proteins on the complex. Strong interactions between S6K1 and 
Rheb proteins were found in particular. SensOR was found to be responsive even in 
cells overexpressing Rheb. The use of this FRET-FLIM method paves the way for 
future technological development to study the effects of AZD2014 direct binding to 
the mTORC1 complex for both medical and pharmaceutical research.   
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5.0 mTORC1 large-scale expression and 
purification 
 
5.1 Brief introduction 
The key objective of structural biology is to provide a detailed atomic map of 
biological macromolecules (Murata and Wolf, 2018). However, a key hurdle before 
obtaining a structure by X-ray crystallography or cryo-Electron Microscopy (cryo-
EM) is to successfully express large quantities of pure and stable (i.e. not misfolded 
or degraded) protein. The requirement for this stability prior to structural 
determination becomes more challenging when dealing with large protein 
complexes. The direction of the work taken in the previous results chapters is one 
which supports S6K1 directly complexed onto mTORC1 aided by raptor interaction. 
As no such structure of the complex has been published to date, this aspect of the 
work aimed to purify raptor and S6K1 together for a future structural analysis. 
Structural information could ultimately aid the development of novel strategies to 
prevent S6K1 recruitment and hence phosphorylation. This chapter also sought to 
purify the novel FRET biosensor (SensOR) developed in Chapter 3 capable of 
determining S6K1 phosphorylation (i.e. mTOR activity) that was used for preliminary 
in vitro spectroscopy studies; these results are presented in Chapter 3.  
The main hypothesis of this chapter is: 
• The stability of S6K1 bound onto mTORC1 heavily depends on its interaction 
with raptor and thus subsquent mTOR phosphorylation is aided by subtle 
S6K1 conformational changes related to the phosphorylated state of S6K1 
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5.2 Results 
5.2.1 PCR screen validation of mCherry-S6K1-EGFP-STREP (SensOR) 
To purify the mCherry-S6K1-EGFP (SensOR) protein for in vitro characterisation, a 
new plasmid construct was prepared containing a STREP purification tag for large 
scale insect cell expression. As described in Chapter 2, the combined mCherry-
S6K1 gene product was infused with separately isolated EGFP and cloned into the 
pOPINEneo-3C-2STREPStop vector. Individually isolated PCR products were used 
to avoid any primer mismatching. A PCR screen using agarose gel electrophoresis 
was performed to determine success of cloning using a T7F (forward) and a 
NeoRev2 (reverse) primer. A single band corresponding to 3871 bp upon UV 
illumination was detected matching to the DNA base pair lengths of mCherry, S6K1 
and EGFP combined (see Figure 5.1). Further validation of the construct was 
provided by Sanger sequencing.  
 
 
Figure 5.1: Reverse PCR screen of SensOR-STREP construct. Analysis of PCR products 
separated by agarose gel electrophoresis. Marker is shown on the left (bp) with insert 
product on the right with bands corresponding to mCherry-S6K1 and EGFP combined in the 
pOPINEneo-3C-2STREPStop vector.  
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5.2.2 Expression and pilot purification of mCherry-S6K1-EGFP-STREP 
(SensOR)  
Having confirmed the integrity of the cloned STREP tagged mCherry-S6K1-EGFP 
biosensor, the plasmid was combined with a bacmid and transfected in Sf9 insect 
cells. Upon confirmation of expression by wide-field fluorescence imaging in both 
green and red channels, virus generation from P0 was taken to P1 and to P2 
stages. However, following expression and pilot purification, major degradation 
products were observed using a fluorescence gel imaging system as evident by 
multiple EGFP and mCherry bands at incorrect molecular weight sizes and detection 
of a weak red intensity signal, given in Appendix D.1. Attempts were made to 
prevent degradation by optimisation of expression conditions; harvesting samples at 
different time points and infecting cells with different dilutions of virus. However, this 
was unsuccesful. The observed degradation may have been related to the protease 
activity of the bacmid. A bacmid deficient of proteases has shown less protein 
degradation and corresponding improvement in expression (Park, Abe and Kato, 
2008).    
Therefore, a recombinant bacmid that was deficient in proteases (see Chapter 2 for 
details) was produced and co-transfected with the SensOR-STREP construct in Sf9 
insect cells and amplified to P2 virus generation, as described above. As shown in 
Figure 5.2, wide-field fluorescence imaging confirmed high expression of the 
SensOR construct in both P0 and P1 stages with high levels of fluorescence in both 
green and red channels. The transfection efficiency was determined to be between 
70-80%. Western blot analysis verification using various concentrations of P1 
infected virus cells at 48-hour or 72-hour time points showed single high molecular 
weight (MW) bands corrosponding to the combined MWs of mCherry, S6K1 and 
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GFP (~130 kDa) indicating that intact full length SensOR was expressed a high 
levels (Figure 5.3).  
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Figure 5.2: Expression of SensOR-STREP in insect cells. Wide-field fluorescence images 
showing A) GFP of SensOR B) mCherry of SensOR and C) transmitted light of P0 virus after 
72 hours expression in Sf9 cells. Fluorescence images showing D) GFP of SensOR E) 
mCherry of SensOR and F) transmitted light of P1 virus after 72 hours expression in Sf9 
cells. All scale bars = 400 µm. High expression was observed at each stage P0-P1.  
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Figure 5.3: Western blot validation of SensOR expression. A) Western blot loaded with 
various P1 virus concentrations expressing SensOR (lanes 2,4,6) and GFP control (lanes 
3,5,7) at 48 hours. B) Western blot loaded with various P1 virus concentrations expressing 
SensOR (lanes 2,4,6) and GFP control (lanes 3,5,7) at 72 hours. Moleculer weight markers 
are shown on the left of blots. Blots labelled with anti-STREP antibody.  
5.2.3 Purification of mCherry-S6K1-EGFP-STREP (SensOR)  
After validating the expression of mCherry-S6K1-STREP in Sf9 cells, a 2.5 litre 
scale up using P2 virus (1/1000) was performed and infected cells harvested into 6 
aliquots (~400 ml) after 72 hours of infection. One of the 6 pellets was lysed as 
described in Chapter 2 and purified using a StrepTrap column on a ÄKTA Xpress 
system followed by gel filtration chromatography (SEC) to separate the SensOR 
protein on the basis of its size (by a set of standard proteins, per manufacturer’s 
protocol). As shown in Figure 5.4, a monodisperse peak indicating a monomer form 
of the protein was detected. SDS PAGE gel electrophoresis of eluted sample 
fractions confirmed a single band at a 130 kDa as determined by in-gel fluorescence 
and by gel coomassie stain, demonstrating that the protein was monomeric and of 
high purity (Figure 5.4). The protein was also subjected to QC analysis 24 hours 
after purification and both in-gel fluorescence and gel coomassie stain confirmed 
protein stability, with no aggregation or degradation detected. A faint band was 
occasionally observed in highly concentrated samples and this may be related to a 
post-modification of S6K1 which may have changed the apparent electrophoresis 
mobility of the protein. Although, human S6K1 is not known to be glycosylated, goat 
S6K1 has been reported to undergo a glycosylation post-modification (Manlin et al., 
2013). A final high yield concentration of 3.65 mg/ml SensOR protein was obtained.  
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Figure 5.4: Large scale purification of SensOR. A) Chromatogram obtained for mCherry-
S6K1-EGFP-STREP after purification using the ÄKTA Xpress protein purification system. (x 
axis = volume; y axis = absorbance at 280 nm). The blue peak represents the eluted proteins 
and the red dashed box represents fraction used for SDS PAGE confirmation. Other peaks 
may represent small aggregation of protein or free fluorescent protein. Gel electrophoresis of 
purified SensOR fractions from the ÄKTA Xpress system showing B) in-gel fluorescence 
overlay of both GFP and RFP channels and C) gel coomassie staining. Molecular weight 
markers are also shown. 
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5.2.4 Generation of mTORC1 virus for structural studies 
The mTORC1 constructs for insect cell expression were designed and made by 
GenScript®, see Chapter 2 for details. These constructs were co-transfected into 
Sf21 cells with bacmid for baculovirus expression and P0, P1 and P2 viruses were 
successfully generated. As these constructs do not have a fluorescence tag to 
determine expression, a change in both mean cell size and cell viability was used as 
a measure to validate protein expression (Janakiraman et al., 2006). As shown in 
Table 5.1, an increase in mean cell size from 11.9 µm in non-infected cells to 14-16 
µm was observed in all P2 post-72 hour generated virus infected cells. In addition, 
the cells also showed a decline in viability compared to non-infected cells which is 
another indication of successful virus infection in insect cells. Non-infected Sf21 
cells are expected to double every 24 hours and a decrease in doubling time in 
infected cells, as given in Table 5.1, can be used as a final marker for successful 
infection. 
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Table 5.1: mTORC1 P2 virus generation results in SF21 cells. (n=1) 
Construct Protein(s) Live cell 
count 
(106) 
 
Cell 
viability 
(100%) 
Cell 
size 
(µm) 
Non-infected N/A 9.1 99 11.9 
EV5831 raptor-His 1.7 88 14 
EV5832_EV5831 S6K1-
FLAG + 
raptor-His 
3.3 94 14.5 
EV5830_EV5831 FLAG-
S6K1 + 
raptor-His 
2.7 94 14.5 
EV5834_EV5831 ΔS6K1-
FLAG + 
raptor-His 
2.2 93 14.4 
EV5833_EV5828 myc-
ΔmTOR + 
mLST8 
2.4 89 14.7 
EV5827_EV5828 myc-mTOR 
+ mLST8 
5.1 96 15.3 
EV5832_ EV5827_ EV5828 S6K1-
FLAG + 
myc-mTOR 
+ mLST8 
4.5 98 16.2 
EV5831_EV5832_EV5827_EV5828 raptor-His + 
S6K1-
FLAG + 
myc-mTOR 
+ mLST8 
2.0 94 14.7 
 
5.2.5 Small scale scouting expression of mTORC1 proteins in insect cells  
To find the best conditions for protein expression, different time-points and 
multiplicity of infection (MOI) were investigated. Using the Baculovirus Infected 
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Insect Cells (BICCs) described above, Sf21 cells were infected using 0.2, 1 or 5 MOI 
and harvested at 24 hours or 72 hours post-infection and these results are shown in 
Table 5.2 and Table 5.3. An increase in cell size and decrease in viability indicated 
that cells were successfully infected. To validate the expression and levels of protein 
production from these cells, lysates were prepared and subjected to Western blot 
analysis using antibodies. As shown in Figures 5.5 and Figure 5.6, the S6K1 and 
truncated S6K1 with raptor constructs appeared to express highest post 72 hours of 
infection, evident by an increase in intensity of the protein bands compared to 48 
hours of infection. S6K1 with mTOR and mLST8, and S6K1 with mTOR, raptor and 
mLST8 also showed S6K1 expression (bands at 75 kDa), see Figure 5.7. 
Expression with an MOI of 5 yielded highest protein production. It was also 
observed that both full length and truncated S6K1 (38 kDa) were soluble as shown 
by the levels of protein in the soluble fractions correlating to the total fractions. A 
faint band at 76 kDA for truncated S6K1 was observed which may represent the MW 
of the protein in its dimer form. On the other hand, raptor did not co-express well for 
any of the constructs as anti-His antibody labelling did not detect any bands at 150 
kDa (representating that of raptor) although faint bands were faintly visible, shown in 
Figure 5.6, suggesting that either the raptor protein is expressed at very low levels, 
failed to fold correctly or the His tag attached to the raptor protein is masked, 
resulting in poor labelling efficiency with the anti-His antibody. For the construct 
containing S6K1 with raptor, mTOR and mLST8, a raptor specific antibody was used 
which showed bands at ~150 kDa indicating that raptor levels are poorly expressed 
and a more sensitive antibody is required to validate its expression (Figure 5.7).  
The expression of full length mTOR and truncated mTOR were also tested under 
different MOI conditions. Infection post 72 hours was only investigated as 
expression with the constructs above yielded low levels of protein. Figure 5.8 shows 
that full length mTOR failed to express correctly as evident by the lack of bands at 
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its correct molecular weight size of 289 kDa as well as intense degradation bands 
(~15 kDa) detected by the anti-myc antibody. However, the truncated mTOR 
construct (1376-2549 amino acid residues) expressed well with an expected band 
size of ~150 kDa. Moreover, when comparing total fractions to soluble fractions, no 
bands for truncated mTOR were observed in the soluble lanes (Figure 5.8), 
indicating that the protein must be in the insoluble fraction of the cell lysate (i.e. 
associated with membrane bound organelles and structures). It is highly likely that 
the truncated form of mTOR lacks the correct localisation sequences and therefore 
may not localise properly.   
Reasons for degradation and poor raptor expression in insect cells may be due to 
the absence of human chaperones within the insect cell system required to correctly 
fold such large proteins and this is discussed in section 5.3. These findings are 
investigated further in the next sub-chapter where S6K1-raptor constructs were 
subjected to manual purification from a larger infected culture volume.  
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Table 5.2: Scouting expression results post-48 hours infection. Live cell count (C), cell 
viability (V) and cell size (S) are given. (n=1). 
48 hours  MOI 0.2 MOI 1 MOI 5 
Construct Protein 
(s) 
C 
(106) 
 
V 
(100%) 
S 
(µm) 
C 
(106) 
 
V 
(100%) 
S 
(µm) 
C 
(106) 
 
V 
(100%) 
S 
(µm) 
Untransfected N/A 2.4 97 12.6 - - - - - - 
EV5831 raptor-
His 
1.2 97 15.9 1.3 98 16.9 1.2 91 15.8 
EV5832_EV5831 S6K1-
FLAG + 
raptor-
His 
2.2 93 16 1.1 96 15.6 0.93 90 15.3 
EV5830_EV5831 FLAG-
S6K1 + 
raptor-
His 
1.5 95 16.5 1.1 96 16.1 0.82 85 14.5 
EV5834_EV5831 ΔS6K1-
FLAG + 
raptor-
His 
1.2 96 14.9 1.4 94 15.7 8.1 97 15.5 
EV5833_EV5828 myc-
ΔmTOR 
+ 
mLST8 
1.9 96 14.9 0.74 95 14.3 0.72 90 12.6 
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Table 5.3: Scouting expression results post-72 hours infection. Live cell count (C), cell 
viability (V) and cell size (S) are given. (n=1). 
72 hours  MOI 0.2 MOI 1 MOI 5 
Construct Protein (s) C 
(106) 
 
V 
(100
%) 
S 
(µm) 
C 
(106) 
 
V 
(100%) 
S 
(µm) 
C 
(106) 
 
V 
(100
%) 
S (µm) 
Untransfected N/A 9.8 99 12.8 - - - - - - 
EV5831 raptor-His 1.9 96 15.9 1.9 92 16.2 1.4 83 16.6 
EV5832_EV5831 S6K1-FLAG + 
raptor-His 
1.5 93 15.9 0.87 89 16.0 1.6 92 16.6 
EV5830_EV5831 FLAG-S6K1 + 
raptor-His 
1.0 92 15.5 1.2 93 15.1 0.8
5 
86 15.6 
EV5834_EV5831 ΔS6K1-FLAG 
+ raptor-His 
1.5 94 16.0 1.2 93 15.0 1.5 96 14.9 
EV5833_EV5828 myc-ΔmTOR 
+ mLST8 
1.5 88 14.6 0.9 83 13.1 1.6 81 13.1 
EV5827_EV5828 myc-mTOR + 
mLST8 
5.4 95 15.7 2.4 94 16.6 7.8 96 17.2 
EV5832_ EV5827_ 
EV5828 
S6K1-FLAG + 
myc-mTOR + 
mLST8 
2.2 90 16.6 0.7 72 16.7 0.8 74 15.6 
EV5831_EV5832_EV
5827_EV5828 
raptor-His + 
S6K1-FLAG + 
myc-mTOR + 
mLST8 
2.7 95 15.2 2.5 96 16.0 1.7 95 15.5 
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Figure 5.5: Scouting expression results for post 48 hours infection of S6K1-raptor 
constructs. Western blot analysis using both anti-His and anti-FLAG antibodies at the same 
time for A) total lysate samples B) soluble fraction lysate samples. Molecular weights shown 
on the left with marker. GFP control contains His tag. Non-infected (NI) total and soluble 
control samples also shown. 
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Figure 5.6: Scouting expression results for post 72 hours infection of S6K1-raptor 
constructs. Western blot analysis using both anti-His and anti-FLAG antibodies at the same 
time for A) total lysate samples B) soluble fraction lysate samples. Molecular weights shown 
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on the left with marker. GFP control contains FLAG tag. Non-infected (NI) total (T) and 
soluble (S) control samples also shown; (*) may represent high MW mTORC1 complex. 
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Figure 5.7: Scouting expression results for post 72 hours infection of S6K1-mTOR-
mLST8 and S6K1-raptor-mTOR-mLST8 constructs. Western blot analysis of total and 
soluble lysates using A) anti-raptor antibodies and B) anti-FLAG antibodies. Non-infected 
(NI) total and soluble control samples also shown.  
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Figure 5.8: Scouting expression results for post 72 hours infection of mTOR-mLST8, 
S6K1-mTOR-mLST8 and S6K1-raptor-mTOR-mLST8 constructs. A) and B) Western blot 
analysis of total and soluble lysates using anti-myc antibodies. Non-infected (NI) total and 
soluble control samples also shown.  
5.2.6 Small scale purification of S6K1-raptor constructs 
Having established that raptor may be expressed at extremely low levels in insect 
cells, a larger volume from 3 ml to 45 ml of insect cells was infected with an MOI of 
5 and harvested after 72 hours (determined to be the optimised expression 
conditions; see sub-chapter above). Cell pellets were lysed and subjected to manual 
batch-bind purification using Ni-NTA resin. Protein levels as total, soluble and eluted 
fractions for all S6K1-raptor and mutated S6K1-raptor constructs were evaluated by 
Western blot analysis as shown in Figure 5.9. Strong bands at 150 kDa were 
observed for full length raptor using anti-raptor antibodies as well as fainter bands 
higher than 250 kDa (possible undenatured mTORC1 dimer). Strong bands at 75 
kDa for full length S6K1 and at 38 kDa for the truncated S6K1 sequence using anti-
FLAG antibodies were detected. Both S6K1 and raptor bands were observed in the 
elution lanes (Figure 5.9) indicating that both proteins were bound together, 
supporting the FRET-FLIM data in Chapter 3. Interestingly, truncated S6K1 and 
raptor was also found in the elution fractions suggesting that this construct does 
interact with raptor. This may be a consequence due to the TOS motif that was 
artificially added before the truncated S6K1 sequence that allowed this construct to 
bind to raptor. This result further validates the S6K1 TOS motif in substrate 
recruitment carried out using imaging in Chapter 3. Non-specific bands were 
observed in the elution fractions (Figure 5.9), these may have arisen from the lack 
of optimisation of the purification protocol used. Modifications to the salt, incubation 
time and imidazole concentrations could yield cleaner product elution. 
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Figure 5.9: Expression and batch-binding purification of S6K1-raptor constructs. 
Western blot analysis of total lysate, soluble lysate and eluted sample using A) anti-raptor 
antibodies and B) anti-FLAG antibodies. Non-infected (NI) total and soluble control samples 
also shown. (*) may represent high MW mTORC1 complex.  
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5.2.7 Large scale pilot expression and purification of S6K1-raptor  
Upon confirmation that S6K1 and raptor are complexed together in insect cells from 
small scale purification results, a larger scale purification with a 5 litre culture was 
attempted. Two 2.5 litre flasks were infected with S6K1-raptor P2 BIICs and 
monitored after 48 hours and 53 hours (Table 5.4) for cell viability. Cells were 
harvested after 53 hours as the cell viability decreased to 90%. An average increase 
from 12.3 ± 0.4 µm to 15.2 ± 0.4 µm taken from both flasks was observed at the 53-
hour time-point indicating successful infection of the S6K1-FLAG + raptor-His 
construct.  
Table 5.4: Large scale S6K1-raptor infection results in SF21 cells. (n=1). 
Time point Flask 
number  
Construct Volume Live cell 
count 
Cell 
viability  
Cell size 
0 1 EV5831_32 2.5 litre 1.5 x 10
6
 98% 12.6 µm 
0 2 EV5831_32 2.5 litre 1.2 x 10
6
 98% 12 µm 
48 hours 1 EV5831_32 2.5 litre 1.7 x 106 92% 14.0 µm 
48 hours 2 EV5831_32 2.5 litre 2 x 106 93% 14.3 µm 
53 hours 1 EV5831_32 2.5 litre 1.2 x 10
6
 94% 14.8 µm 
53 hours 2 EV5831_32 2.5 litre 1.4 x 10
6
 90% 15.5 µm 
 
A cell pellet of 29.3 g was obtained following harvesting and was then lysed as 
described in Chapter 2. Soluble lysate was loaded onto an ÄKTA purifier for 
immobilized metal affinity chromatography (IMAC) using a nickel resin column 
(HisTrap), designed to bind to raptor with S6K1 bound (ÄKTA results given in 
Appendix D.3). Following overnight purification, eluted protein fractions were 
subjected to SDS-PAGE gel separation and Western blot analysis for verifying 
success of purification. Although the coomassie SDS-PAGE staining showed 
multiple non-specific protein contaminant bands (see Appendix D.4), Western blot 
analysis (Figure 5.10) using anti-His antibodies detected low levels of the raptor 
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protein at 150 kDa. Intense bands at around 100 kDa were also observed, these 
bands were probabably due to natural histidine expressing proteins within insect 
cells that may have bound to the Ni resin column.  
 
Figure 5.10: Purification of S6K1-raptor construct. Western blot analysis of total lysate, 
soluble lysate and eluted sample fractions using anti-His antibodies. Non-infected (NI) and 
GFP-His control samples also shown. (*) Bands may be contaminants.  
Following the IMAC purification, the eluted protein in the fractions were concentrated 
and then subjected to size-exclusion chromatography (SEC) in an attempt to 
separate the raptor-S6K1 complex from the other contaminants that are likely to be 
natural insect cell histidine containing proteins. SEC results (Figure 5.11) showed a 
broad peak of absorbance (i.e. concentration), indicating multiple species of high 
molecular weights (>200 kDA). Following overnight purification, fractions were 
eluted and analysed by SDS-PAGE with coomassie staining (Figure 5.11). The 
staining again showed multiple bands in the elution products indicating presence of 
non-specific proteins/ contaminants. Distinct and clear bands at 150 kDa, ascribed 
to the MW of raptor, were not observed indicating that there has been loss of protein 
from IMAC to the SEC purification.  
raptor 
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Further attempts were carried out to yield purer S6K1-raptor protein complex. Eluted 
samples from the SEC were loaded onto the automated Phynexus purification 
system with Ni affinity resin PhyNexus PhyTips and eluted in smaller volumes to 
remove the non-specific contaminants and concentrate the S6K1-raptor complex. 
The analysis of the coomassie stain of the eluted samples showed cleaner bands 
with some non-specific contaminants. Intense bands at 150 kDa (raptor) and at 75 
kDa (S6K1) were observed (given in Appendix D.5). The concentration of raptor 
calculated as an average from all three eluted fractions was determined to be 931 
ng (~1 mg of protein) using the known concentration of purified GFP loaded as a 
standard. As a cross-check given in Figure 5.12, Western blot analysis of these 
purified fractions showed bands for raptor as well as bands for S6K1. However due 
to the poor purity and poor yield of the raptor protein, no further work in insect cells 
was carried out.  
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Figure 5.11: SEC purification of S6K1-raptor construct. A) Chromatogram obtained for 
S6K1-FLAG + raptor-His after SEC using the ÄKTA protein purification system. The blue 
peak represents the eluted protein fractions (x axis = volume; y axis= absorbance at 280 
nm).  B) Coomassie stain of SEC elution fractions. GFP control and markers shown.  
 
 
 
Figure 5.12: Phynexus purification of S6K1-raptor construct. A) Western blot of eluted 
fractions using anti-raptor antibody. B) Western blot of eluted fractions using anti-FLAG 
antibody. GFP control and markers shown. GFP-FLAG control also shown (containing other 
impurities).  
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5.3 Discussion 
The baculovirus expression system has been used throughout this chapter to 
produce mTORC1 subunit proteins. Firstly, the results demonstrate that that 
SensOR, a live cell FRET sensor for determining mTOR activity (see Chapter 3), 
can be produced in large quantities (~3.7 mg) from Sf9 insect cells. This tandem 
construct with the full length S6K1 at its heart and a STREP tag purification epitope 
attached, highlights the flexibility of insect cells in producing full length mammalian 
kinase proteins (Li et al., 2011). It is intriguing to discover that there is to date, 
currently no full length structure of the S6K1 kinase protein despite many published 
X-ray crystallography structures deposited in the RCSB PDB Protein Data bank 
showing truncated forms of the protein using both E.coli and baculovirus-infected 
insect cell expression systems (summarised in Table 5.5) (Wang et al., 2013; Niwa 
et al., 2014; Qin et al., 2015). Crystallisation trials of full length S6K1 may have been 
attempted but have failed to produce significantly useful good quality diffraction data 
(resolution) due to possible highly disordered regions within the protein sequence, 
as predicted using bioinformatics tools (given in Appendix D.6). However, by having 
the addition of fluorescent proteins to the S6K1 structure, future crystal studies of 
SensOR could provide a novel full length S6K1 structure locked into one its 
phosphorylated states and thus provide a direct link between S6K1 structural 
change and mTOR phosphorylation. Secondly, the use of the STREP tag in this 
section of the results chapter also validates the superiority of the epitope tag for 
purification, supporting the findings that STREP tag does not interfere with protein 
folding (Kimple, Brill and Pasker, 2018) and enables a one-step purification with 
minimal contaminants due to the high affinity between the STREP peptide and 
StrepTactin resin in the purification column (Maertens et al., 2015; Schmidt and 
Skerra, 2015). Natural biotinylated proteins or free biotin found internally in 
mammalian cells could bind to StrepTactin resin leading to unspecific binding, 
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however these proteins are less abundant in insect cells as described in the 
manufacturer's protocol, and thus allow for elution of ultrapure protein.  
Table 5.5: Summary of S6K1 expression systems for X-ray crystallography work 
PDB code: Resolution Length 
(amino acids) 
Vector/ 
tags 
Complex
or alone 
Expression 
system  
4RLO/ 4RLP 2.53 Å Truncated 
S6K1 
constructs 
(84–384, 1–
421, 1–421 
T412E) 
Cloned 
into 
pFASTba
c 
HTB vecto
r 
Alone Baculovirus
-infected 
insect cells 
3WF4/5/6/7/8/
9 
2.04 Å Truncated 
S6K1 (75–
399) 
Cloned 
into 
pDEST 10 
vector  
Alone Baculovirus
-infected 
insect cells 
4C33 1.7 Å Truncated 
S6K1 
(residues 1-
421) 
HIS/ GST With 
PKA 
Escherichia 
coli 
4L3J 2.1 Å Truncated 
kinase 
domain 
(residues 52–
379) and the 
kinase 
domain plus 
the 
hydrophobic 
motif 
(residues 52–
394) 
pFastHTB 
vector  
Alone Baculovirus
-infected 
insect cells 
3A62 2.35 Å Truncated -
75–399 of 
human 
p70S6K1 
pVL1392 
(Pharming
en) 
with HIS 
tag 
Alone  Baculovirus
-infected 
insect cells 
 
The results obtained in this chapter also show that the expression of other larger 
mTORC1 proteins, namely mTOR and raptor in SF21 insect cells using the 
baculovirus system was highly inefficient for large quantities (milligrams) of pure 
protein essential for structural studies. The findings that raptor expressed at poor 
levels and that the mTOR protein was degraded, are in support of eukaryotic 
membrane proteins expression work that that found membrane proteins misfolded 
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and inactive in baculovirus-infected insect cells whilst the same proteins extracted 
from mammalian cells were found to be folded and active (Thomas and Tate, 2014). 
Moreover, the insect cell lacks the human chaperone machinery required to fold 
eukaryotic proteins. Other studies have co-expressed various human chaperones 
(e.g. Hsp70) with relevant co-factors to increase the solubility and expression of a 
target protein by up to 7-fold using the insect cell system (Tate, Whiteley and 
Betenbaugh, 1999; Yokoyama et al., 2000). Thus, trials using various human 
chaperones with raptor and mTOR in insects may improve protein production in 
insect cells. The poor and misfolded expression of raptor and mTOR using the Sf21 
insect cell expression system observed in this work differ to previous work that has 
expressed large quantities of the raptor-mTOR-mLST8 complex together in SFf21 
insect cells (Aylett et al., 2016). In comparison, similar culture reagents and lysis 
buffer were used with the exceptions that the insect cells in the present study were 
cultured in the presence of 2.5 µM rapamycin and that the mTORC1 complex was 
purified via FLAG tag. In addition, the mTORC2 complex (mTOR-mLST8-Rictor-
SIN1-Protor-1) has also been recently purified from Sf21 insect cells via FLAG tag. 
Interestingly, low yields of the mTORC2 complex was found, within the nmol range 
from a 10 litre expression (Stuttfeld et al., 2018), indicating that mTOR components 
may struggle to express and come together in the insect cell system. In addition, the 
mTOR protein was found to be unstable after purification and was stabalised by 
fixation (Stuttfeld et al., 2018). Purification through the FLAG tag epitope (Gerace 
and Moazed, 2015) is often preferred over His tag purification as both insect and 
mammalian cells contain high levels of endogenous histidine containing proteins 
which tend to bind to the nickel resin (Kimple, Brill and Pasker, 2018) and this was 
evident in the results of this chapter as several non-specific protein contaminant 
bands were observed.  
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Another alternative strategy to express the mTORC1 complex containing raptor, has 
relied on mammalian cell expression (Yang et al., 2013, 2016, 2017). The 
expression of mTORC2 containing proteins to form mTORC2 has also been 
performed in mammalian HEK293 cells using the maltose-binding protein (MBP) 
epitope tag for purification (Chen et al., 2018). The mammalian expression system is 
advantageous for eukaryotic proteins as post-modifications required for protein 
functionality are maintained (Khan, 2013). However, although production time-scale 
is shorter compared to that of the insect cell expression, differences in lead time of 
2-3 weeks, milligrams-to-grams of pure transfection quality DNA plasmid is required 
compared to nanogram quantities used in baculovirus insect cell infection. A 
summary of the expression systems and their respected structures of mTORC1 
available on the RCSB PDB Protein Data bank is given in Table 5.6.  
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Table 5.6: Summary of mTORC1 expression systems for Cryo-EM work 
PDB 
code: 
Resolution Length 
(amino 
acids) 
Vector/ tags Complex 
or alone 
Expression 
system  
6BCX 3.0 Å Cryo-EM 
 
 
Full pcDNA3.1(+) 
vector. 
FLAG tag. 
pFastBac1 
with GST. 
Complex/ 
raptor 
alone (not 
human) 
HEK293-F cell 
line that was 
stably 
transfected. 
Insect cell for 
raptor (at) 
5H64 
 
4.4 Å Cryo-EM Full FLAG and 
Myc tagged 
mTORC1 
subunits, 
separate 
vectors 
Complex HEK293F 
cells in 
suspension 
culture. Anti-
Flag affinity 
resin, followed 
by ion 
exchange and 
gel filtration 
5FLC 
 
5.9 Å X-ray 
combined with 
Cryo-EM to 
give 
reconstruction 
Full  A fusion 
vector 
containing 
mTORC1 
(pAB2G-
mTOR, 
pIDK-His10-
myc-flag-
Raptor, 
pIDC-
mLST8) 
Complex 
and raptor 
alone 
(also not 
human)  
“MultiBac” 
system in 
Insects cells. 
Expression 
with 
rapamycin  
addition; 
stabilisation by 
glutaraldehyde 
gradient 
fixation 
4JSV 
 
3.5 Å X-ray 
crystallagraphy 
Truncated 
(1376–
2549) 
mTOR 
with 
mLST8  
FLAG 
tagged 
mTOR and 
mLST8 
Complex HEK293-F cell 
line that was 
stably 
transfected 
 
Similarities between the overall 3D structures of mTORC1 and mTORC2 have been 
identified (Yang et al., 2018) with a tighter conformation of the complex found in 
mTORC2, shown to sterically hinder the binding of the rapamycin-FKBP12 complex 
(Karuppasamy et al., 2017; Chen et al., 2018). These structural differences explain 
the mechanism behind why mTORC2 is not sensitive to rapamycin treatment. 
However, the possible role of raptor in bringing the mTORC1 components together 
is still not fully examined. On one hand, it has been indicated that raptor indirectly 
mediates the dimerisation of mTOR (Jain et al., 2014; Aylett et al., 2016), whilst in 
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TORC1 (yeast) it has been shown that raptor binding directly facilitates the 
formation of the TOR dimer (Baretić et al., 2016). Other studies in yeast have 
genetically engineered chimeric TORC1 and TORC2 proteins each containing 
elements of the other TOR protein, that still function and stably associate with its 
respected TOR subunit proteins (Hill et al., 2018). These results redefine the 
structural basis of TOR by proposing a new model where complex specificity is 
regulated. In a similar line of direction, the downstream target for TORC1 activity 
(RPS6) involved in protein synthesis, has been found to be phosphorylated by both 
TORC1 and TORC2 in yeast (Yerlikaya et al., 2016). Previously, it has been found 
that the Ypk3 kinase protein shares similar homology to S6K1 and directly 
phosphorylates RPS6 in a TORC1-dependent fashion (Gonzalez et al., 2015). Thus, 
questions are raised if Ypk3/ S6K1 are targets for TORC2/mTORC2 mediated 
phosphorylation and can associate with the TORC2/mTORC2 complexes.  
Having discussed the pitfalls in the approaches used in this work, the significance of 
obtaining a structure of S6K1 and raptor complexed together or S6K1 bound onto 
mTORC1 must not be overlooked. Acquiring such structural information is seen as 
critical to the generation of novel mTORC1 treatments where targeting S6K1 
recruitment can provide selectivity against mTORC1 disease states as targeting 
both mTOR complexes with current pan-mTOR inhibitors can result in undesirable 
side effects such as hyperglycaemia and hyperinsulinemia (Ong et al., 2016). Such 
a strategy is currently being proposed for selectively inhibiting mTORC2 by targeting 
mTORC2 substrate recruitment to avoid inhibition of vital biological processes such 
as protein synthesis regulated by mTORC1 (Yang et al., 2018).  
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 5.4 Conclusions 
The expression of full length S6K1 with and without the addition of fluorescent 
protein tags has been attempted in insect cells using the baculovirus expression 
system. The FRET bio-sensor (SensOR) was successfully produced and purified in 
large quantities. Some S6K1-raptor complex was produced with an estimated 
quantity of less than 1 mg, but this low yield combined with other protein impurities 
is not suitable for X-ray crystallography or cryo-EM. The expression of raptor and 
mTOR in insect cells resulted in poor quantities and misfolding of protein; a different 
expression system such as the mammalian expression system with alternatve  
purification tags or supplementing insect cell media with rapamycin could provide 
larger yields of pure mTORC1 protein for future work.   
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6.0 Overall summary and future work 
 
6.1 Overall summary 
This body of research has focused on four main areas. They are (1) identifying the 
localisation and interaction of S6K1 protein in relation to the mTORC1 pathway, (2) 
the phosphorylation of S6K1 in live cells, (3) identifying the localisation and 
interaction of the AZD2014 drug with other mTORC1 components, and (4) large 
scale production of the S6K1-mTORC1 complex at high quantities for future 
structural studies. 
This work has shown the S6K1 protein localises equally in both the cytoplasm 
(~52%) and the nucleus (~48%) of living mammalian cells (HEK293, HeLa and 
U20S) using GFP technology and advanced light microscopy. This subcellular 
localisation observed in this research project was found to be similar to that reported 
in plants (Mahfouz, 2006) whilst cell fractionation studies have also suggested both 
nuclear and cytoplasmic localisations for S6K1 (Rosner and Hengstschläger, 2011). 
However, fixed cell studies have shown only cytoplasmic localisation (Lun et al., 
2017) and this may be due to cell fixative induced influences (Schnell et al., 2012). 
The results from this project agree with previously published studies involving cell 
fractionation, and have the added advantage of being performed in living cells under 
in vivo conditions that closely resemble the physiological environment.  
Tagging S6K1 and other mTOR proteins with fluorescent labelling technology 
(acceptor and donor combinations) has provided new real-time evidence of the 
interactions of the S6K1 protein with mTORC1 in living cells. The evidence for this 
interaction is obtained from FRET-FLIM results and pull-down assays. Both 
techniques indicate that S6K1 is physically bound to raptor ( with ~200 ps change in 
donor lifetime following FLIM studies) and supports previous published work (Nojima 
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et al., 2003; Mahfouz, 2006) and indicate S6K1 within binding proximity to mTOR 
(~100 ps change in donor lifetime). Although previous pull-down interaction studies 
indicate an interaction between S6K1 and mTOR (Ali and Sabatini, 2005), the 
outcome of the work from this project shows that this interaction may be bridged by 
raptor, a tertiary component.  This advances current knowledge which postulates 
that S6K1 is separate to the rest of the mTOR complex (Saxton and Sabatini, 2017). 
The docking of S6K1 onto mTORC1 is highest for raptor (in order of binding 
efficiency of raptor with mTOR and with Rheb) supports the ‘scaffold’ function of  the 
raptor protein in recognising and recruiting mTORC1 substrates (Nojima et al., 
2003).  
The overexpression of both S6K1 and raptor together is identified to cause 
translocation of S6K1 (Chapter 3) out of the nucleus into the cytoplasm, correlating 
with increased levels of raptor co-expression in the cytoplasm. The translocation 
process has been shown to be mediated by the TOS motif of S6K1 and not 
triggered by mTOR mediated phosphorylation. A similar translocation event was 
also observed with 4EBP1, which moves out of the nucleus when co-expressed with 
the raptor protein. Using three-colour live cell imaging the main mTORC1 substrates 
with TOS motifs (S6K1, 4EBP1 and PRAS40) have been shown to compete for 
raptor binding, resulting in a 2x decrease in S6K1 recruitment as measured by 
confocal imaging when 4EBP1 or PRAS40 are expressed. These findings go 
beyond other studies that observed similar results in vitro (Nojima et al., 2003; 
Schalm et al., 2003; Wang et al., 2007; Dennis, Kimball and Jefferson, 2013) by 
providing novel dynamic insights into mTORC1 behaviour in the live cell. Thus, if 
raptor functions to recognise and recruit mTOR substrates onto mTORC1, the 
translocation of these downstream target proteins could be used as a visual marker 
for recruitment. Although raptor may be involved in the primary stages of substrate 
recruitment onto the complex, a secondary recruitment mechanism involving a full 
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functioning mTOR found from mutations studies in Chapter 3 appears to exist. This 
supports recent structural studies that found a fragment of the S6K1 bound to 
mTOR (Yang et al., 2017). Looking to the future, new fourth generation inhibitors 
could be designed and made to block S6K1 recruitment onto mTORC1 to provide 
selective mTOR inhibition. 
The protein overexpression system has been proven throughout this project to be a 
key tool in using living cells as metaphorical ‘test tubes’ for studying cellular 
signalling events. However, the possibility that protein overexpression introduces 
artefacts or that excess protein levels mask endogenous protein behaviours must be 
considered. It has been reported in imaging studies that the transient overexpression 
of GFP tagged mTORC1 proteins, particularly raptor and mTOR, do not localise to 
lysosomes upon amino acid starvation, whilst endogenously tagged raptor and 
mTOR have been found to do so (Manifava et al., 2016). With regard to the work 
performed in this thesis, the overexpression system offers an advantage for 
identifying intracellular mechanisms due to perturbations caused by high levels of 
protein expression (in excess of endogenous) such as S6K1 recruitment and 
translocation. 
Co-localisation and FRET-FLIM results from this project showed that S6K1 poorly 
co-localises with the Rheb protein, particularly in the ER/Golgi sub-localised regions 
of the cell despite a 128% increase in S6K1 phosphorylation with Rheb co-
expression. The work in this thesis also shows that S6K1 does not physically 
interact with Rheb, as shown by a lack of change in donor lifetime from the FRET-
FLIM studies. Despite a lack of interaction, the mechanism of S6K1 phosphorylation 
by Rheb induction, in the context of the living cell, remains unknown. Moreover, 
rapamycin studies indicated that rapamycin inhibition of S6K1 was dependent on 
Rheb. Whilst some studies have shown rapamycin alone to effectively inhibit S6K1 
phosphorylation, others have obtained varied results for different cell lines and 
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concentration effects (Choo and Blenis, 2009; Mukhopadhyay et al., 2016) and this 
may explain any discrepancies observed with rapamycin not effectively functioning 
alone.   
The use of cell fixation with immunofluorescence labelling was shown to be 
unreliable for determining the localisation of cytosolic proteins and in particularly 
phosphorylated S6K1 in cells. Both paraformaldehyde and methanol fixation caused 
artefacts marked by loss of soluble GFP tagged S6K1 protein from either the 
cytoplasm (by 37%) or nucleus (by 19%). Cell fixation also caused leakage of GFP 
tagged protein into the nucleolus of cells as well as masking epitopes of S6K1 for 
efficient phospho-S6K1 labelling. Sensitivity and specificity of antibodies against the 
S6K1 target protein also resulted in the generation of artefacts such as non-specific 
binding and poor labelling determined by immunofluorescence studies. Taken 
together, these findings cast doubt on other indirect methods of studying phospho-
S6K1 that greatly rely on cell fractionation studies (Rosner, Schipany and 
Hengstschläger, 2012) and immunofluorescence labelling of fixed cells (Kim et al., 
2013).  
Using the concept developed for FRET sensors (Lindenburg and Merkx, 2014), 
where the protein is closed upon phosphorylation and reopened upon 
dephosphorylation, EGFP was tagged to the C-terminus of S6K1 with mCherry on 
the N-terminus. The biologically relevant environment of S6K1 phosphorylation has 
been examined using a novel live cell FRET biosensor (named SensOR) that 
successfully reports on mTOR activity in living cells. The functionality of SensOR 
has been validated by western blot analysis which shows a 6-times increase in 
RPS6 (downstream S6K1 target) phosphorylation. SensOR relies on FRET-FLIM 
technology to identify structural changes in S6K1 upon phosphorylation. Folded 
SensOR in the cytoplasm (lifetime of ~2.3 ns) has been shown to be directly 
responsive to serum starvation and rapamycin treatment. Real-time imaging showed 
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unfolding of SensOR resulting in longer lifetimes (~2.5 ns) in live cells. AZD2014 
addition to cells expressing SensOR also showed a conformational change to longer 
lifetimes as evidenced by an increase of 120 ps in the natural lifetime of the FRET 
biosensor. These changes in lifetime are similar to a study using EGFP-aurora 
kinase A-mCherry as a FRET bio-sensor which reported a 130 ps lifetime change 
(Bertolin et al., 2016) for aurora kinase activity. Such lifetime differences seen 
between rapamycin and AZD2014 may be due to AZD2014 additionally binding to 
S6K1, (discussed further later) and locking S6K1 into a more rigid conformation. It is 
worth emphasising that lifetime alone cannot be used to report changes in single 
GFP-tagged mTORC1 proteins, whereas the dual FP tagged SensOR construct 
can. Activation of SensOR with amino acids (e.g. leucine and arginine) re-folds the 
SensOR protein indicating it is regulated by mTOR mediated phosphorylation. 
Purified SensOR in vitro showed temperature dependent kinetic unfolding at lower 
temperatures and re-folding at higher temperatures, in support of preliminary 
SensOR temperature dependent in vivo studies. The direct relationship between 
observed changes in the lifetime of SensOR with conformational change was 
confirmed with the addition of ATP to purified SensOR, which showed 
responsiveness (change in lifetime to 2.3 ns) during the activation (phosphorylation) 
of S6K1. The lower lifetime observed in the cytoplasm can be taken as the site of 
phosphorylation and supports previous work where other mTORC1 proteins, namely 
mTOR, raptor, and Rheb, are found to assemble to the same cytoplasmic 
localisation site (Yadav et al., 2013). In comparison to current alternative mTOR 
related FRET bio-sensors, only SensOR is capable of localising to both the nucleus 
and cytoplasm whilst at the same time directly reporting on mTOR mediated 
phosphorylation that is rapamycin sensitive (Komatsu et al., 2011; Zhou et al., 
2015). 
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Pan-mTOR inhibitors such as AZD2014 and INK128 display natural fluorescence 
properties which can be exploited using light microscopy. AZD2014 has been shown 
to be highly fluorescent molecule (quantum yield of 0.47 in DMSO, reducing to 0.11 
in PBS) with a dual-absorbance at 284 nm (ε=36,790 M−1cm−1 in DMSO) and 393 
nm (ε=1,166 M−1cm−1 in DMSO), and fluorescence peak emission at 460 nm. Both 
single (λex=405 nm) and two-photon excitation (λex=600 nm) microscopy were used 
to investigate AZD2014. Longer AZD2014 lifetimes and emissions are observed in 
polar aprotic solvents such as DMSO compared to protic solvents like PBS. This 
correlates with preferred localisation of AZD2014 in lipid rich cytosolic substructures 
such as ER/perinuclear membranes and the Golgi apparatus, known for mTOR 
localisation (Betz and Hall, 2013). AZD2014 is taken-up rapidly by mammalian cells 
within one minute of administration, and accumulates at a concentration 30 times 
greater than the administered dose (7 μM). Human clinical doses have been trialled 
at 25-100 mg (Basu et al., 2015; Powles et al., 2016) and pre-clinical doses in mice 
are as high as 7.5-15 mg/kg (Guichard et al., 2015). Considering the range of these 
doses, the drug’s property for heightened accumulation could explain undesirable 
side effects reported in trials such as fatigue (78%) and nausea (51%) (Basu et al., 
2015). 
Using multi-cellular spheroids to represent tumour environment, AZD2014 is taken 
up at similar rates (≥1 minute) in the outer spheroid compared to monolayer cell 
culture with the inner core of the spheroid showing a slower uptake rate (≥5 
minutes). These uptakes support similar findings of the uptake of E- combretastatins 
in spheroids (Scherer et al., 2015). Furthermore, the combination of 405 nm 
illumination and AZD2014 treatment resulted in cell death of cells, leading to 
doubling of spheroid diameter. This photo-activated effect makes AZD2014 a 
possible candidate for future Photodynamic Therapy (PDT) studies (Bisby et al., 
2012), although the precise mechanism of cell death has not been determined. 
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AZD2014 was established to co-localise strongly with fluorescently tagged Rheb in 
living cells, which is known to tether mTORC1 to lysosomes, ER, and Golgi 
substructures (Yadav et al., 2013; Hao et al., 2018). Therefore, one of the ways 
AZD2014 may function to inhibit mTOR is by automatically localising to mTORC1 
subcellular sites. Two-photon excitation of AZD2014 using 600 nm excitation is 
better suited for determining interactions between AZD2014 and EGFP-mTORC1 
using FRET-FLIM. The lifetime of AZD2014 varies (± 0.5 ns), in similar range of that 
reported recently (Conway et al., 2018), indicating AZD2014 may be 
photochemically unstable and this would support the spheroid studies. AZD2014 
interacts with all mTORC1 subunit proteins although it interacts more strongly with 
S6K1 (~800 ps change in lifetime) and Rheb (~600 ps change in lifetime). These 
findings open up newer avenues to combat mTOR disease states such as cancer by 
directly targeting S6K1 or Rheb (Qin et al., 2015; Mahoney et al., 2018).  
Spectroscopic studies on INK128 found this pan-mTOR inhibitor to be less 
fluorescent (Abs = 293 nm, Em = 400 nm) than AZD2014 as evident by (quantum 
yield of 0.33 and molecular coefficient of 16,215 M−1cm−1 in DMSO) but shows 
similar favourability to solvent environments such as DMSO. INK128 can be taken 
up into cells within 42 seconds and has comparable sub-cellular localisation to that 
of AZD2014 in living mammalian cells (i.e. cytosolic/ peri-nuclear localised). Taken 
together, second generation mTOR inhibitors may have common localisation 
properties. 
Generation of large quantities of human mTORC1 complexes in this project have 
been attempted as a means to provide sufficient material for structural determination 
of S6K1 bound to mTORC1. Using an insect cell expression system, ~1 mg of 
raptor-S6K1 protein was produced which although high in concentration, other 
protein impurities made it insufficient to continue on with for structural studies. The 
level produced improves upon lower quantities of mTOR complex produced 
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previously in insect cells (Stuttfeld et al., 2018). However, the mammalian cell 
seems to be the most popular choice of expression system for generating large 
quantities of mTORC1 (Yang et al., 2013, 2016, 2017) and the findings here support 
such a protocol. Human full length and truncated S6K1 have been found to express 
in high amounts in baculovirus-infected insect cells whilst full length human mTOR 
and raptor express very poorly or are degraded. This may be due to the lack of the 
human chaperone system in insect cells that is required to fold eukaryotic proteins 
(Yokoyama et al., 2000). The use of the His-tag epitope has been found unsuitable 
for the purification of S6K1-raptor complexes as natural histidine containing proteins 
non-specifically interact with the purification column, yielding impurities. On the other 
hand, insect cell expression system combined with the STREP tag purification 
epitope can produce large quantities of pure SensOR protein with single step 
purification. On the whole, the expression and purification results shows the 
dependability of the STREP purification epitope for protein purification and brings 
attention to its implementation for future protein purification work (Kimple, Brill and 
Pasker, 2018).  
6.2 Future work 
This research has applied overexpression of proteins to investigate the interactions 
of S6K1 in live cells. Although, this ‘test tube’ approach has worked well, 
endogenous levels of protein expression need to be further examined. Future work 
entailing the use of CRISPR/Cas9 to tag endogenous mTORC1 proteins with GFP 
could be used to achieve this goal and further assayed to determine endogenous 
mTORC1 protein-protein interactions with FRET-FLIM imaging (Lackner et al., 2015; 
Ratz et al., 2015; Manifava et al., 2016; Khan et al., 2017). Although it has been 
suggested that S6K1 functions through the mTORC1 pathway, S6K1 has been 
reported to phosphorylate the mTORC2 pathway (Treins et al., 2010). The 
interaction between S6K1 and the rictor protein using FRET-FLIM technology could 
277 
 
be investigated in future studies. The implication of S6K1 within the mTORC2 
pathway and its synergy across both mTOR complexes would help identify the 
architectural and structural functions of the mTOR protein. A hybrid mTOR complex 
consisting of both mTORC1 and mTORC2 subunit proteins and complexes without 
mTORC1 and mTORC2 subunits have been identified (Jain et al., 2014; Gough, 
2016), proposing that the differentiation and specificity of either mTORC1 or 
mTORC2 from a single complex origin could exist. The first steps towards achieving 
this goal would entail determining the live cell localisation of fluorescently tagged 
rictor with respect to S6K1. The rictor protein tagged with GFP on the N-terminus 
has been published and shows localisation predominately in the cytoplasm whilst 
some localisation in the nucleus can also be seen (Tao et al., 2015). It would be 
interesting to determine interaction, if any, between S6K1 and rictor as well as 
whether S6K1 is capable of translocating with rictor co-expression (Ali and Sabatini, 
2005). The mSin1 protein in mTORC2 has been reported to act as a scaffold, similar 
to raptor’s role in mTORC1, to maintain firstly the stability of mTORC2 and secondly 
to recruit mTORC2 substrates such as AKT, PKCα and SGK1 (Karuppasamy et al., 
2017; Tatebe et al., 2017). A better understanding of the recruitment of mTOR 
substrates could be aided by determining the live cell co-localisations and 
interactions of the mTORC2 substrates with mTORC2 subunit proteins such as 
mSin1, rictor, mTOR and Protor1/2 using the combination of GFP and FRET-FLIM 
technology. The interplay between the recruitment mechanisms of mTORC1 and 
mTORC2 could be critical in providing novel treatments against mTOR disease 
states as well as combatting cancers that have developed resistance against current 
clinical drugs that target only the mTORC1 pathway.  
The S6K2 homologue protein of S6K1 is also a direct substrate of mTOR mediated 
phosphorylation (Park et al., 2002). The localisation and role of S6K2 and its 
interaction with mTORC1 have to date not been thoroughly investigated. The only 
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published live cell image of the S6K2 protein is in a plant cell, indicating a 
predominantly nuclear localisation (Mahfouz, 2006). The sub-cellular localisation of 
S6K2 in living mammalian cells is yet unknown. Overexpressed S6K2 has been 
labelled using immunofluorescence techniques and has shown strong staining 
mostly in the nucleus with some staining in the cytoplasm. Investigating whether 
S6K2 interacts with the mTORC1 subunit proteins provide a possible inhibition 
target for the mTOR complex. This may lead to newer strategies to target mTORC1 
by exploiting other Ribosomal S6 kinase (RSK) targets.  
Determining multiple protein interactions in a cell simultaneously is imperative to 
defining exact mechanisms of intricate protein cascade events in cellular signalling 
pathways. The application of dual-channel FRET-FLIM or three-colour FRET with 
multiple donor-acceptor combinations (Grant et al., 2008; Sun et al., 2010; Scott and 
Hoppe, 2015; Laviv et al., 2016; Bunt and Wouters, 2017) could provide sub-
nanosecond time resolution in detecting multiple mTORC1 or mTORC2 protein 
subunit interactions and any connection between them. The ability to probe multiple 
interactions could verify formations of downstream substrate proteins onto mTOR 
complexes as well as concisely determining their subcellular localisation and exact 
positions of binding.  
In addition, improvements in the FRET-FLIM methodology could be made by 
implementing more stable and brighter FP proteins. For example, the recently 
developed mScarlet, has been reported to have a quantum yield of 0.7 (Bindels et 
al., 2016) whilst the quantum yield of mCherry is 0.22. Such acceptors with EGFP 
donor tagged proteins could provide better FRET efficiency as equal amounts of 
donor: acceptor levels can be determined more efficiently during FRET-FLIM 
measurements. The lifetime of mTurqouise2 (donor) when directly interacting with 
the mNeonGreen (acceptor) protein has been shown to result in a lifetime change of 
almost 2 ns (Mastop et al., 2017). Thus, using newer donor-acceptor FP pairs could 
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be more suitable for studying direct interactions between S6K1 and mTOR. Any long 
distance interactions (>10 nm) between S6K1 and mTOR could also be investigated 
using Fluorophore Localisation Imaging with Photobleaching (FLImP), which is 
capable of defining interactions from around 10 nm up to 100 nm (Needham et al., 
2016).  
The enhanced resolution offered by super-resolution microscopy techniques such as 
stimulated emission depletion (STED) and structured illumination microscopy (SIM) 
techniques have furthered the understanding of cellular signalling mechanisms 
(D’Abrantes et al., 2018). Currently, there is a lack of super-resolution imaging 
studying the mTOR pathway. Such work could provide novel insights into mTORC1 
sub-cellular localisation. In addition, the combination of these super-resolution 
techniques (i.e. STED or SIM) with FRET-FLIM technology (Lenz et al., 2011; 
Görlitz et al., 2017) could further map mTORC1 spatial interactions and dynamics 
that have been otherwise undetected using conventional diffraction limited 
microscopy.   
Implementation of the donor-acceptor FP pair improvements described above could 
also be applied to the live cell SensOR construct for directly reporting on mTORC1 
activity. Future work may involve developing a high-throughput FRET-FLIM 
screening method (Margineanu et al., 2016) where mammalian cells expressing 
mTurq2-S6K1-EGFP or mTurq2-S6K1-mNeonGreen in a 96-well plate are screened 
against a selection of pre-clinical and clinical mTOR inhibitors. Any changes in 
lifetime could be used as a marker for determining the efficiency of the drugs in 
targeting mTOR mediated phosphorylation. The instrumental operation in a clinical 
context could help provide better treatments whilst as well as the development of 
new designs for the next generation mTOR inhibitors.   
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Research into establishing the photosensitising properties of AZD2014 as well as its 
mechanism could enhance the potency of the anti-cancer drug in clinical trials. Such 
work would be aided by better understanding the photostability and photophysical 
characteristics of the drug. Other pan-mTOR inhibitors such as AZD8055 and OSI-
027 (Xie, Wang and Proud, 2016), based upon their chemical structure, may display 
fluorescent properties. Similar studies to that performed with AZD2014 on these 
second generation inhibitors would help identify common localisation properties and 
binding mechanism amongst these types of inhibitors. These studies could also be 
extended to investigating the mechanism and localisation of third generation mTOR 
inhibitors such as RapaLink where the second generation mTOR moiety in its 
chemical structure could be utilised as a fluorophore marker (Fan et al., 2017).  
Although many dimeric raptor-mTOR based cryoEM structures, resolved at good 
resolution (4.4 - 5.9 Å) are available, the structure of mTORC1 substrates such as 
S6K1 or 4EBP1 bound onto the complex is still unknown. Identifying how S6K1 
binds mTORC1 at the atomistic level can be expected to lead to improving the ability 
to design novel inhibitor candidates that are able to disrupt the recruitment 
mechanism (i.e. fourth generation mTOR inhibitors). Generating large and stable 
quantities of mTORC1 protein complex may be helped by using human chaperone 
proteins in the baculovirus-infected insect cell system for assisting the folding of 
mTOR and raptor proteins (Yokoyama et al., 2000). Other mTORC1 expression 
attempts could be trialled in the mammalian cell system using Expi293 or ExpiCHO 
Expression Systems. In addition, the use of other epitope purification tags, 
particularly the STREP or FLAG tag, could be developed for a one-step purification, 
to give clean and purer S6K1-mTORC1 complexes (Gerace and Moazed, 2015; 
Schmidt and Skerra, 2015). Since no full length S6K1 crystal structure is available, 
X-ray crystallisation or cryoEM trials of the purified SensOR generated from the 
programme of this work, may provide a structure of S6K1 locked into one of its 
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phosphorylated states. Identifying the structural basis/conformational workings of 
S6K1 with respect to mTOR phosphorylation is seen as imperative to preventing 
and controlling hyperactive mTOR mutations in cancer patients.  
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Appendices 
Appendix A 
A.1 NucleoSpin® Gel and PCR Clean-up Kit contents 
 
 50 preps 
Binding buffer NTI 40 ml 
Wash buffer NT3 (concentrate) 25 ml 
Elution buffer NE* 13 ml 
NucleoSpin® Gel and PCR Clean-up 
columns 
50 
Collection tubes (2 ml) 50 
 
* = 5 mM Tris/HCl, pH 8.5 
 
A.2 Quick-Fusion cloning kit contents 
 40 reactions 
Fusion enzyme 40 µl 
5x Fusion buffer 80 µl 
Linearized control vector- 2.7 kb 5 µl 
Control DNA fragment – 500 bp 5 µl 
 
A.3 Protocol for LB Agar 
25 g of LB, plus 20 g of Bactoagar (BD) was prepared in 1 litre of water (Milli-Q) and 
autoclaved in an autoclave (Rodwell) (15 minutes per cycle at 121ºC with ~8 
cycles).  
A.4 Protocol for LB  
25g of LB (Melford) was prepared in 1 litre of water (Milli-Q) and autoclaved as 
described above. 
A.5 Protocol for LB glycerol 
70 ml of LB was mixed with 30 ml of sterile glycerol (Sigma-Aldrich). Glycerol was 
autoclaved prior to use. 
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A.6 QIAprep Spin Miniprep kit contents 
 50 reactions 
QIAprep 2.0 Spin columns 50 
Buffer P1 20 ml 
Buffer P2 20 ml 
Buffer N3 30 ml 
Buffer PB 30 ml 
Buffer PE (concentrate) 2 x 6 ml 
Buffer EB 15 ml 
LyseBlue 20 µl 
Loading dye 110 µl 
RNase A 2 mg 
Collection tubes (2 ml) 50 
 
A.7 pOPIN primers 
The pOPIN Forward primer is based on the T7 forward priming sequence and is 
present in most pOPIN vectors. The sequence is shown below: 
pOPIN Forward primer GAC CGA AAT TAA GAC TCA CTA TAG GG 
pOPIN NeoRev2 primer GGA ATG CTC GTC AAG AAG ACA  
 
A.8 QIAGEN Plasmid Plus Maxi kit contents 
 25 reactions 
QIAGEN Plasmid Plus Spin columns 25 
QIAfilter Midi Cartridges 25 
Caps for QIAfilter 25 
Tube Extenders (20 ml) 25 
Collection Tubes (2 ml) 25 
Buffer P1 110 ml 
Buffer P2 110 ml 
Buffer S3 2 x 70 ml 
Buffer ETR 25 ml 
Buffer BB 70 ml 
Buffer PE (concentrate) 6 ml 
Buffer EB 15 ml 
RNase A 11 mg 
LyseBlue 110 µl 
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A.9 QuikChange Multi Site-Directed Mutagenesis Kit 
 30 reactions 
QuikChange Multi enzyme blend (2.5 U/µl) 80 U 
10 x QuikChange Multi reaction buffer 200 µl 
QuikSolution 500 µl 
dNTP Mix 30 µl 
Dpn 1 restriction enzyme (10 U/µl) 300 U 
QuikChange Multi control template (50 ng/ µl) 5 µl 
QuikChange Multi control primer mix (100 ng/ µl 
of each of three primers)  
5 µl 
XL10-Gold ultracompetent cells  10 x 135 µl 
XL10-Gold β-mercaptoethanol mix  2 x 50 µl 
pUC18 control plasmid (0.1 ng/µl in TE buffer) 10 µl 
 
A.10 pOPIN vectors  
A.10.1 pOPINN-EGFP 
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A.10.2 pOPINE-3C-mCherry 
 
 
 
A.10.3 pOPINE-3C-mTurq2 
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A.10.4 pOPINE-3C-EGFP 
 
 
A.10.5 pOPINE-3C-YFP 
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A.10.6 pOPINEneo-3C-2STREP 
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A.10.7 pBAC4x-1 
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A.11 mLST8 sequence  
 
A.12 TBST (1X) 
For 1 litre of working solution, 100 ml of TBS stock (10X) was diluted in 899 ml of water 
(Milli Q) and stirred with a magnetic stirrer for 15 minutes. 1 ml of Tween-20 (Sigma-
Aldrich) was added and left to stir for 15 minutes.  
To make 10X TBS - 500 mM Tris was made from Trizma base (Sigma-Aldrich) with 1.5 M 
NaCl in 1 litre of water (Milli Q) and stirred with a magnetic stirrer for 15 minutes. The pH of 
the solution was adjusted to pH 7.4.  
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Appendix B 
B.1. Western blot analysis of endogenous and overexpressed pS6K1  
 
 
  
Endogenous p70 S6K1 
p70 EGFP-S6K1 
Phospho p70 EGFP-S6K1 
Vinculin 
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B.2. Co-localisation of S6K1 with Rheb in live cell 
 
Deconvolved confocal images of A) EGFP-S6K1 with B) mDsRed-Rheb co-expression in live 
HEK293 cells. C) Co-localisation scatter plot of EGFP-S6K1 and mDsRed-Rheb generated 
in ImageJ using Co-localisation tool which calculates the thresholds for the co-localisation 
analysis, the Pearson's correlation (Rcolo) and Manders coefficients (M1, M2).  Rcolo value 
close to 1 indicates 100% co-localisation. Scale bar = 10 μm in all images. 
 
 
  
Co-localisation 
scatter plot 
Rcoloc = 0.1326 
R theshold= 0.313 
M1= 0.78 
M2= 0.99 
EGFP-S6K1 mDsRed-
Rheb 
A B 
C 
Hyvolution Hyvolution 
HEK293 HEK293 
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B.3 Full length blots for mTORC1 pull-down 
 
  
E H
A B C D
S6K1 mTOR raptor
raptor
Rheb
mTOR
S6K1
His-EGFP-S6K1
mCherry-raptor
FLAG-mTOR
Natural HEK His proteins
I
G
1      2       3         4         5        6           7        8   
F
Full lengths gels for Figure 3.15. Western blot of eluted mTORC1 complexes shown for A 
S6K1 using anti-His antibodies. B mTOR using anti-FLAG antibodies. C raptor using anti-
raptor antibodies. D Rheb using anti-Rheb antibodies. Western blots of soluble mTORC1 
lystates for E S6K1 using anti-His. F mTOR using anti-FLAG. G raptor using anti-raptor. H 
Rheb using anti-Rheb antibodies. I Comassie of mTORC1 eluted fractions. Marker, GFP 
and no transfection (NI) controls are also shown on blots. 
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B.4 Lifetime comparison of EGFP in live vs fixed HEK293 cells 
 
 
 
 
 
 
 
 
 
 
EGFP only live cells media τm= 
2.6 ns 
EGFP only live cells PBS 
(1X) 
τm= 
2.6 ns 
EGFP only fixed cells PBS τm= 
2.4 ns 
321 
 
B.5 High Rheb expression does not lead to correlated phospho-S6K1 levels 
 
 
Confocal images of HEK293 cells fixed in PFA, A) S6K1-GFPSpark co-expressed with B) 
mDsRed-Rheb with C) anti-phopho-S6K1 and Cy5 labelling. D) Graph to show mean 
intensities of equal regions of interests per cell of mDsRed-Rheb levels plotted against 
phospho-S6K1 labelled with Cy5. E) Graph to show mean intensities of equal regions of 
interests per cell of S6K1-GFPSpark levels plotted against phospho-S6K1 labelled with Cy5. 
Data representative of one of three reproducible independent experiments where the errors 
shown are standard deviations in intensities of regions of interests (ROIs) encompassing 
both the nucleus and cytoplasm of each cell. Scale bar = 10 μm in all images. 
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B.6 Differences in endogenous phospho-S6K1 localisation with various 
antibodies 
 
 
Confocal images of anti-phospho-S6K1 (Cell Signalling) and Alexa 488 labelling in A) 
HEK293 cells and B) HeLa cells, anti-phospho-S6K1 (Millipore) and Alexa488 labelling in C) 
HEK293 cells and D) Hela cells, anti-phospho-S6K1 (Thermofisher) and Cy3 labelling in E) 
A431 cells and F) MCF7 cells. All cells fixed in PFA. Scale bar = 10 μm in all images. 
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B.7 Immunofluorescence secondary antibody controls 
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B.8 Endogenous phospho-S6K1 may be mostly nuclear and induced by Rheb 
overexpression 
 
 
A) confocal image of fixed HEK293 cells labelled with phospho-S6K1 and Alexa 488 
antibodies. B) trans white light image. C) merged image. D) fixed HEK293 cells labelled with 
anti-phospho S6K1 and Alexa 488 antibodies. E) trans white light image. F) merged image. 
G) mDsRed-raptor expressing fixed cells labelled with anti-phospho S6K1 and Alexa 488 
antibodies. H) mDsRed-raptor expression. I) merged image. J) mDsRed-Rheb expressing 
pS6K1-Alexa488 Trans Merge 
HEK293 
S6K1-Alexa488 Trans Merge 
HEK293 
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B C 
E F 
H I 
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fixed cells labelled with anti-phospho S6K1 and Alexa 488 antibodies. K) mDsRed-Rheb 
expression. L) merged image. Scale bar = 10 μm in all images. 
B.9 Quantifying endogenous phospho-S6K1 with overexpressed Rheb 
 
Confocal images of PFA fixed HEK293 cells labelled for A) phospho-S6K1 and Alexa488 
staining with B) mDsRed-Rheb co-expression. C) graph showing phospho-S6K1 intensities 
per cell plotted against respective Rheb intensities. Data representative of one of three 
reproducible independent experiments where the errors shown are standard deviations in 
intensities of regions of interests (ROIs) encompassing both the nucleus and cytoplasm of 
each cell in both x and y as intensity levels vary in ROIs . Scale bar = 10 μm in all images. 
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B.10 EGFP-mTOR FRET-FLIM interaction with mCherry-raptor  
 
 
 
 
 
 
 
  
EGFP-mTOR FLIM 
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Appendix C 
 
C.1 UV-VIS spectrum of DMSO only 
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C.2 Molar extinction coefficients (ε) of AZD2014, INK128 and rapamycin  
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C.3 Excitation spectra of AZD2014 in various solvents 
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C.4 AZD2014 two-photon excitation and single photon calibration 
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C.5 AZD2014 two-photon excitation and single photon calibration 
 
 
A) Log-log plot 600 nm excitation of AZD2014 in DMSO with increasing laser power. 
The value of the slope gives the power of a power relationship which in this case is 
2 because of two-photon excitation. B) Counts against increasing [AZD2014] in 
DMSO using 405 nm pulsed excitation. 
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C.6 Multiphoton (600 nm) FLIM of HEK293 only at 0.5 mW 
 
Image on left shows transmission of cells. Image on right shows a FLIM of the same 
cells. Emission band with filter, 460/60 with 600 nm excitation and 0.5 mW 
combined should give minimal excitation and emission of tryptophan  
  
FLIM 
3500                             4700 ps 
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C.7 Multiphoton (600 nm) FLIM of EGFP-S6K1 only at 0.5 mW 
 
 
 
 
 
 
 
 
 
 
Image on left shows confocal of cells expressing EGFP-S6K1. Image on right shows 
a FLIM of the same cells. Emission band with filter, 460/60 with 600 nm excitation 
and 0.5 mW combined should give minimal excitation and emission of EGFP  
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Appendix D 
 
D.1 Pilot expression and purification of SensOR 
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D.2 QC expression and purification of raptor and S6K1 constructs 
 
 
 
A 
B 
raptor? 
S6K1? 
raptor? 
S6K1? 
ΔS6K1? 
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D.3 Chromatagram obtained for S6K1-FLAG + raptor-His after purification 
using the ÄKTA protein purification system.  
 
 
The blue peak represents the eluted protein fractions. B) Curved obtained for 
pressure loading (cyan curve) and protein UV absorbance (dark blue) using the 
ÄKTA protein purification system 
A B 
337 
 
D.4 Coomassie of large scale iMAC of raptor and S6K1 
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D.5 Coomassie Phynexus run raptor and S6K1 elutions 
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D.6 Sequence Annotated by Structure (SAS) of S6K1 
 
 
 
 
 
 
